University of South Florida

Scholar Commons
Graduate Theses and Dissertations

Graduate School

January 2015

Sigma Receptor Activation Mitigates Toxicity
Evoked by the Convergence of Ischemia, Acidosis
and Amyloid-beta
Adam Alexander Behensky
University of South Florida, abehensk@health.usf.edu

Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the Neurosciences Commons, Pharmacology Commons, and the Physiology Commons
Scholar Commons Citation
Behensky, Adam Alexander, "Sigma Receptor Activation Mitigates Toxicity Evoked by the Convergence of Ischemia, Acidosis and
Amyloid-beta" (2015). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/5641

This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.

Sigma Receptor Activation Mitigates Toxicity Evoked by the
Convergence of Ischemia, Acidosis and Amyloid-β

by

Adam A. Behensky

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy in Medical Sciences
Department of Molecular Pharmacology and Physiology
College of Medicine
University of South Florida

Major Professor: Javier Cuevas, Ph.D.
Thomas E. Taylor-Clark, Ph.D.
Jerome W. Breslin, Ph.D.
Kay-Pong Yip, Ph.D.
Mack H. Wu, MD

Date of Approval:
June 11, 2015

Keywords: intracellular calcium, whole-cell currents, ASIC1a, fluorescent imaging,
stroke, vascular dementia
© Copyright 2015, Adam A. Behensky

ACKNOWLEDGMENTS

First of all, I like to think my mentor, Dr. Javier Cuevas, for giving me the
opportunity to become a scientist and future independent investigator. Through his
support and mentorship I have thrived in the field of stroke research. I would also like to
thank my committee members, Drs. Thomas Taylor-Clark, Jerome Breslin, Kay-Pong
Yip and Mack Wu for their advice and support through these years. I would also like to
extend thanks to my external examiner Dr. Donna Wilcock, for accepting to chair my
dissertation committee and for her constructive criticism and comments on my
dissertation.
I would also like to thank Dr. Chris Katnik and Dr. Parmvir Bahia for providing
advice and troubleshooting for various experiments and offer my thanks to Dr. Sarah
Yuan, the chair of the Department of Molecular Pharmacology and Physiology, for all of
her support as well as our department staff, Bridget Shields, Stacy Reed, Suzanne
McMahon and Dr. Eric Bennett our department vice chair and PhD program director.
Lastly, I would like to thank the vivarium staff, Haley, Karen and Jill for providing
assistance with our experimental animals.
This work was funded in part by a pre-doctoral fellowship from the American
Heart Association to AAB (14PRE19570010).

TABLE OF CONTENTS

LIST OF TABLES ...................................................................................................... iv
LIST OF FIGURES ...................................................................................................... v
ABSTRACT ................................................................................................................. ix
CHAPTER 1 Introduction .............................................................................................1
Significance ...........................................................................................................1
Background ...........................................................................................................2
Pathobiology of Ischemic Stroke ...........................................................................4
Amyloid-β ..............................................................................................................7
Microglia ................................................................................................................9
Sigma Receptors.................................................................................................11
Afobazole ............................................................................................................14
CHAPTER 2 In Vitro Evaluation of Guanidine Analogues as Sigma
Receptor Ligands for Potential Anti-Stroke Therapeutics .......................................... 17
Introduction .........................................................................................................17
Materials and Methods ........................................................................................19
Preparation of Cortical Neurons................................................................. 19
Calcium Imaging ........................................................................................ 20
In Vitro Competition Binding Assays .......................................................... 21
Primary Cultures of Microglia ..................................................................... 21
Microglia Migration ..................................................................................... 22
Drugs and Chemicals................................................................................. 23
Data Analysis ............................................................................................. 24
Results ................................................................................................................24
Discussion ...........................................................................................................39
CHAPTER 3 Afobazole Activation of Sigma-1 Receptors Modulates
Neuronal Responses to Amyloid-β25-35 ...................................................................... 45
Introduction .........................................................................................................45
Materials and Methods ........................................................................................48
Preparation of Rat Cortical Neurons .......................................................... 48
Calcium Imaging ........................................................................................ 49
ROS and NO Imaging ................................................................................ 49
Cytotoxicity Assay ...................................................................................... 50
Immunocytochemistry ................................................................................ 51
i

Compounds, Reagents and Antibodies...................................................... 52
Data Analysis ............................................................................................. 52
Results ................................................................................................................52
Discussion ...........................................................................................................66
CHAPTER 4 Stimulation of Sigma Receptors With Afobazole Blocks
Activation of Microglia and Reduces Toxicity Caused by Amyloid-β25-35 .................... 72
Introducation .......................................................................................................72
Materials and Methods ........................................................................................74
Primary Cultures of Microglia ..................................................................... 74
Membrane Morphology and Migration Assay............................................. 75
Calcium Imaging Measurements ............................................................... 76
ROS and NO Imaging ................................................................................ 77
Cell Death Assay ....................................................................................... 77
Immunocytochemistry ................................................................................ 78
Reagents and Antibodies ........................................................................... 79
Data Analysis ............................................................................................. 79
Results ................................................................................................................79
Discussion ...........................................................................................................94
CHAPTER 5 Activation of Sigma Receptors via Afobazole Modulates
Microglial but not Neuronal Apoptosis-Related Gene Expression in
Response to Long-Term Ischemia Exposure ........................................................... 101
Introduction .......................................................................................................101
Materials and Methods ......................................................................................103
Primary Cultures of Microglia ................................................................... 103
Preparation of Cortical Neurons............................................................... 104
Live/Dead Cell Assay ............................................................................... 104
Immunocytochemistry .............................................................................. 105
Calcium Imaging ...................................................................................... 106
Compounds, Reagents and Antibodies.................................................... 107
Data Analysis ........................................................................................... 107
Results ..............................................................................................................107
Discussion .........................................................................................................119
CHAPTER 6 Afobazole Abolishes Amyloid-β25-35 Potentiation of IschemiaAcidosis Evoked Increases in Neuronal Intracellular Calcium Levels ...................... 124
Introduction .......................................................................................................124
Materials and Methods ......................................................................................126
Preparation of Rat Cortical Neurons ........................................................ 126
Calcium Imaging ...................................................................................... 126
Electrical Recordings .............................................................................. 127
Compounds, Reagents and Peptides ...................................................... 128
Data Analysis ........................................................................................... 128
Results ..............................................................................................................129
Discussion .........................................................................................................141
ii

CHAPTER 7 Discussion .......................................................................................... 146
Conclusion ........................................................................................................146
LIST OF REFERENCES .......................................................................................... 168
APPENDICES .......................................................................................................... 182
Permissions to Reprint Previously Published Materials ....................................182

iii

LIST OF TABLES
Table 2.1 o-DTG binds to both σ receptor subtypes with greater affinity
than p-BrDPhG.............................................................................................. 38

iv

LIST OF FIGURES

Figure 1.1

Pathoneurobiology of ischemic stroke ....................................................... 5

Figure 2.1

Shifting the location of the methyl moiety produces o-DTG
analogues that inhibit ischemia-induced increases in [Ca2+]i
similar to the parent compound................................................................ 25

Figure 2.2

Removal, but not migration, of the methyl moiety increases
capacity of o-DTG analogues to inhibit acidosis-evoked
elevations in [Ca2+]i .................................................................................. 26

Figure 2.3

Fluoro substitution does not affect o-DTG analogue inhibition
of ischemia- or acidosis-evoked increases in [Ca2+]i ................................................28

Figure 2.4

Chloro substitution at the meta and para positions increase
inhibition of intracellular calcium elevations ............................................. 30

Figure 2.5

Substitution of the methyl moiety with bromide at the meta
and para positions enhances [Ca2+]i inhibition ......................................... 32

Figure 2.6

Inhibition of ischemia-evoked increases in [Ca2+]i by p-BrDPhG
is concentration-dependent...................................................................... 33

Figure 2.7

p-BrDPhG inhibits acidosis-evoked increases in [Ca2+]i in a
concentration-dependent manner ............................................................ 35

Figure 2.8

σ-1 receptor antagonist BD-1063 attenuates p-BrDPhG inhibition
of acidosis-evoked increases in [Ca2+]i ..............................................................................36

Figure 2.9

p-BrDPhG blocks the migration of microglia elicited by ATP .................... 37

Figure 3.1

Aβ25-35 promotes time-dependent elevations in neuronal
intracellular calcium ................................................................................. 53

Figure 3.2

Afobazole inhibits increases in [Ca2+]i evoked by Aβ25-35 ........................ 55

Figure 3.3

Afobazole does not inhibit Aβ25-35 evoked ROS production but
does inhibit nitric oxide production in neurons ......................................... 57
v

Figure 3.4

Afobazole, but not DTG, reduces neuronal death produced by
application of Aβ25-35 ................................................................................ 59

Figure 3.5

Afobazole prevents upregulation of the pro-apoptotic gene
product, Bax, caused by application of Aβ25-35 in neurons ....................... 61

Figure 3.6

Afobazole reduces expression of activated caspase-3 in
response to application of Aβ25-35 in neurons ........................................... 63

Figure 3.7

Afobazole prevents Bcl-2 down-regulation following 48 hr
exposure of neurons to Aβ25-35................................................................. 65

Figure 4.1

Afobazole blocks membrane ruffling induced by ATP in
microglial cells .......................................................................................... 80

Figure 4.2

Afobazole blocks membrane ruffling induced by Aβ25-35 in
microglial cells .......................................................................................... 81

Figure 4.3

Afobazole blocks the migration of microglia elicited by Aβ25-35 ..........................84

Figure 4.4

Afobazole does not decrease microglial ROS or NO production
induced by Aβ25-35 .................................................................................... 85

Figure 4.5

Afobazole decreases microglial cell death produced by
application of Aβ25-35 ........................................................................................................................87

Figure 4.6

Afobazole reduces Aβ25-35-evoked expression of the proapoptotic gene product Bax, in microglia ................................................. 88

Figure 4.7

Afobazole reduces expression of activated caspase-3 in
response to application of Aβ25-35 in microglia ......................................... 90

Figure 4.8

Afobazole has minor effects on Bcl-2 levels in microglia following
application of Aβ25-35 ................................................................................ 91

Figure 4.9

Afobazole preserves [Ca2+]i responses to ATP in microglial cells
exposed to Aβ25-35 .................................................................................... 93

Figure 5.1

Afobazole reduces microglia death produced by application of
ischemia................................................................................................. 108

Figure 5.2

Afobazole prevents upregulation of the pro-apoptotic gene, Bax,
observed in response to ischemia in microglia ...................................... 110

Figure 5.3

Afobazole reduces expression of caspase-3 in response to
ischemia in microglia .............................................................................. 111
vi

Figure 5.4

Afobazole enhances Bcl-2 expression under control conditions
and following ischemia in microglia ........................................................ 113

Figure 5.5

Afobazole reduces neuronal death induced under ischemic
conditions ............................................................................................... 114

Figure 5.6

Afobazole fails to prevent upregulation of the pro-apoptotic gene,
Bax, observed in response to extended ischemia in neurons ................ 115

Figure 5.7

Afobazole fails to reduce expression of caspase-3 in response to
prolonged ischemia in neurons .............................................................. 116

Figure 5.8

Afobazole alone upregulates the anti-apoptotic gene, Bcl-2, but
does not enhance Bcl-2 levels following 24 hr ischemic
incubation in neurons ............................................................................. 117

Figure 5.9

Afobazole prolongs neuronal survival from extended exposure
of cortical neurons to ischemia, but does not maintain
functionality ............................................................................................ 118

Figure 6.1

Incubation for 12 hr with amyloid-β25-35 does not potentiate
intracellular calcium responses to focal ischemia, acidosis or
ischemia + acidosis application.............................................................. 130

Figure 6.2

24 hr incubation with amyloid-β25-35 significantly potentiates the
intracellular calcium responses to ischemia, acidosis and
ischemia + acidosis application.............................................................. 131

Figure 6.3

Amyloid-β fragments 25-35 and 1-42 potentiate ischemia +
acidosis induce [Ca2+]i increases ........................................................... 132

Figure 6.4

Oligomerized amyloid-β25-35 fails to potentiate ischemia +
acidosis evoked increases in [Ca2+]i following a 1 hr incubation ............ 133

Figure 6.5

Afobazole inhibits increases in [Ca2+]i evoked by ischemia +
acidosis application following 24hr Aβ25-35 incubation ............................ 135

Figure 6.6

Amyloid-β25-35 incubation potentiates proton-evoked currents in
cortical neurons.......................................................................................... 136

Figure 6.7

Aβ potentiated calcium influx involves reversal of the sodium/
calcium exchanger ................................................................................. 137

Figure 6.8

Amyloid-β25-35 potentiation of [Ca2+]i increases evoked by
ischemia + acidosis is not dependent of the sodium/calcium
potassium-dependent exchanger (NCKX) ............................................. 139
vii

Figure 6.9

Amyloid-β25-35 potentiation of the net [Ca2+]i increases evoked
by ischemia + acidosis may involve intracellular protons ....................... 140

viii

ABSTRACT

Stroke is the fifth leading cause of death in the United States and a major cause
of long-term disability in industrialized countries. The core region of an ischemic stroke
dies within minutes due to activation of necrotic pathways. Outside of this core region is
the penumbral zone, where some perfusion is maintained via collateral arteries. Delayed
cell death occurs in this area due to the triggering of apoptotic mechanisms, which
expands the ischemic injury over time. The cellular and molecular events that produce
the expansion of the ischemic core continue to be poorly understood. The increases in
the amyloid precursor protein and pathogenic secretases lead to the increase in amyloidβ (Aβ) production. The relatively small amount of research in this area has hampered
development of stroke therapy designed to prevent neuronal and glial cell degeneration
in the penumbra. Currently, there is a significant lack of therapeutic options for acute
ischemic stroke, and no drug has been approved for treating patients at delayed time
points (≥ 4.5 hr post-stroke).
Afobazole, an anxiolytic currently used clinically in Russia, has been shown to
reduce neuronal and glial cell injury in vitro following ischemia, both of which have been
shown to play important roles following an ischemic stroke. Treatment with afobazole
decreased microglial activation in response to ATP and Aβ, as indicated by reduced
membrane ruffling and cell migration. Prolonged exposure of microglia to ischemia or Aβ
conditions resulted in glial cell death that was associated with increased expression of
ix

the pro-apoptotic protein, Bax, the death protease, caspase-3 and a reduced expression
in Bcl-2. Co-application of afobazole decreased the number of cells expressing both Bax
and caspase-3, while increasing the cells expressing Bcl-2 resulting in a concomitant
enhancement in cell survival. While afobazole inhibited activation of microglia cells by
Aβ25-35, it preserved normal functional responses in these cells following exposure to the
amyloid peptide. Intracellular calcium increases induced by ATP were depressed in
microglia after 24 hr exposure to Aβ25-35. However, co-incubation with afobazole returned
these responses to near control levels. Therefore, stimulation of σ-1 and σ-2 receptors
by afobazole prevents Aβ25-35 activation of microglia and inhibits Aβ25-35-associated
cytotoxicity.
Examining the molecular mechanisms involved in the increased neuronal survival
demonstrates that ischemia or Aβ results in an increased expression of the pro-apoptotic
protein Bax and the death protease caspase-3, while at the same time decreasing
expression of the anti-apoptotic protein, Bcl-2. However, unlike observations made with
microglia, afobazole was unable to modulate this ischemia-induced expression, but was
able to modulate Aβ-induced expression of apoptotic proteins while still rescuing
neurons from death. Additional experiments were carried out to understand this disparity
between the failures of afobazole to prevent the up-regulation of pro-apoptotic genes
while retaining the ability to mitigate neuronal death. Although the neurons were still alive
they were in a senescent state and were unresponsive to depolarization by high K+.
However, these findings are still positive due to the ability of afobazole to delay neuron
death, thus minimalizing the toxic environment of the penumbra.

x

These comorbidities of ischemia and Aβ toxicity may lead to potentiated
responses and increase the risk for various vascular dementias. It was of particular
interest to study how the convergence of ischemia, acidosis and Aβ influence cellular
activity and survival within core and penumbral regions. Application of Aβ increased the
[Ca2+]i overload produced by concurrent ischemia + acidosis application in isolated
cortical neurons. We found that the acid-sensing ion channels 1a (ASIC1a) are involved
in the potentiation of [Ca2+]i overload induced by Aβ. Furthermore, afobazole (100 µM)
abolished Aβ potentiation of ischemia + acidosis evoked [Ca2+]i overload, which may
represent a therapeutic strategy for mitigating injury produced by Aβ and stroke.

xi

CHAPTER 1

Introduction

Significance
Ischemic stroke often overlaps with diseases involving Aβ, such as Alzheimer’s
disease (AD) and cerebral amyloid angiopathy. These comorbidities can lead to
potentiated responses that ultimately result in vascular dementia (Wilcock et al., 2009,
Nelson et al., 2013, Sudduth et al., 2014). The mechanisms contributing to this
potentiation remain poorly understood. One key player in the pathobiology both of stroke
and Aβ toxicity is the dysregulation of [Ca2+]i homeostasis (Cuevas et al., 2011a, Cuevas
et al., 2011b, Behensky et al., 2013a, b). Previous studies have suggested that a link
may exist between cerebral ischemia and AD (Koistinaho and Koistinaho, 2005, Pluta et
al., 2013) due to the increased Aβ expression following an ischemic stroke (Selkoe,
2001, Shiota et al., 2013). The Aβ fragment, Aβ25-35, which has been found in AD brains,
has been proposed as a contributor to the pathogenesis of AD (Kaminsky et al., 2010).
This Aβ fragment has been shown to induce injury via various mechanisms including
production of reactive oxygen species (ROS) (Schubert et al., 1995), dysregulation in
intracellular Ca2+ (Joseph and Han, 1992), enhanced NMDA channel activity (Molnar et
al., 2004), and increased activation of caspase-3 (Marin et al., 2000). In addition, Aβ has
been shown to initiate a sequence of events in microglia, including a pro-inflammatory
1

cascade and enhanced hemichannel formation, which ultimately results in neuronal and
glial cell death (Orellana et al., 2011). Aβ toxicity is therefore of particular interest in
lacunar stroke, where following a micro infarct, Aβ production increases thereby
disrupting both the microvascular and the intracellular calcium levels in the neighboring
neurons. This resulting Aβ toxicity may promote future infarcts with potentiated injury.
Studies have shown that in mice with increased amyloid precursor protein expression,
there is an increased risk of ischemic stroke, but as of yet there are no studies that can
elucidate the molecular mechanisms by which this injury occurs (Zhang et al., 1997).

Background
Stroke is the second leading cause of death globally and continues to be a major
cause of serious long-term disability (Go et al., 2013). In 2013 the reported annual cost
associated of this disease in the United States was approximately $35 billion. This
economic strain has driven the search for potential treatments to alleviate the debilitating
effects of this disease. Stroke is the sudden loss or interruption of blood circulation to the
brain. There are two types of stroke. Hemorrhagic stroke, where a blood vessel ruptures
and bleeds into the brain. Although hemorrhagic only accounts for a small percentage of
all strokes the survival rate for these patients is low with 60% dying within the first year
following the insult. An ischemic stroke in the most common type of stroke accounting for
about 87% and occurs when blood flow to the brain is interrupted. The clot can occur
locally by a thrombus or from an embolus forming elsewhere in the body and migrating
into the brain. For the present study, when referring to a stroke we are denoting an
ischemic stroke. The central region affected by the ischemic insult, or the core, is an
2

area with little to no blood perfusion and dies within minutes of stroke onset via necrosis.
Outside of this core region is the penumbral zone, where some perfusion is maintained
by collateral arteries. In this area, delayed cell death occurs due to the triggering of
apoptotic mechanisms, and over the course of hours to days the size of the lesion
expands. The cellular and molecular events that produce the expansion of the ischemic
core continue to be poorly understood, which has hampered development of stroke
therapies designed to prevent neuronal and glial cell degeneration in the penumbra. In
addition to large vessel ischemic strokes there are also small vessel ischemic strokes.
Known as lacunar infarcts, these strokes account for approximately 25% of all ischemic
insults (Samuelsson et al., 1996). They result from the blockage of small penetrating
arteries to the subcortical regions of the brain (Kang et al., 2012). While the injury from
these strokes were once thought to be negligible, lacunar infarcts can and do result in
death and long-term disability. This type infarct is a leading cause of cognitive
impairment and vascular dementia (Charidimou and Werring, 2012). While the risk
factors resulting in lacunar verse large artery infarcts differ, the resulting cellular cascade
promoting cerebral cell death most likely have overlapping mechanisms.
Treatments have been explored to provide neuroprotection in an effort to mitigate
neuronal injury following ischemic stroke. One main area of research had been to inhibit
N-methyl-D-aspartate (NMDA) and (±)-α-Amino-3-hydroxy-5-methylisoxazole-4-propionic
acid (AMPA) receptors. While some in vitro studies were promising, the in vivo results
were less assuring. One such drug was Selfotel, a synthetic NMDA antagonist, which
showed significant improvements in an animal model of transient focal ischemia
(Finnegan et al., 1993). However, Selfotel needed to be administered 1hr prior to the
3

ischemic insult for best results, and showed no benefit if treatment was started >60 min
post stroke (Smith et al., 2008). Furthermore, clinical trials were terminated early due to
adverse effects (Kurokawa et al., 2011a). One potential reason for the failures of
neuroprotective drugs that target a single ion channel is the fact that ischemic stroke is a
complex syndrome acting on a multitude of ion channels and receptors. Furthermore,
recent studies have shown that microglia, part of the immune/inflammatory response,
migrate to the site of insult, become over-activated and contribute to the stroke injury
(Eichhoff et al., 2011).
The only treatment currently approved by the FDA for ischemic stroke is
recombinant tissue plasminogen activator (tPA), a thrombolytic agent used to restore
blood-flow interrupted by a blood clot (Weintraub, 2006). However, tPA therapy is time
sensitive, and the drug must be administered < 4.5 hours post-infarct. In addition, aging
patients presenting various comorbidities lead to an increase in tPA’s risk to benefit ratio,
resulting in less than 4% of patients being able to use it (Armstead et al., 2010). The goal
of future therapies would be to treat these patients at 24 to 48 hrs follow the insult.
However, for this to be accomplished the mechanisms of stroke must be further
elucidated.

Pathobiology of Ischemic Stroke
To better understand neurodegeneration following an ischemic stroke, it is
important to study the mechanisms underlying stroke. Figure 1.1 shows a simplified
overview of the biochemical events that are involved in ischemic stroke. Following an
ischemic insult, the core rapidly depletes its energy stores due to decreased blood flow.
4

Figure 1.1
Pathoneurobiology of Ischemic Stroke. Intracellular calcium plays an important role in the
events during ischemia. Ischemia leads to acidosis in the core and penumbra regions,
which contributes to further calcium dysregulation. Calcium toxicity results in the
activation these secondary events that result in apoptosis and subsequent expansion of
the core.
The susceptibility of neurons to ischemia is in part due to their high consumption of
oxygen and glucose. Penumbra cell death is delayed in part due to blood flow from
collateral arteries supplying minimal oxygen and glucose. This reduced supply, however,
is not enough to maintain normal cellular respiration and neurons are forced to switch
from oxidative metabolism to anaerobic glycolysis. This provides neurons with some
energy in the hopes that blood flow will be restored. However, lactate builds up within the
5

cells reducing the surrounding pH (Munoz Maniega et al., 2008). This drop in tissue pH,
along with synaptic proton release triggered in neurons by ischemia, activates the acid
sensing ion channel 1a (ASIC1a) (Xiong et al., 2004, Mari et al., 2010). ASIC1a is
permeable to both Na+ and Ca2+ (Xiong et al., 2004) and following activation contributes
to the intracellular Na+ loading and [Ca2+]i dysregulation seen following an ischemic
stroke. This convergence of ischemia and acidosis has been shown to potentiate [Ca2+]i
dyshomeostasis (Mari et al., 2010).
Despite neuronal attempts to generate ATP, the reduction in cerebral blood flow
causes a massive energy shortage. Energy depletion triggers cell depolarization due to
the failure of Na+/K+ ATPase (Besancon et al., 2008) and results in cations, Na+ and
Ca2+, rushing into the cell. The increasing presence of calcium triggers the release of
glutamate from the extracellular stores, which then over-activate NMDA and AMPA
receptors (Mark et al., 2001, Lipton, 2004, Muir, 2006), thus resulting in wide spread
intracellular ionic imbalances. In addition, because the Na+/K+ ATPase cannot function
there is a buildup of intracellular sodium ([Na+]i) and extracellular potassium ([K+]o). The
increase in [K+]o triggers neighboring neurons to depolarize. Whereas, sodium loading
leads to edema and results in the reversal of the Na+/Ca2+ and Na+/Ca2+ K+-dependent
exchangers, which contribute to [Ca2+]i dysfunction (Kiedrowski, 2007). This calcium
overload triggers reactive oxygen species (ROS) and nitrite oxide (NO) production, which
in turn breakdown proteins, lipids and nucleic acids (Mattson, 2000, Camello-Almaraz et
al., 2006). Additionally, the buildup of [Ca2+]i triggers the activation of secondary events
including the release of cytochrome c from the mitochondria initiating the expression of
pro-apoptotic genes and the release of pro-inflammatory mediators (Figure 1.1). This in
6

turn triggers the activation of microglia and reactive astrocytes, which are then capable
of exacerbating neuronal injury and expanding the ischemic core (Takano et al., 2009).
Moreover, despite studies which have shown that following an ischemic stroke there is
an increase the expression of amyloid precursor protein (APP) and both β and γ
secretase, which lead to increased Aβ production, there have been little to no studies
addressing the neuronal and glial injury induced by Aβ following ischemia (Popa-Wagner
et al., 1998, Guglielmotto et al., 2009, Pluta et al., 2013).

Amyloid-β
Amyloid-β (Aβ) is a peptide found in many diseases and is best known with
contributing to Alzheimer’s disease. Aβ is formed following cleavage of the amyloid
precursor protein (APP) by secretases. It was once believed that cleavage of APP would
enter one of two pathways which would either result in a physiological (secretases α and
γ) or pathological (secretases β and γ) peptide (Zhang et al., 2011). However, we now
know this to be incorrect and that both pathways produce physiologic and pathologic
peptides. The functions of Aβ have been largely debated to have no physiological
endogenous function, only pathological. However, in recent years low picomolar (pM)
concentrations of Aβ has been shown to promote platelet aggregation and be essential
to synaptic plasticity, memory formation and fear conditioning (Shen et al., 2008,
Lawrence et al., 2014). It is only when concentrations of Aβ elevate ≥ 200 pM that it
becomes toxic (Puzzo and Arancio, 2013). It was previously thought that amyloid
precursor protein was acting as a signaling molecule rather than Aβ to promote synaptic
plasticity (Octave et al., 2013). However, studies by (Puzzo and Arancio, 2013) revealed
7

that siRNA against APP could impaired synaptic plasticity, which was rescued with
concurrent Aβ1-42 application. While there have been studies for (Nagele et al., 2002)
and against (Small et al., 2007) Aβ binding to α-7 nicotinic acetylcholine receptors
(α7nAChRs), it was only recently that studies from (Lawrence et al., 2014) showed that
Aβ (pM) worked as an agonist on presynaptic α7nAChRs to enhance long-term
potentiation (LTP). The controversy as to whether Aβ functions as agonist or antagonist
is dependent on which fragment is binding. Aβ1-40 has been shown to inhibit
glutamatergic transmitter release via the antagonism of α7nAChRs (Nery et al., 2013, Ju
et al., 2014, Salamone et al., 2014), whereas, the fragments 1-42 and 25-35 both bind to
α7nAChRs and enhance their synaptic transmission (Talantova et al., 2013, Lee et al.,
2014).
Amyloid-β accumulation is more commonly associated with diseases such as
Alzheimer’s (AD) and cerebral amyloid angiopathy. However, an ischemic insult has
been shown to increase APP mRNA by >200% (Pluta et al., 2009). It been suggested
that this increase in APP might be protective following an insult (Koike et al., 2012).
However, the additional up-regulation of the β and γ secretases lead to increased
cleavage of APP and the deposition of Aβ in the penumbral zone (Guglielmotto et al.,
2009, Pluta et al., 2013). These depositions were found to be significantly higher on day
4 following the ischemic episode with peak tissue levels at day 7 (Stephenson et al.,
1992, Jablonski et al., 2011). Aβ levels remained significantly high when checked during
a one year follow up, which has been postulated as a potential risk factor for developing
AD (Jablonski et al., 2011). In addition to an increase Aβ, there is also an increase in the
hyperphosphorylation of tau following a stroke, which is known to contribute to AD (Wen
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et al., 2004). There is some evidence that a stroke or other cerebrovascular disease
liken the chances of developing AD. It was found during the autopsies of AD patients that
approximately 40% had some form of cerebrovascular incident prior to developing AD.
With studies showing the increase in Aβ, many view Aβ as a potential target in the
prevention of AD. However, there are virtually no studies looking at the injury Aβ incurs
directly following a stroke. There are more than a few overlapping mechanisms between
ischemia and Aβ induced toxicity. Aβ has been shown to disrupt ionic homeostasis
through several pathways, which involve Aβ having a direct and indirect action on
neuronal and glial cells. Aβ can cause the release of astrocytic and microglial glutamate
that activates neuronal AMPA, NMDA or metabotropic glutamate receptors, as well as,
being able to directly bind to neuronal NMDA receptors, whereby increasing the influx of
Na+ and Ca2+ ions (Alberdi et al., 2010, Texido et al., 2011, Talantova et al., 2013). This
influx of Na+ and Ca2+ leads to an increase in Ca2+ dyshomeostasis, triggering
mitochondrial dysfunction and initiating apoptosis (Cha et al., 2012, Oseki et al., 2014,
Ferreira et al., 2015). As previously mentioned, the dysregulation of [Ca2+]i leads to
secondary responses including activation of reactive astrocytes and microglia (Figure
1.1).

Microglia
Microglia are the resident macrophages of the brain, and constitute nearly 10% of
the total cell population of this organ. The function of these cells in normal and
pathological conditions has been an area of significant research, and considerable
controversy surrounds the role of these cells in diseases of the CNS. It has been shown
9

that microglia transform from a resting to an activated state in response to various
stimuli, such as neuronal injury, release of ATP, or pathogen infiltration (Melani et al.,
2005, Hanisch and Kettenmann, 2007). Upon stimulation, these cells migrate to the site
of injury, phagocytose debris and release pro-inflammatory compounds (Hanisch and
Kettenmann, 2007). Such a microglial response has been reported to occur as a result of
a cerebral ischemic insult, following which microglia are attracted to the site of injury and
proliferate (Weinstein et al., 2010). In addition, microglial cells have been shown to be
attracted to, and are required for, the clearance of Aβ (Wilcock et al., 2004, Morgan,
2009). Once phagocytosed, Aβ is degraded by the endothelin-converting enzymes in the
endosomal/ lysosomal pathway (Pacheco-Quinto and Eckman, 2013).
Since it has been shown that Aβ concentrations increase following an ischemic
insult it has been suggested that these microglia then contribute to the
neuroinflammatory response that results in the demise of neurons (Rogove et al., 2002,
Streit et al., 2004, Dheen et al., 2007). It is plausible that in brains with abnormally high
concentrations of Aβ, the inflammatory injury normally caused by microglial migration
following ischemia increases. This dual insult of ischemia and Aβ results in the overactivation of microglial cells and maintaining prolonged microglia activation leads to cell
death or senescence. The loss of functional microglia to clear the accumulation Aβ may
lead to various vasculature dementias including cerebral amyloid angiopathy and AD. As
of yet, there have been no successful therapies in the treatment of stroke or AD. These
failures are compounded by not addressing the multiple receptor and/or pathways to
injury, in addition to not accounting for the interactions between multiple cell types. One

10

potential target for the treatment of stroke are the sigma receptors, which have been
shown to interact with multiple receptors, pathways and cell types.

Sigma Receptors
Sigma (σ) receptors were first identified by(Martin et al., 1976) and classified as
an opioid receptor following the binding actions observed with racemic benzomorphans.
However, it was later discovered that only the (+) enantiomer of benzomorphans bound
to σ receptors, which was found to be inaccessible to naloxone placing them in their
current class of “opioid-like receptors” (Walker et al., 1990). σ receptors have been
shown to bind to a wide variety of substances including antipsychotics, opiates and
antidepressants to name a few. Studies by (Hellewell and Bowen, 1990) showed a
decreased affinity for (+)-benzomorphans in PC12 cells suggesting a second σ subtype.
Thus far there have been two σ receptor subtypes identified pharmacologically, termed
σ-1 and σ-2. Receptors that bind (+)-benzomorphans with high affinity are classified as
σ-1receptors. Whereas, those that have a high affinity for ibogaine are labeled σ-2
receptors (Bowen, 2000, Vilner and Bowen, 2000). Moreover, some drugs have been
shown to be pan-selective for both sigma receptors. This includes the pan-agonist 1,3-dio-tolyguanidine, the pan-antagonist metaphit and the σ-1 antagonist and σ-2 agonist
haloperidol.
Thus far, only the σ-1 receptor has been cloned. Consisting of 223 amino acids,
this receptor shows no homology with any other mammalian protein (Seth et al., 1998,
Mei and Pasternak, 2001). Predictions from the early studies of the amino acid sequence
suggested two different but possible transmembrane configurations. The first was a
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single transmembrane domain with an extracellular N-terminus and intracellular Cterminus. Whereas, the second possibility retain the N- and C-termini intracellularly with
two transmembrane spanning domains (Guitart et al., 2004), with more recent studies
favoring the latter (Pal et al., 2007). Moreover, these studies predict that σ-1 receptors
have two intracellular drug binding domains. In depth pharmacological studies by
(Glennon, 2005) describe the σ-1 receptor binding site as a figure eight configuration
with a central amine moiety flanked by two hydrophobic regions, one of which consisting
an aromatic ring. These studies were reaffirmed with the discovery of the σ receptors
endogenous ligand N,N-dimethyltryptamine (DMT) (Fontanilla et al., 2009). Furthermore,
σ-1 receptors were shown to have a DMT concentration dependent action, which at low
concentrations of DMT, σ-1 receptors would act as a chaperone between the rough
endoplasmic reticulum (ER) and the mitochondria at the mitochondrion-associated ER
membrane (MAM) to regulate intra-mitochondrial calcium concentrations. However, at
high DMT concentrations, σ-1 receptors would migrate to the plasma membrane or
subplasmalemmal ER to regulate various channels and receptors (Su et al., 2009, Tsai
et al., 2009, Su et al., 2010). This makes σ-1 receptors highly attractive as a therapeutic
target for numerous neurological diseases.
Despite years of study, the identity of σ-2 receptors is still unknown. There have
been studies in recent years suggesting the σ-2 receptors might be either a histone
binding protein (Colabufo et al., 2006, Abate et al., 2010) or the progesterone receptor
membrane component-1 (PGRMC-1) (Xu et al., 2011, Abate et al., 2015). However, the
molecular identity of σ-2 receptors has not been unequivocally established. In studies
using human SK-N-SH neuroblastoma cells there is evidence to support that σ-2
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receptors also localize with the ER, mitochondria, lysosomes and plasma membrane
(Vilner and Bowen, 2000, Zeng et al., 2007, Cassano et al., 2009). It has been
suggested that σ-2 receptors may be a splice variant of the σ-1 receptor (Monassier and
Bousquet, 2002). However, this hypothesis was refuted by the finding that σ-1 receptor
knockout mice still retained σ-2 receptor function (Langa et al., 2003).
The distribution of σ receptor in the mammalian body is quite ubiquitous being
expressed in the central nervous, liver, kidney, immune and cardiac cells (Dumont and
Lemaire, 1991, Wolfe and De Souza, 1993, Hellewell et al., 1994). Not much is known
about the functions of σ-2 receptors. However, what is known about their function varies
greatly depending on the cell type. In cancer cells, activation of σ-2 receptors causes the
toxic release of calcium from ER stores leading to apoptosis (Vilner and Bowen, 2000,
Cassano et al., 2009). Whereas, in immune cells σ-2 receptors are protective by
mitigating the activation and migration of microglia and T lymphocytes. Additional, σ-2
receptors have been shown to inhibit high-voltage-activated calcium channels in
intracardiac neurons (Zhang and Cuevas, 2002, Hall et al., 2009a, Iniguez et al., 2013).
In contrast to σ-2, σ-1 receptors have been identified as having extensive physiological
and pathophysiological functions. They are known to promote learning, memory and
synaptic plasticity in normal and in experimental stroke models (Ruscher et al., 2011,
Kourrich et al., 2012). Moreover, σ-1 receptors maintain intracellular ionic homeostasis
through regulation of 1,4,5-triphosphate (IP3) and ryanodine receptors at the
endoplasmic reticulum, as well as calcium signaling and the influx of Na+ and Ca2+
through voltage-gated, ionotropic and metabotropic receptors (Hayashi et al., 2000, Su
and Hayashi, 2003, Tchedre et al., 2008, Mueller et al., 2013).
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There are numerous studies showing the cytoprotective ability of σ-1 receptors,
both in neurons and glial cells. σ-1 receptors have been shown to regulate intracellular
calcium increases following in vitro models of ischemia, acidosis and ischemia-acidosis
(Katnik et al., 2006, Herrera et al., 2008, Mari et al., 2014). In addition, σ-1 receptor
activation reduces oxidative and nitrosative stresses, while inhibiting apoptosis (Tchedre
and Yorio, 2008, Meunier and Hayashi, 2010, Pal et al., 2012). Following the in vivo
middle cerebral artery occlusion (MCAO) stroke model σ receptor activation was able to
reduce the injury of both white and grey matter when the agonist was administered 24
hours after the insult (Ajmo et al., 2006, Leonardo et al., 2010). Lastly, σ receptor
activation has been shown to be neuroprotective against Aβ-induced toxicity (Marrazzo
et al., 2005, Behensky et al., 2013a, b), which as previously mentioned is up-regulated
following an ischemic stroke. Therefore, σ receptor agonists offer great potential for the
treatment of ischemic stroke and related Aβ toxicity. One such pan-selective σ receptor
agonist which has shown promise is afobazole.

Afobazole
Afobazole (5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole), is a drug
currently used in Russia to treat anxiety and has shown the potential to be
neuroprotective in both in vitro and in vivo models (Galaeva et al., 2005, Zenina et al.,
2005, Seredenin et al., 2008). In vitro and in vivo studies have shown that afobazole can
decrease neuronal death caused by oxidative stress and glutamate excitotoxicity and
increase survival rates, while decreasing neurological deficits in rats suffering from a
post-traumatic hematoma, respectively (Galaeva et al., 2005, Zenina et al., 2005).
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Similarly, afobazole was shown to be neuroprotective in rats after bilateral local
photothrombosis of vessels in the prefrontal cortex and after global transient ischemia
(Seredenin et al., 2008, Baykova et al., 2011). Previous work in our laboratory has
shown that afobazole can reduce ischemic injury following a stroke. These studies
showed that afobazole affects cellular responses to ischemia via the stimulation of σ
receptors (Cuevas et al., 2011a, Cuevas et al., 2011b). Activation of σ-1 receptors by
afobazole blocks intracellular calcium overload produced by ischemia and acidosis and
reduces neuronal death after in vitro ischemia (Cuevas et al., 2011a). This activation of
σ-1 receptors results in the block of multiple ion channels that are functionally
upregulated following ischemia and acidosis, including the acid-sensing ion channel 1a
(ASIC1a) (Cuevas et al., 2011a). In microglia, activation of both σ-1 and σ-2 receptors by
afobazole reduces membrane ruffling and migration of these cells in response to ATP
(Cuevas et al., 2011b). Moreover, afobazole prevents microglial cell death following
ischemia, even when the drug was applied after the ischemic insult (Cuevas et al.,
2011b). Lastly, in vivo studies using the middle cerebral artery occlusion (MCAO) stroke
model showed that afobazole through σ receptor activation was able to reduce the total
stroke injury, which resulted in and increased survival of both neuronal and glial cells
even when administered 24-48 hrs post infarct (Katnik et al., 2014). The protection
conveyed by afobazole translated to an increase in the animal’s behavior and cognition.
Therefore, studies suggest that afobazole, acting on σ receptors, can decrease ischemic
brain injury as well as improving functional outcomes. This makes afobazole an attractive
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drug, not only for the treatment of ischemic stroke but also for the treatment of Aβinduced toxicity, which may contribute to secondary infarcts.

16

CHAPTER 2

In Vitro Evaluation of Guanidine Analogues as Sigma Receptor
Ligands for Potential Anti-Stroke Therapeutics

Introduction
Treatments that provide neuroprotection have been explored in an effort to
mitigate neuronal injury following ischemic stroke. The main area of research has been
inhibition of N-methyl-D-aspartate (NMDA) and (±)-α-Amino-3-hydroxy-5methylisoxazole-4-propionic acid (AMPA) receptors. While some in vitro studies were
promising, the in vivo results were less assuring. For example, Selfotel, a synthetic
NMDA antagonist, showed significant improvements in an animal model of transient
focal ischemia (Finnegan et al., 1993). However, Selfotel needed to be administered 1hr
prior to the ischemic insult for best results, and showed no benefit if treatment was
started >60 min post stroke (Smith et al., 2008). Furthermore, clinical trials were
terminated early due to adverse effects (Kurokawa et al., 2011a).
One reason for the failure of neuroprotective drugs that target a single ion channel
is the fact that ischemic stroke is a complex syndrome. For example, after an ischemic
insult, neurons switch from oxidative metabolism to anaerobic glycolysis, leading to the

Reprinted with permission of the American Society for Pharmacology and Experimental Therapeutics.
Copyright © 2013 by the American Society for Pharmacology and Experimental Therapeutics

17

buildup of lactate within the cells and a reduction in tissue pH (Munoz Maniega et al.,
2008).
This drop in tissue pH, along with synaptic proton release triggered in neurons by
ischemia, activates the acid sensing ion channel 1a (ASIC1a) (Xiong et al., 2004, Mari et
al., 2010). These channels contribute directly and indirectly to [Ca2+]i dysregulation in
neurons during ischemia (Herrera et al., 2008), and are responsible for significant NMDA
channel-independent brain injury following an stroke (Xiong et al., 2004). In addition,
activated microglia migrate to the site of insult and are part of the immune/inflammatory
response that significantly contributes to stroke injury (Eichhoff et al., 2011).
Sigma (σ) receptors have been shown to be widely expressed in mammalian
brain tissue (Cobos et al., 2008) and perform a number of functions, including regulation
of plasma membrane ion channels and expression of anti-apoptotic transcription factors
(Zhang and Cuevas, 2002, 2005, Meunier and Hayashi, 2009, Kurokawa et al., 2011b).
Activation of σ receptors was shown to regulate multiple Ca2+ influx pathways known to
be functionally upregulated during stroke, including ASIC1a (Katnik et al., 2006, Mari et
al., 2010). In light of these findings and other reports in the literature, there has been
much interest in exploring σ receptors as neuroprotective mediators during an ischemic
stroke. One of the most exciting discoveries relating to σ receptors in stroke therapeutics
is the potential of these receptors as viable targets for stroke therapy at delayed time
points. Our group showed that activation of σ receptors using o-DTG reduced neuronal
injury in an animal model of ischemic stroke even when the drug was administered 24 hr
post-stroke (Ajmo et al., 2006).
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o-DTG is a pan-selective agonist of σ receptors, binding to both σ-1 and σ-2
receptors at nanomolar concentrations, interacting with the σ-1 receptor via an amine
moiety on the guanidine core (Glennon, 2005). From this parent molecule, novel
compounds were designed and synthesized with the objective of developing σ ligands
that inhibit increases in [Ca2+]i with higher potency during in vitro experiments.
Experiments were conducted to compare the capacity of DTG analogues to affect three
important contributors to the demise of brain cells following ischemic stroke: intracellular
Ca2+ dysregulation produced in neurons by 1) acidosis and 2) ischemia, and 3) activation
and migration of microglial cells. While previous studies using guanidine substitutions
were made in an attempt to characterize the structure-affinity relationships (Reddy et al.,
1994, Schetz et al., 2007) our focus was to identify what affects steric hindrance,
electrostatic interactions, or increased lipid permeability had on the structure-activity
relationship in mitigating increases in [Ca2+]i. p-BrDPhG showed the greatest block in
inhibiting increase in [Ca2+]i evoked via ischemia or acidosis and in mitigating activation
and migration of microglial cells.

Materials and Methods

Preparation of Cortical Neurons
All experiments were carried out on cultured cortical neurons from mixed sex
embryonic day 18 (E18) Sprague-Dawley rats (Harlan, Indianapolis, IN). Methods used
here were identical to those previously reported for the isolation and culturing of these
cells (Katnik et al., 2006). Cortical neurons were used between 10-21 days in culture,
which permits synaptic contact formation and yields the most robust responses to
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ischemia and acidosis. Animals were cared for in accordance with the regulations and
guidelines set forth by the University of South Florida’s College of Medicine Institution on
Animal Care and Use Committee.

Calcium Imaging
Intracellular Ca2+ concentration was measured in isolated cortical neurons using
ratiometric fluorometry as previously described (Katnik et al., 2006). Cells plated on polyL-lysine coated coverslips were incubated at room temperature for 1 hr in B27
supplemented Neurobasal medium (Invitrogen) containing 3 µg/ml of the
acetoxymethylester form of fura-2 (fura-2 AM) in 0.3% DMSO. Prior to beginning the
experiments, the coverslips were rinsed with physiological saline solution (PSS). For
experiments in which cells were exposed to in vitro ischemia, the control PSS (PSS-1)
consisted of (in mM): 140 NaCl, 3 KCl, 10 HEPES, 7.8 glucose, 2.5 CaCl2, and 1.2
MgCl2 (pH to 7.2 with NaOH). The control PSS (PSS-2) for acidosis experiments
contained (in mM): 140 NaCl, 4.5 KCl, 25 HEPES, 20 glucose, 1.3 CaCl2, and 1.0 MgCl2
(pH to 7.4 with NaOH).
PSS was used as the control solution in all experiments. Solutions were delivered
onto the cells via a rapid application system identical to that described previously
(Cuevas and Berg, 1998). In vitro ischemia was achieved using glucose-free PSS-1
containing 4 mM sodium azide (NaN3) (Katnik et al., 2006) and acidosis was evoked via
application of PSS-2 with a pH of 6.0 (Herrera et al., 2008). Cells were only exposed to
three or fewer episodes of ischemia or acidosis separated by 10 min wash to prevent
rundown of cellular responses. For both ischemia and acidosis experiments, control
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recordings were made prior to application of σ ligands. In experiments using the σ-1
inhibitor, BD-1063, a second control recording was made in the presence of the inhibitor
prior to application of p-BrDPhG. All test compounds were applied in PSS for 10 min
prior to ischemia or acidosis onset, and throughout the ischemic or acidic insult.

In Vitro Competition Binding Assays
Rat liver P2 membrane (~350 µg protein) was used for all σ binding assays.
Membrane homogenates were incubated for 120 min in 50 mM Tris-HCl buffer, pH 8.0,
with radioligand and various concentrations of test ligand in a total volume of 500 µl, at
25⁰C, in 96-well Unifilter GF/B filter plates (Perkin Elmer 50-905-1601). σ-1 receptors
were labeled with 5 nM [3H](+)-pentazocine, and σ-2 receptors were labeled with 3 nM
[3H]o-DTG in the presence of 300 nM (+)-pentazocine to block σ-1 receptors. Ten
concentrations of each test ligand (0.001-10,000 nM) were run in triplicate. Nonspecific
binding was determined in the presence of 50 µM haloperidol, with filters pre-soaked in
polyethyleneimine for 45 min. Following incubation and subsequent equilibrium, the
samples were harvested, washed three times, and the bound radioactivity was counted.
Data from the competition binding studies were analyzed using GraphPad Prism (San
Diego, CA) and nonlinear regression to determine the concentration of test ligand that
inhibits 50% of the specific binding of the radioligand (IC50 value). Ki values were
calculated using the Cheng-Prusoff equation.

Primary Cultures of Microglia
Primary cultures of microglia were prepared from Sprague-Dawley mixed sex rat
pups (post-natal day 2-3) as previously described by our laboratory (Hall et al., 2009a,
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Cuevas et al., 2011b). The mixed glial cultures were incubated for 7-12 days at 37 o C
prior to experiments being carried out. Microglia were mechanically separated from the
cultures by brief shaking. Isolated microglia were resuspended in DMEM PLUS
containing: 500 mL Dulbecco’s Modified Eagle Medium with 4.5 g/L glucose, L-glutamine
and sodium pyruvate (DMEM) (Corning Cellgro, Manassas, VA), 40 mL horse serum
(Corning Cellgro), 12.5 mL heat-inactivated fetal bovine serum (Thermo Scientific
Hyclone, Logan, UT ), and 5 mL 10x antibiotic/antimycotic (Corning Cellgro). These cells
were used immediately for migration and cytotoxicity assays or plated on glass
coverslips for one day for imaging experiments.

Microglial Migration
The migration assays were carried out using a 48-well microchemotaxis chamber
(Neuro Probe, Inc., Gaithersburg, MD) as described previously (Cuevas et al., 2011b).
The bottom wells of the chamber were filled with DMEM containing the chemoattractant,
ATP (100 µM), and 0.1% DMSO. In the upper chamber, 1x106 freshly isolated microglia
were applied in DMEM. The test compounds, p-BrDPhG (30 µM) and o-DTG (30 µM),
were applied both with the ATP and the microglia in the appropriate wells. These
chambers were separated by a polycarbonate membrane containing 8 µm pores at a
density of 1 x 103 pores/mm2. Each well has an exposed filter area of 8 mm2. Prior to
experiments, the membrane was coated with fibronectin at 10 µg/ml in phosphate buffer
solution (PBS) for 1 hr at room temperature. The microglia were permitted to migrate for
2 hr in a CO2 incubator (5% CO2) at 37oC. The membrane was then removed and nonmigrating microglia adhering to the top of the membrane were scraped off. The
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membrane was then incubated in 4% paraformaldehyde in PBS for 15 min at room
temperature, washed 2 times in ice cold PBS, and washed once in distilled water. The
membrane was then cut to separate the wells and placed on microscope slides, bottom
of the membrane facing up. Once the membrane dried, Vectashield Hardset mounting
media containing 4'-6-diamidino-2-phenylindole (DAPI) (Vector Labs, Burlingame, CA)
was applied to the membrane and a coverslip affixed to the slide. Cells were illuminated
at 359 nm and visualized at 461 nm using a Zeiss Axioskop 2 outfitted with a 20X
objective. DAPI positive cells were identified and counted using Image-J in four random
fields/well and the average for the fields used as the value for the well. For each
experiment, a minimum of three wells were used, and the results of at least three
experiments were averaged together.

Drugs and Chemicals
The following drugs were used in this investigation: o-DTG and BD-1063 (Tocris
Biosciences, Ellisville, MO); adenosine 5′-triphosphate disodium salt hydrate (SigmaAldrich, St. Louis, MO); and fura-2 acetoxymethyl ester (Invitrogen). The DTG analogues
were synthesized in our laboratory via copper-catalyzed-cross-coupling guanidinylation
as we have previously reported (Cortes-Salva et al., 2010). The structures of the DTG
analogues synthesized were subjected to verification via 13C-, 1H-NMR and mass
spectrometry. Vehicles for drugs used were either dimethyl sulfoxide (DMSO) or ethanol
(EtOH).
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Data Analysis:
Fluorescence intensities were recorded from cortical neurons in the same manner
as previously described (Katnik et al., 2006, Herrera et al., 2008). Data were analyzed
using Sigma Plot/Sigma Stat 11(Systat Software, Inc., San Jose, CA). Data points
represent peak means ± standard error of the mean (S.E.M.). Paired and unpaired
Student’s t tests were used to determine significant differences within- and betweengroups, respectively. Results were considered statistically significant if p < 0.05. Oneand two-way analysis of variance were used for determining significant differences for
multiple group comparisons, as appropriate, followed by post hoc analysis using either a
Tukey or Dunn’s test. Mean relative inhibitions were calculated using the following

equation: Mean Relative Inhibition =

𝐶𝐶−𝑋𝑋
𝐶𝐶
𝐶𝐶−𝐷𝐷𝐷𝐷𝐷𝐷
� 𝐶𝐶 �

where C is the control response, X is the response in the presence of the test compound,
and DTG represents the response in the presence of 100 µM o-DTG. The Langmuir-Hill
equation was used to analyze concentration-response data.

Results
Experiments were conducted to determine the effects of o-DTG and derivatives
on elevations in [Ca2+]i induced in cultured cortical neurons by ischemia. Figure 2.1A
shows representative traces of [Ca2+]i as a function of time recorded from four neurons
during ischemia in the absence (Control) and presence of the indicated drugs (all at 100
µM). Similar inhibitions were observed for all of the compounds shown. Identical
experiments showed that while removal of the methyl moiety resulted in a compound
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(DPhG) that was more potent than m-DTG and p-DTG, none of these compounds were
statistically more potent than o-DTG in this assay (Figure. 2.1B).

Figure 2.1
Shifting the location of the methyl moiety produces o-DTG analogues that inhibit
ischemic-induced increases in [Ca2+]i similar to the parent compound. A, representative
traces of intracellular calcium as a function of time recorded from four neurons during
chemical ischemia in the absence (Control) and presence of the indicated compounds.
B, mean change in peak relative inhibition of [Ca2+]i (±S.E.M.) obtained in response to
ischemia for the indicated compounds all at 100 µM. Experiments preformed are
identical to those in (A) (n > 47). Dagger indicates significant difference between DPhG
and m-, p-DTG (p < 0.05).
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Recent studies have shown that activation of σ receptors inhibit acidosis-evoked
[Ca2+]i overload (Herrera et al., 2008, Cuevas et al., 2011a). Experiments were
conducted to determine whether migration or removal of the methyl moiety would alter

Figure 2.2
Removal, but not migration, of the methyl moiety increases capacity of o-DTG analogues
to inhibit acidosis-evoked elevations in [Ca2+]i. A, representative traces of [Ca2+]i as a
function of time recorded from four neurons during acidosis in the absence (Control) and
presence of the indicated drug. B, bar graph of mean change in peak relative inhibition of
acidosis-evoked [Ca2+]i (±S.E.M.) for the indicated compounds, all at 100 µM;
experiments are identical to (A). For each condition, n > 50. Asterisk denotes significant
difference between o-DTG and DPhG (p < 0.05); Dagger represents significance
between DPhG and m-DTG (p < 0.05).
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the ability of the o-DTG derivatives to inhibit acid-evoked elevations in [Ca2+]i. Figure
2.2A shows representative traces of [Ca2+]i recorded from four neurons during acidosis in
the absence (Control) and presence of the indicated DTG analogues. Data show that all
of these compounds inhibit the acid-induced elevations in [Ca2+]i. While m- and p-DTG
showed similar potency relative to o-DTG, DPhG, which lacks the methyl moiety,
produced a block statistically greater than the parent compound (p < 0.05) (Figure 2.2B)
Fluoro substitution of piperidine compounds has been shown to increase the
lipophilicity of the molecules (de Candia et al., 2009) and several piperidine derivatives
have long been used as σ receptor ligands (Nakazawa et al., 1998, Schetz et al., 2007).
Further experiments were conducted to evaluate whether methyl-to-fluoro substitution of
o-DTG would result in increased drug potency. Representative traces of [Ca2+]i as a
function of time recorded from three neurons are shown in Figure 2.3A. Cells were
exposed to ischemia in the absence (Control) and presence of fluoro substituted
guanidine analogues in the ortho, meta, and para positions. Inhibitions of [Ca2+]i
elevations were noted for all compounds. Identical experiments revealed that while these
compounds produced statistically significant inhibitions of ischemia evoked increases in
[Ca2+]i, none of the compounds were more potent than o-DTG (Figure 2.3B).
Furthermore, only p-FDPhG produced inhibition which was greater than that observed
for the compound with the methyl moiety at the same site (i.e. p-DTG). Figure 2.3C
shows representative traces of [Ca2+]i recorded from three neurons evoked by acidosis in
the absence (Control) and presence of the specified fluoro substituted analogues (all at
100 µM). In experiments identical to those previously shown, the fluoro substituted
guanidine analogues did not produce greater inhibitions relative to o-DTG or when
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Figure 2.3
Fluoro substitution does not affect o-DTG analogue inhibition of ischemia- or acidosisevoked increases in [Ca2+]i. A, representative traces [Ca2+]i as a function of time
recorded from three neurons during chemical ischemia in the absence (Control) and
presence of the indicated drug. B, mean change in peak relative inhibition of [Ca2+]i
(±S.E.M.) evoked by ischemia for the indicated compounds at 100 µM; measurements of
experiments are identical to those in (A) (n > 58). Daggers indicate significance between
o- and p-FDPhG from m-FDPhG (p < 0.05.). Pound symbol represents significant
difference from relative inhibition produced by the methyl moiety in the equivalent
position (p < 0.05). For comparison, block by the methyl compound is indicated by the
line and arrow. C, representative traces of [Ca2+]i as a function of time recorded from
three neurons during acidosis in the absence (Control) and presence of the indicated
drugs. D, bar graph of mean change in peak relative inhibition of [Ca2+]i (±S.E.M.)
obtained in response to acidosis for the indicated compounds at 100 µM (n > 67). There
is no significant difference between o-DTG and the analogues.
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compared to the compounds with a methyl moiety at the same site (i.e. m-DTG and pDTG; Figure 2.3C).
Halogen substitution is often used for enhancing permeability of a drug. It has
been shown that replacing a single hydrogen residue with a chloro moiety in compounds
with comparable size to DTG increased the hydrophobicity of a compound (Gerebtzoff et
al., 2004). Experiments were carried out to assess how methyl-to-chloro substitution of
DTG in the ortho, meta, and para positions altered the ability of the compounds to affect
[Ca2+]i increases evoked by ischemia and acidosis. Figure 4A shows representative
traces of [Ca2+]i recorded from three neurons during episodes of ischemia in the absence
(Control) and presence of the chloro substituted compounds. Inhibition of ischemiaevoked elevations in [Ca2+]i was observed for all compounds. However, only the chloro
moiety substituted at either the meta or the para position increased the potency of the
drug (Figure 2.4B). Both m- and p-ClDPhG yielded statistically significant increases in
inhibition p < 0.05 and p < 0.001, respectively, of ischemia-induced elevations in [Ca2+]i
relative to o-DTG. These compounds were also more potent than the compounds with a
methyl moiety at the equivalent position (Figure 2.4B). Figure 2.4C shows representative
traces of [Ca2+]i obtained from three neurons in response to acidosis in the absence
(Control) and presence of the indicated drugs. The pattern of inhibition of acidosisevoked elevations in [Ca2+]i produced by the chloro substituted compounds was similar
to that observed in the ischemia experiments. While the block produced by o-ClDPhG
did not show a significant difference when compared to o-DTG at the same
concentration, both m-ClDPhG and p-ClDPhG produced a statistically significant (p <
0.001) increase in the degree of block of acidosis-elicited [Ca2+]i overload that was >229

fold greater than that of o-DTG, and greater than that of the equivalent methyl
substitutions (Figure 2.4D).

Figure 2.4
Chloro substitution at the meta and para positions increase inhibition of intracellular
calcium elevations. A, representative traces of [Ca2+]i as a function of time recorded from
three neurons during ischemia in the absence (Control) and presence of the drugs
shown. B, bar graph of mean change in peak relative inhibition of [Ca2+]i (±S.E.M.)
induced by ischemia for the drugs indicated at 100 µM (n > 55). C, representative traces
of [Ca2+]i from three neurons recorded as a function of time induced by acidosis in the
absence (Control) and presence of the drugs shown. D, bar graph of mean change in
peak relative inhibition of [Ca2+]i (± S.E.M.) evoked via acidosis for the drugs indicated at
100 µM (n > 59). For both (B) and (D), asterisks indicate significant differences between
o-DTG and m- and p-ClDPhG groups (p < 0.001), daggers indicate statistical difference
from o-ClDPhG (p < 0.001), and pound symbols represent significant differences from
relative inhibition produced by the methyl moiety in the equivalent position (p < 0.001 for
all). Lines and arrows in (B) and (D) mark the block by the methyl compound at each
site, and are shown for comparison.
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Experiments were also carried out to determine if the substitution of a bromo
moiety could likewise affect the potency of the compounds. Figure 2.5A shows
representative traces of [Ca2+]i recorded from three neurons responding to ischemia in
the absence (Control) and presence of o-, m-, or p-BrDPhG, with all compounds
producing some degree of block. The attenuation of ischemia-evoked elevations in
[Ca2+]i resulting when the ortho substituted compound (o-BrDPhG) was applied was
similar to that seen with o-DTG. However, both m-BrDPhG and p-BrDPhG blocked the
[Ca2+]i overload to a greater degree with the inhibition produced by each compound
being statistically greater than o-DTG, p < 0.001. The bromo substituted compounds also
inhibited acidosis-evoked [Ca2+]i increase. Representative traces of [Ca2+]i recorded from
three neurons and demonstrating such inhibition by all of these compounds are shown in
Figure 2.5C. As with the ischemia assay, the m-BrDPhG and p-BrDPhG compounds
were significantly more potent than o-DTG at inhibiting acidosis-induced [Ca2+]i increases
p < 0.001, but o-BrDPhG was comparable in effectiveness to o-DTG (Figure 2.5D). In
both the ischemia and acidosis experiments, the m- and p-BrDPhG were more potent
than the equivalent methyl substitutions (Figure 2.5B and 5D).
The guanidine analogue that exhibited the most pronounced inhibition of [Ca2+]i
overload in both assays was p-BrDPhG. Thus, further experiments were carried out to
precisely measure the concentration response relationship for p-BrDPhG inhibition of
[Ca2+]i overload produced by ischemia. Representative traces of [Ca2+]i as a function of
time recorded from two neurons in response to ischemia in the absence (Control) and
presence of 10 µM and 100 µM o-DTG and p-BrDPhG are shown in Figure 2.6A and 6B,
respectively. Inhibitions of the [Ca2+]i elevations by both of these compounds showed a
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Figure 2.5
Substitution of the methyl moiety with bromide at the meta and para positions enhances
[Ca2+]i inhibition. A, representative traces of [Ca2+]i as a function of time recorded from
three neurons induced via chemical ischemia in the absence (Control) and presence of
the indicated bromo derivatives at 100 µM. B, mean relative inhibition of ischemiainduced change in peak [Ca2+]i (±S.E.M.) evoked by bromo derivatives at 100 µM for
each drug (n > 55). C, representative traces of [Ca2+]i as a function of time recorded from
three neurons during acidosis in the absence (Control) and presence of the drugs
shown. D, bar graph of mean relative inhibition of change in peak [Ca2+]i (±S.E.M.)
induced via acidosis for the drugs indicated (all at 100 µM, n > 53). For both (B) and (D),
asterisks indicate statistical differences from o-DTG (p < 0.001), daggers indicate
significant difference from o-BrDPhG (p < 0.001), and pound symbols represents
significant differences from the methyl moiety in that position (p < 0.001). For
comparison, block by the methyl compounds in the equivalent site is indicated by the
lines and arrows in (B) and (D).
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concentration dependence. Plots of the mean relative change in [Ca2+]i as a function of
drug concentration for both o-DTG and p-BrDPhG are shown in Figure 2.6C. The data
were best fit by single-site Langmuir-Hill equations, and indicate a 34-fold greater
potency for p-BrDPhG in inhibiting ischemia-evoked increases in [Ca2+]i relative to oDTG.

Figure 2.6
Inhibition of ischemia-evoked increases in [Ca2+]i by p-BrDPhG is concentrationdependent. Representative traces of [Ca2+]i recorded as a function of time from a single
neuron during chemical ischemia in the absence (Control) and presence of 10 and 100
µM o-DTG (A) or in the absence (Control) and presence of 10 and 100 µM p-BrDPhG
(B). C, concentration-response relationship for mean change in peak [Ca2+]i (±S.E.M.)
measured during chemical ischemia in the presence of o-DTG (open circle) and pBrDPhG (closed circle). Drugs were normalized to their respective controls (ischemia in
absence of drug for each cell). Lines were best fit to the data using single-site LangmuirHill equations with IC50 values and Hill coefficients of 74.7 µM and 0.58 (o-DTG), and 2.2
µM and 0.63 (p-BrDPhG), respectively. For each data point, n > 65.
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Similar experiments were carried out to determine the concentration-response
relationship for p-BrDPhG inhibition of elevations in [Ca2+]i caused by acidosis. Figure
2.7A shows representative traces of [Ca2+]i recorded as a function of time from a single
neuron during acidosis in the absence (Control) and presence of 10 and 100 µM pBrDPhG. Increasing the p-BrDPhG concentration resulted in further depression of
acidosis-induced [Ca2+]i overload. Figure 2.7B shows a plot of the mean change in peak
[Ca2+]i as a function of p-BrDPhG concentration obtained from multiple experiments.
These results show an 8-fold greater potency of p-BrDPhG in inhibiting increases in
[Ca2+]i induced via acidosis when compared to o-DTG. The efficacy of p-BrDPhG was
similar to that of o-DTG in both the ischemia and the acidosis assay.
To determine if the o-DTG derivative p-BrDPhG retains the σ receptor binding
properties of the parent compound, a binding assay was performed using o-DTG for
comparison. Results of the binding study are presented in Table 2.1 and show that pBrDPhG binds both σ-1 and σ-2 receptors. However, the affinity for both receptors was
decreased, with the affinity for σ-2 decreasing to a greater extent. The Ki for p-BrDPhG
was statistically less than o-DTG at both σ-1 and σ-2 receptors, and the affinity of pBrDPhG for σ-2 receptors was significantly lower than for σ-1 receptors (for all, p <
0.001; Table 2.1. While the binding study suggests that p-BrDPhG can act via σ
receptors to inhibit [Ca2+]i dysregulation, functional experiments were carried out using
the σ-1 receptor antagonist, BD-1063, to confirm this possibility. Figures 2.8A and 8B
show representative traces of [Ca2+]i as a function of time recorded from two neurons in
response to acidosis in the absence (Control) and presence of 30 µM p-BrDPhG (Figure
2.8A) or p-BrDPhG with 10 nM BD-1063 (Figure 2.8B). p-BrDPhG produced a reduction
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Figure 2.7
p-BrDPhG inhibits acidosis-evoked increases in [Ca2+]i in a concentration-dependent
manner. A, representative traces of [Ca2+]i recorded as a function of time from a single
neuron during acidosis in the absence (Control) and presence of p-BrDPhG at the
indicated concentrations. B, concentration-response relationship for mean change in
peak [Ca2+]i (±S.E.M.) recorded during acidosis in the absence and presence of pBrDPhG. Responses obtained in the presence of p-BrDPhG were normalized to control
(absence of drug) for each cell (n > 72). Black line represents best fit to the data pBrDPhG using a Langmuir-Hill equation with an IC50 value of 13.5 µM and a Hill
coefficient of 1.2. Presented for comparison was the best fit to the data obtained for oDTG inhibition of acid-evoked elevations in [Ca2+]i (gray line, IC50 = 109.3 µM; Hill
coefficient, 0.9) (Herrera et al., 2008).
in [Ca2+]i in the absence and presence of BD-1063. However, less block by p-BrDPhG
was noted when BD-1063 was included with the guanidine analogue. In identical
experiments, a reduction in [Ca2+]i was noted for both p-BrDPhG and p-BrDPhG + BD1063. However, the effects of p-BrDPhG were significantly reduced in the presence of
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the σ-1 antagonist and this decrease was statistically significant (p < 0.001) (Figure
2.8C). BD-1063 alone had no effect on acidosis-induced [Ca2+]i elevations (Figure 2.8C).

Figure 2.8
σ-1 receptor antagonist BD-1063 attenuates p-BrDPhG inhibition of acidosis-evoked
increases in [Ca2+]i. A, representative traces of [Ca2+]i as a function of time recorded from
a single neuron during acidosis in the absence (Control) and presence of 30 µM pBrDPhG. B, representative traces of [Ca2+]i as a function of time recorded from a single
neuron during acidosis in the absence (Control) and presence of 10 nM BD-1063, or 10
nM BD-1063 + 30 µM p-BrDPhG (p-BrDPhG + BD-1063). C, Bar graph of relative mean
change in peak [Ca2+]i induced by acidosis (n > 50). Data were normalized to values
obtained for each cell in the absence of σ ligands. Asterisks denote significant
differences between p-BrDPhG and their respective DMEM (p > 0.001), and a dagger
indicates a statistical difference between the p-BrDPhG groups of Control and BD-1063
(p > 0.001), pound denotes significance between p-BrDPhG with BD-1063 and the
DMEM Control (p > 0.001). There was no difference between DMEM groups.
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Figure 2.9
p-BrDPhG blocks the migration of microglia elicited by ATP. A, concentration-response
relationship for p-BrDPhG (closed circles) and o-DTG (open circles) inhibition of ATPinduced (100 µM) migration of microglial cells. The black line represents the best fit to
the o-DTG data using a Langmuir-Hill equation with an IC50 value and Hill coefficient of
23.33 µM and 0.67, respectively. The grey line represents the best fit to the p-BrDPhG
data using a Langmuir-Hill equation with an IC50 value and Hill coefficient of 6.53 µM and
0.75, respectively. Points represent mean (±S.E.M.) and for all points, n > 9.
Recently, our laboratory showed that activation of σ receptors with pan-selective
ligands such as o-DTG or afobazole modulates microglial activation, and inhibits
microglial cell migration in response to chemoattractants such as ATP (Cuevas et al.,
2011b). This effect on microglial cell activation has been postulated to be a mechanism
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by which σ receptor activation reduces ischemic stroke injury (Cuevas et al., 2011b). For
this reason, experiments were carried out to determine if p-BrDPhG is also more potent
than o-DTG in preventing microglial cell migration. Figure 2.9 shows a plot of the mean
number of migrating microglial cells as a function of p-BrDPhG concentration obtained
from multiple experiments. Data from 30 µM p-BrDPhG were best fit using the LangmuirHill equation with an IC50 value of 6.53 µM and a Hill coefficient of 0.53. Data from 30 µM
o-DTG were best fit using the Langmuir-Hill equation showed an IC50 = 23.33 µM and Hill
coefficient of 0.67. These results represent just under a 4-fold greater potency of pBrDPhG in inhibiting microglial migration induced via 100 µM ATP when compared to oDTG.
Table 2.1
o-DTG binds to both σ receptor subtypes with greater affinity than p-BrDPhG.
Average Ki values ± S.E.M. determined from binding assays using membrane protein
extracts from rat livers. σ-1 receptors were labeled with 5 nM [3H](+)-pentazocine and σ2 receptors were labeled with 3 nM [3H] o-DTG in the presence of 300 nM (+)pentazocine to block σ-1 receptors. Nonspecific binding was determined in the presence
of 50 µM haloperidol. Asterisks indicate significant difference between p-BrDPhG and oDTG binding at σ-1 (p < 0.01) and σ-2 (p < 0.001) receptors. Pound symbol denotes
significant difference between p-BrDPhG affinity for σ-1 versus σ-2 sites.

p-BrDPhG

o-DTG

Receptor

Average Ki (nM)

SEM

Sigma-1

296

46.01

Sigma-2

800.33

56.96

Sigma-1 *

91.02

9.7

Sigma-2 *

60

8.76
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Discussion
This study demonstrates three novel findings. First, methyl-to-chloro or methyl-tobromo substitution of DTG in the meta and para positions results in new compounds with
greater potency relative to o-DTG for inhibiting [Ca2+]i overload induced by chemical
ischemia or acidosis in neurons. Of the compounds tested, p-BrDPhG, is the most potent
in these assays. Second, our data show that p-BrDPhG binds σ receptors with a reduced
affinity relative to o-DTG, but that the inhibition of [Ca2+]i overload continues to be
dependent on σ-1 receptor activation. The fact that p-BrDPhG has reduced σ receptor
binding but increased potency in the functional assay suggests that increased lipid
permeability may account for the enhanced inhibition. Finally, p-BrDPhG is also more
potent than o-DTG in preventing microglial migration in response to ATP, indicating that
this novel compound can effectively reduce microglial activation at lower concentrations
relative to o-DTG.
Our initial experiments involved shifting and removal of the methyl moiety of DTG
to ascertain effects on in vitro functional assays used to predict therapeutic potential in
ischemic stroke. Our findings with the DTG analogues show that rearrangement of the
methyl moiety does not produce a compound which behaves differently from the parent
compound in terms of modulating [Ca2+]i increases induced via ischemia and acidosis.
Removal of the group entirely (DPhG) produces a significant 18.3 ± 0.05% increase over
o-DTG in inhibiting elevations in [Ca2+]i during acidosis. Similarly, DPhG show a 12.2 ±
0.04% greater inhibition than o-DTG in the ischemia assay, but this difference was not
statistically significant. Previous studies have reported that the σ receptor binding
affinities for o-, m-, and p-DTG are approximately 30, 50, and 530 nM, respectively;
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whereas the affinity of DPhG for σ receptors is ~400 nM (Scherz et al., 1990, Reddy et
al., 1994). Results from our functional studies, therefore, do not reflect the decrease in
affinity observed for the p-DTG or DPhG. Calcium elevations evoked by ischemia and
acidosis are in part due to activation of NMDA receptors (Katnik et al., 2006, Herrera et
al., 2008). However, neither p-DTG nor DPhG shows increased affinity for NMDA
receptors compared to o-DTG (Scherz et al., 1990, Reddy et al., 1994), and thus actions
on that receptor cannot account for the discrepancy between σ receptor binding and
functional effects. Since the earlier studies did not examine specifically σ receptor
subtype binding affinity, the difference may be due to changes in affinity for one receptor
subtype versus the other (i.e. σ-2 receptor affinity decreases significantly but σ-1
receptor affinity remains unchanged).
While migration and removal of the methyl moiety failed to alter functional
properties of the molecule significantly, pronounced enhancement in potency were found
with halide substitutions. Data presented here show that substituting a chloro for a
methyl moiety in the meta and para positions of DTG produced compounds that had
~15% higher potency relative to the parent compound (o-DTG) at 100 µM concentration
in the ischemia-induced increases in [Ca2+]i assay. The enhancement in potency was
even more pronounced in the acidosis-evoked [Ca2+]i dysregulation assay. In this assay,
m- and p-ClDPhG (100 µM) produced blocks of >100% greater than o-DTG. In contrast,
substitution of a chloro moiety in the ortho position did not alter the functional effects of
the parent compound in either the ischemia or acidosis assay. Similar observations were
made using compounds with bromo substitutions (BrDPhG) of DTG in the meta and para
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positions with an ~22% increase of inhibition during ischemia and an ~160% increase
during acidosis applications over o-DTG, respectively. The most potent compound tested
was p-BrDPhG, which had an IC50 indicating 8-fold and 34-fold greater potency over that
of o-DTG in the acidosis [Ca2+]i and ischemia [Ca2+]i assays, respectively.
Functional assays indicated that p-BrDPhG was significantly more potent than oDTG, but a radioligand binding assay showed decreased affinity for both σ receptor
subtypes. Our experiments showed that o-DTG binds σ-1 and σ-2 receptors with an
affinity in the range of 60-90 nM, which is similar to what was previously reported in the
literature (Torrence-Campbell and Bowen, 1996). In contrast, p-BrDPhG was found to
bind σ-1 and σ-2 receptors with 296 ± 46 nM and 800 ± 57 nM affinities, respectively,
with the σ-2 receptor affinity being significantly lower. These values are similar to a
previous report which indicates that p-BrDPhG binds guinea pig brain membrane
extracts with an affinity of 540 ± 25 nM (Scherz et al., 1990). That study also
demonstrated that p-BrDPhG has lower binding affinity for the NMDA receptor than the
parent compound (o-DTG), and therefore, the increased functional potency cannot be
explained by increased action at the NMDA receptor.
Confirmation that p-BrDPhG mitigates [Ca2+]i dysregulation via activation of σ-1
receptors was achieved via the use of the σ-1 receptor antagonist BD-1063. Using the
acidosis [Ca2+]i functional assay, BD-1063 was shown to inhibit the effects of p-BrDPhG
by >50% at a concentration of 10 nM, which is consistent with p-BrDPhG acting via σ-1
receptors (Matsumoto et al., 1995, Herrera et al., 2008). To date, only activation of the σ1 receptor has been shown to affect ischemia- and acidosis-evoked [Ca2+]i dysregulation
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(Katnik et al., 2006, Herrera et al., 2008), and thus effects by the σ-2 receptor were not
tested in these assays.
The current study shows that p-BrDPhG also inhibits microglial activation and this
DTG analogue is 4-fold more potent than the parent compound and a second panselective σ agonist, afobazole (Hall et al., 2009a, Cuevas et al., 2011b). Unlike ischemiaand acidosis-evoked [Ca2+]i dysregulation, which appears to be exclusively affected by σ1 receptor activation, both σ-1 and σ-2 receptors can modulate microglial migration
(Cuevas et al., 2011b). This observation may explain why p-BrDPhG, which has even
lower affinity for σ-2 than σ-1, is only 4-fold more potent than o-DTG in the microglial
migration assay but 8- to 34-fold more potent than the parent compound in the [Ca2+]i
dysregulation experiments. The observation that p-BrDPhG is more potent than o-DTG
in inhibiting microglial activation may have important therapeutic implications. Previous
studies have demonstrated that activation of microglia following an ischemic insult
results in the release of pro-inflammatory cytokines by these cells, which promotes
neuronal death (Lee et al., 2001).
One mechanism which may explain the discrepancy between decreased binding
affinity but increased functional potency of p-BrDPhG may be increased membrane
permeability of the compound. It has been shown that chloro and bromo substitution in
the para position on phenylalanine increases hydrophobicity and blood-brain barrier
permeability of a drug (Gentry et al., 1999). Likewise, halogenation of small molecules
has been demonstrated to increase membrane permeation (Gerebtzoff et al., 2004). It
has been shown that increasing membrane permeability of a σ ligand by deprotonation
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increases potency of the compound, which was interpreted to suggest that the binding
site for ligands such as BD-1063 are intracellular (Vilner and Bowen, 2000). Immunolabeling studies have confirmed this hypothesis, showing that σ-1 receptors localize to
the endoplasmic reticulum (Dussossoy et al., 1999, Seminerio et al., 2012). Moreover,
the proposed binding site for drugs such as o-DTG are, in part, located in the
transmembrane domain of the receptor (Pal et al., 2007). Thus, by increasing membrane
permeability, chloro and bromo substitution more than compensate for the decreased
binding affinity.
Our data, however, also suggest that factors other than membrane permeability
are likely involved in the effects of the halogenation and methylation. Electronegativity
and conformation of the molecule are also important. For example, fluoro substitution of
a distal phenyl group of a piperidine greatly increased the lipophilicity of the compound
(de Candia et al., 2009). Despite the likely increased lipid permeability, our findings show
that fluoro substitution does not result in increased inhibition of [Ca2+]i dysregulation
evoked via ischemia or acidosis relative to o-DTG. One possibility is that while the fluoro
substitution may increase the drugs lipophilicity, the added increase in electronegativity
caused by addition of a fluoro moiety may have disrupted binding of the compound to the
σ receptors. While fluorine has an electronegativity of 4.0, that of chlorine and bromine
are ~ 3.0. Moreover, our data suggest that location of chloro and bromo substitutions on
the phenyl ring for enhanced potency were limited to either the meta or para positions. A
previous report on structure-activity relationship of DTG analogues suggested that the
ortho position was the most tolerant to structural modifications, including addition of
electronegative moiety (Scherz et al., 1990). However, that report did not distinguish
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between σ-1 and σ-2 receptor binding, and thus the effects of those modifications on the
respective receptors remains to be determined.
In conclusion, these findings show that the chloro and bromo substituted
analogues of DTG have potential applications as anti-stroke therapeutics, showing a
greater potency for inhibiting intracellular calcium dysregulation over o-DTG. In addition,
p-BrDPhG blocks microglial migration with greater potency than o-DTG, indicating that
this DTG analogue will both provide neuroprotection and mitigate the neuroinflammatory
response known to contribute to stroke injury. It is of significant interest to determine if
the noted enhancement in potency of p-BrDPhG in vitro translates to superior in vivo
outcomes.
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CHAPTER 3

Afobazole Activation of Sigma-1 Receptors Modulates
Neuronal Responses to Amyloid-β25-35
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is the
most common form of senile dementia in the United States (Gaugler et al., 2013). While
the full pathophysiological underpinnings of AD remain elusive, one of the hallmarks of
AD is an increase in amyloid-β (Aβ) plaque formation in the brain (Selkoe, 2001). The Aβ
fragment, Aβ25-35, which has been found in AD brains, has been proposed as a major
contributor to the pathogenesis of AD (Kaminsky et al., 2010). This Aβ fragment has
been shown to induce injury via various mechanisms including production of reactive
oxygen species (ROS) (Schubert et al., 1995), dysregulation in intracellular Ca2+ (Joseph
and Han, 1992), enhanced NMDA channel activity (Molnar et al., 2004), and increased
activation of caspase-3 (Marin et al., 2000).
Previous studies have shown that a possible link might exist between sigma
receptors and the etiology of AD. A loss of sigma binding sites has been observed in AD,
and specific σ-1 receptor polymorphisms have been associated with altered risk for this

Reprinted with permission of the American Society for Pharmacology and Experimental Therapeutics.
Copyright © 2013 by the American Society for Pharmacology and Experimental Therapeutics

45

disease (Jansen et al., 1993, Uchida et al., 2005, Mishina et al., 2008, Feher et al.,
2012).
Sigma-1 selective agonists have also been shown to reduce memory loss
produced by Aβ25-35 injections in mice (Maurice et al., 1998). Recently, tetrahydro-N, Ndimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) was shown to
reduce tau hyperphosphorylation and Aβ1-42 generation in a mouse model of Alzheimer’s
disease via the activation of both σ-1 and muscarinic receptors (Lahmy et al., 2013).
However, it is unclear if other sigma receptor ligands, particularly ligands that do not
affect muscarinic receptors, have similar neuroprotective properties. The molecular
mechanism(s) by which σ-1 receptors decrease neuronal injury upon Aβ exposure have
not been identified, and the effects of σ-2 receptor activation on neuronal responses to
Aβ need to be elucidated.
Sigma (σ) receptors, once thought to be a class of opioid receptors, are known to
have widespread regulatory actions during neuropathophysiological states (Tsai et al.,
2009). The σ-1 receptor has been shown to be an inter-organelle chaperone localized to
the mitochondrion-associated ER membrane (MAM) (Su et al., 2010). The σ-1 receptorMAM relationship plays important roles in cell signaling, mitochondrial function and
maintaining intracellular Ca2+ ([Ca2+]i) homeostasis (Su et al., 2010). Furthermore, upon
stimulation with high agonist concentrations, σ-1 receptors migrate to sub-plasmalemmal
ER or the plasma membrane and interact with various ion channels (Su et al., 2010). In
response to ischemia or acidosis, activation of σ-1 receptors prevents [Ca2+]i overload
and concomitant cell death, likely via actions at multiple targets, including acid-sensing
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ion channels and NMDA receptors (Katnik et al., 2006, Herrera et al., 2008). In addition
to regulation of [Ca2+]i homeostasis, other sigma receptor-mediated effects may
contribute to neuroprotection, including decreased production of ROS and reactive
nitrogen species (RNS), activation of the anti-apoptotic protein Bcl-2, and inhibition of the
pro-apoptotic protein Bax (Tchedre and Yorio, 2008, Meunier and Hayashi, 2009,
Kourrich et al., 2012, Pal et al., 2012). It remains to be established if some or all of these
effects are linked to σ receptor-mediated neuroprotection following neuronal ischemia,
and if they contribute to neuroprotection following Aβ exposure.
Our laboratory recently showed that afobazole (5-ethoxy-2-[2-(morpholino)ethylthio]benzimidazole), a drug currently used in Russia to treat anxiety and panic
disorders, is both a σ-1 and σ-2 receptor agonist, and provides neuroprotection in an in
vitro ischemia model (Cuevas et al., 2011a, Cuevas et al., 2011b). Unlike ANAVEX2-73,
afobazole does not interact with muscarinic receptors (Seredenin and Voronin, 2009).
Activation of σ-1 receptors by afobazole results in a decrease in ischemia-induced Ca2+
overload, which is due in part to inhibition of NMDA channel activation (Katnik et al.,
2006, Cuevas et al., 2011a). Previous studies have suggested other mechanisms for the
neuroprotective properties of afobazole, including decreased caspase-3 activation and
reduced oxidative stress (Zenina et al., 2005, Antipova et al., 2010). Thus, afobazole is
an excellent ligand for examining the relationship between sigma receptors and Aβinduced neurotoxicity, and is a potential candidate for the treatment of Alzheimer’s
disease.
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Experiments were carried out to determine how afobazole affects neuronal
responses to the Aβ fragment, Aβ25-35. Afobazole mitigated Aβ25-35-evoked increases in
[Ca2+]i in neurons and these effects were blocked by inhibition of σ-1, but not σ-2
receptors. Afobazole was also found to lessen NO production in response to Aβ25-35
application, and reduced neuronal death. The decrease in cell death produced by
afobazole was associated with reduced neuronal expression of the pro-apoptotic protein
Bax and the death protease caspase-3 and enhanced expression of the anti-apoptotic
gene product, Bcl-2.

Materials and Methods

Preparation of Rat Cortical Neurons
All experiments were carried out on cultured cortical neurons from mixed sex
embryonic day 18 (E18) Sprague-Dawley rats (Harlan, Indianapolis, IN). Methods used
here were identical to those previously reported for the isolation and culturing of these
cells (Katnik et al., 2006). Cortical neurons were plated on poly-L-lysine coated
coverslips and cultured in B27 and L-glutamine supplemented Neurobasal medium
(Neurobasal Complete) (Life Technologies, Grand Island, NY). Cells were used for
experiments after 10-21 days in culture, which permits synaptic contact formation and
yields robust responses to other pathophysiological conditions such as in vitro ischemia
and acidosis (Katnik et al., 2006, Herrera et al., 2008). Animals were cared for in
accordance with the regulations and guidelines set forth by the University of South
Florida’s College of Medicine Institution on Animal Care and Use Committee.
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Calcium Imaging
Intracellular Ca2+ concentrations were measured in isolated cortical neurons using
ratiometric fluorometry as previously described (Katnik et al., 2006). For most
experiments, cultured neurons were incubated in 25 µM Aβ25-35 for 1-24 hr prior to [Ca2+]i
being measured. Neurons were loaded with fura-2 by adding 3 µg/ml of the
acetoxymethylester form of fura-2 (fura-2 AM) in 0.3% DMSO to the media and
incubating the cells at room temperature for 1 hr. Prior to beginning the experiments, the
coverslips were rinsed with physiological saline solution (PSS) consisting of (in mM): 140
NaCl, 5.4 KCl, 25 HEPES, 20 glucose, 1.3 CaCl2, and 1.0 MgCl2 (pH to 7.4 with NaOH).
For each cell, [Ca2+]i was measured once a second for a 20 second period and the
values averaged to determine baseline [Ca2+]i. The Aβ-induced increases in [Ca2+]i
(∆[Ca2+]i) in experiments using σ receptor antagonists were calculated by subtracting
average [Ca2+]i measured in control cells for each condition tested (i.e. absence or
presence of σ receptor ligand) from those recorded for the individual cells when Aβ was
added under the same conditions. In one series of experiments, the acute effects of
Aβ25-35 on neuronal [Ca2+]i were determined by first loading neurons with fura-2 and then
administering Aβ25-35 via a rapid application system while measuring [Ca2+]i.

ROS and NO Imaging
Intracellular ROS and NO concentrations were measured in isolated cortical
neurons using fluorometric digital microscopy (CoolSnap HQ2; Photometrics, Surrey,
BC, Canada). Cells were plated as described above and incubated for 24 hr at 37
Neurobasal Complete containing 25 µM Aβ25-35 (± afobazole). Cultured cells were then
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incubated at 37°C for 30 min in 10 µM DHE with 0.25% DMSO to measure ROS and for
1 hr in 5 µM DAF-FM with 0.1 % DMSO to measure NO, both in Neurobasal Complete
and with 25 µM Aβ25-35 (± afobazole). The fluorophores were then removed by rinsing
coverslips with physiological saline solution (PSS). DHE and DAF-FM loaded neurons
were excited with light at 518 nm and 495 nm, respectively. ROS and NO
concentrations were then measured as fluorescent emission intensities at 605 nm and
515 nm wavelengths, respectively. Image analysis was performed using Nikon Elements
software (Nikon, Melville, NY, USA). No afobazole autofluorescence was observed at the
wavelengths tested.

Cytotoxicity Assay
Neurons plated on poly-L-lysine coverslips were incubated at 37°C for 72 hr in
Neurobasal Complete with 25 µM Aβ25-35 in the absence (Control) and presence of 100
µM afobazole or 100 µM DTG. The coverslips were rinsed with PBS followed by 30 min
incubation at room temperature in PBS with 4 µL of a 2 mM ethidium homodimer-1
(EthD-1) dissolved in 1:4 DMSO:H2O solution. The coverslips were washed with PBS
and deionized water, dried, and mounted on a microscope slide with Vectashield Hardset
mounting media (Vector Labs, Burlingame, CA). EthD-1 loaded cells were illuminated
with light at 530 nm and visualized at 645 nm using a Zeiss Axioskop 2 equipped with a
20X objective. EthD-1-positive cells were identified and counted using Image-J in four
random fields per slide, and the average for the fields used as the value for the slide. For
each experiment, a minimum of three slides were used, and the results of at least three
experiments were averaged together for each condition tested.
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Immunocytochemistry
Neurons plated on poly-L-lysine coverslips were incubated at 37°C for 24 hr in
Neurobasal Complete with 25 µM Aβ25-35 in the absence and presence of 100 µM
afobazole. The coverslips were rinsed with phosphate-buffered saline (PBS) followed by
an ethanol step-wise fixation. The cells were permeabilized with 0.1% Triton X in PBS for
15 min, then rehydrated with PBS and washed with 0.5% bovine serum albumin (BSA) in
PBS. Blocking was achieved with 45 min incubation in 2% BSA, followed by multiple
washes with 0.5% BSA. Primary antibodies were diluted in PBS with 0.5% BSA and
applied onto cells at 4°C for 24 hr. Primary antibody dilutions were as follows: Bax 1:20,
Caspase-3 1:25 and Bcl-2 1:100. The cells were then washed multiply times with 0.5%
BSA in PBS and then incubated in secondary antibodies for 60 min at room temperature.
Secondary antibodies were Alexa Fluor 488 conjugated anti-mouse or anti-rabbit, as
appropriate, both diluted at a ratio of 1:300 in PBS with 0.5% BSA. Following incubation
in secondary antibodies, cells were washed with 0.5% BSA in PBS and then with PBS
alone. Coverslips were rinsed with deionized water, inverted and sealed onto a slide with
VectaShield containing DAPI. DAPI and the Alexa Fluor 488 conjugated secondary
antibodies were illuminated at 359 and 485 nm and visualized at 461 and 530 nm,
respectively, using a Zeiss Axioskop 2 outfitted with a 40X objective. Images of DAPI
and Alexa Fluor 488 positive cells were counted and merged to demonstrate colocalization using Image-J software. Four random fields per slide were used to determine
an average value for the slide. For each experiment, a minimum of three slides were
used, and the results of at least three experiments were averaged together.
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Compounds, Reagents and Antibodies
The following compounds and reagents were used in this investigation: Aβ25-35
(American Peptides, Sunnyvale, CA); DTG and BD-1047 (Tocris Biosciences, Ellisville,
MO); rimcazole (Sigma-Aldrich, St. Louis, MO); fura-2 acetoxymethyl ester, DHE, DAFFM, Live/Dead Viability/Cytotoxicity Kit (Life Technologies). The following antibodies
were used: Alexa Fluor 488 anti-mouse (A-11001) and anti-rabbit (A-11008) (Life
Technologies); anti-Bax (ab5714), anti-activated caspase-3 (ab32351) and anti-Bcl-2
(ab32370) (abcam, Cambridge, MA). Afobazole was generously provided by IBC
Generium (Moscow, Russian Federation). Vehicle for drugs and reagents used were
either water (H2O), ethanol (EtOH) or dimethyl sulfoxide (DMSO), and appropriate
vehicle controls were carried out for each study.

Data Analysis
Data were analyzed using SigmaPlot 11 software (Systat Software, Inc., San
Jose, CA). Data points represent peak means ± standard error of the mean (S.E.M.).
One- and two-way analysis of variance were used for determining significant differences
for multiple group comparisons, as appropriate, followed by post hoc analysis using the
Holm-Sidak test. Results were considered statistically significant if p < 0.05.

Results
Experiments were first carried out to determine the effects of Aβ25-35 on [Ca2+]i in
isolated cortical neurons from embryonic (E18) rats. Figure 3.1A shows representative
traces of [Ca2+]i measured in cortical neurons exposed to acute applications of 25 µM
Aβ25-35 (≤ 15 min). During this time period, the Aβ fragment did not significantly affect
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[Ca2+]i in the neurons. To examine if extended incubation in Aβ25-35 alters [Ca2+]i, neurons
were incubated from 1 hr to 24 hr in media contain 25 µM Aβ25-35. Figure 3.1B shows a
bar graph of mean [Ca2+]i recorded from different groups of neurons incubated in Aβ25-35
for the indicated time points. The Aβ fragment produced a statistically significant
increase in [Ca2+]i at all time points tested, with peak increases occurring 12 hr after
Aβ25-35 application.

Figure 3.1
Aβ25-35 promotes time-dependent elevations in neuronal intracellular calcium. A,
representative traces of intracellular calcium as a function of time recorded from five
neurons during acute application of 25 µM Aβ25-35. Line above traces indicates duration
of Aβ application. B, Bar graph of mean (±SEM) [Ca2+]i measured in neurons exposed to
media (Control) or media containing 25 µM Aβ25-35 for the indicated times. Control value
is compiled from measurements made at all time points. Asterisk denotes significant
difference from Control (p < 0.05); for all time points, n > 1500 neurons.
Given that activation of σ receptors can inhibit increases in intracellular Ca2+
under various pathological conditions, we hypothesized that activation of σ receptors
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with the pan-selective σ receptor agonists, afobazole or DTG, could affect the elevations
in [Ca2+]i triggered by incubation of cortical neurons in Aβ25-35. Cortical neurons were
incubated in 25 µM Aβ25-35 for 24 hr in the absence and presence of 100 µM afobazole or
100 µM DTG (Figure 3.2A). Following the 24 hr incubation with Aβ25-35, there was a
statistically significant increase in [Ca2+]i consistent with results shown in Figure 3.1B.
Incubation of neurons in media containing afobazole alone did not significantly affect
neuronal [Ca2+]i. However, incubation in afobazole blocked the Aβ25-35-evoked increases
in [Ca2+]i by 58 ± 12% (Figure 3.2A). In contrast, application of DTG (100 µM), failed to
inhibit the Aβ25-35-evoked increase in [Ca2+]i, and instead, potentiated the response by 67
± 21%.
The discrepancy between the results obtained for afobazole and DTG leave doubt
as to the role of σ receptors in the regulation of Aβ25-35-induced increases in [Ca2+]i by
afobazole. Therefore, to test if σ receptors are involved in these effects, selective
inhibitors of σ-1 (BD-1047) and σ-2 (rimcazole) receptors were used (Matsumoto et al.,
1995, Gilmore et al., 2004). Cortical neurons were incubated in 25 µM Aβ25-35 for 12 hr in
the absence and presence of 100 µM afobazole with and without BD-1047 or rimcazole
(Figure 3.2B). Application of afobazole reduced elevations in [Ca2+]i produced by Aβ25-35
by 77 ± 3%, which was statistically significant. While 10 µM BD-1047 alone lessened the
effects of Aβ25-35 on [Ca2+]i, the σ-1 receptor antagonist prevented any further reduction
by afobazole such that the block produced by the combination of afobazole + BD-1047
was almost identical to that produced by BD-1047 alone and 34 ± 4% less than that
produced by afobazole alone. Unlike BD-1047, rimcazole (300 nM) alone did not
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Figure 3.2
Afobazole inhibits increases in [Ca2+]i evoked by Aβ25-35. A, Bar graph of mean (±SEM)
[Ca2+]i measured in neurons incubated for 24 hr in media in the absence (Control) or
presence of 25 µM Aβ25-35 (Aβ) with or without 100 µM Afobazole (Afob) or 100 µM DTG
(DTG). Asterisks denote significant difference between Control and Aβ within the Media,
Afob and DTG groups (p < 0.001 for Media and DTG groups, p < 0.05 for Afob group).
Pound symbols denote significant difference from the Media group within the Aβ group (p
< 0.001 for both). Dagger indicates significant difference between Afob and DTG groups
within Aβ (p < 0.01). For all groups, n ≥ 125 neurons. B, Bar graph of mean (±SEM) Aβinduced increase in [Ca2+]i (∆[Ca2+]i) measured in neurons incubated for 12 hr in 25 µM
Aβ25-35 alone (Aβ) or in 25 µM Aβ25-35 + 100 µM afobazole (Aβ + Afob). Aβ or Aβ + Afob
were applied in media alone (Media), in media with 10 µM BD-1047 (BD), or in media
with 300 nM rimcazole (Rim 0.3) or 10 µM rimcazole (Rim 10). Asterisks denote
significant difference between Aβ and Aβ + Afob within Media and rimcazole groups,
respectively (for all p < 0.001). Pound symbols denote significant difference between BD55

1047 (BD) and all other groups within Aβ and between BD-1047 and the Media and 300
nM rimcazole (Rim 0.3) within Aβ + Afob, respectively (p < 0.01 for all). Dagger indicates
significant difference between Rim 10 and Control groups within Aβ (p < 0.001). C, Bar
graph of relative mean (±SEM) elevations in [Ca2+]i evoked by Aβ25-35 in the presence of
afobazole and in the absence (Control) or presence of 10 µM BD 1047 (BD), 300 nM
rimcazole (Rim 0.3) and 10 µM rimcazole (Rim 10). Data were normalized to mean
∆[Ca2+]i evoked by Aβ in the appropriate control (i.e. media or the corresponding σ
receptor antagonist). Asterisks, pound symbols and dagger denote significant difference
from Control, BD and Rim 0.3, respectively (for all p < 0.05). For all groups in B and C, n
≥ 168 neurons.
significantly inhibit Aβ25-35-evoked increases in [Ca2+]i. When afobazole was co-applied
with the low concentration of rimcazole (300 nM), which primarily affects σ-2 receptors,
afobazole reduced Aβ25-35-evoked [Ca2+]i elevations by 83 ± 5% (Figure 3.2B). This
decrease was similar to that seen with afobazole alone. Like BD-1047, a higher
concentration of rimcazole (10 µM), predicted to interact with σ-1 receptors (Husbands et
al., 1999), reduced Aβ25-35-induced increases in [Ca2+]i, (Figure 3.2B). However, Aβ25-35evoked increases in [Ca2+]i observed in the cells incubated in 10 µM rimcazole +
afobazole were not significantly different from those produced by the Aβ fragment in the
presence of afobazole (p = 0.179). In order to account for these direct effects of the
antagonists on Aβ25-35 evoked elevations in [Ca2+]i, we normalized the increases in [Ca2+]i
observed when afobazole was added along with the σ receptor antagonist to those
observed when Aβ was added with the antagonist alone. The mean normalized
responses observed for the different conditions are shown in Figure 3.2C. The effects of
afobazole were blocked by both BD 1047 and the higher concentration of rimcazole (10
µM, Rim 10), but not by the lower concentrations of rimcazole (300 nM, Rim 0.3) (Figure
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3.2C). Therefore, inhibition of σ-1, but not σ-2 receptors lessened the effects of
afobazole.

Figure 3.3
Afobazole does not inhibit Aβ25-35 evoked ROS production but does inhibit nitric oxide
production in neurons. A, Bar graph of mean (±SEM) DHE fluorescence intensity (ROS
levels) measured in neurons incubated for 24 hr in the absence (Control) or presence of
25 µM Aβ25-35 (Aβ) without (Media) or with 100 µM Afobazole (Afob). Asterisks denote
significant difference between Control and Aβ within Media and Afob groups (p < 0.05 for
both). Pound symbols denote significant difference between Media and Afob groups
within Control (p < 0.001) and Aβ (p < 0.05) groups. B, Bar graph of mean (±SEM) DAFFM fluorescence intensity (NO levels) measured in neurons incubated for 24 hr in media
alone (Control) or media containing 25 µM Aβ25-35 (Aβ), 100 µM Afobazole (Afob) or 25
µM Aβ25-35 and 100 µM Afobazole (Aβ + Afob). Asterisks denote significant difference
between Control and Aβ within Media and Afob (p < 0.001 for both). Pound symbol
denotes significant difference between Media and Afob groups within Aβ (p < 0.001). For
all groups, (n > 108 neurons).
Cortical neuron [Ca2+]i overload has been shown to enhance production of
reactive oxygen species (ROS) and nitric oxide, with the latter molecule being converted
to reactive nitrogen species (RNS) in the presence of ROS. Activation of σ receptors has
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been associated with changes in both ROS and nitric oxide levels. Thus, we evaluated if
afobazole preservation of [Ca2+]i homeostasis consequently affects ROS and/or nitric
oxide levels following exposure to Aβ25-35. Figure 3.3A shows a bar graph of the average
DHE fluorescence intensities measured in neurons in response to 24 hr incubation in
Aβ25-35 in the absence and presence of 100 µM afobazole. Greater DHE fluorescence
was observed in neurons exposed to Aβ25-35 relative to media alone, indicating an Aβinduced increase in ROS production (Figure 3.3A). Incubation of the neurons in
afobazole alone also produced a small but significant increase in neuronal ROS, and a
further increase in ROS was noted when Aβ25-35 was co-applied with afobazole (Figure
3.3A). NO levels were also measured in neurons exposed to Aβ25-35 for 24 hr. Incubation
of neurons in Aβ25-35 significantly enhanced neuronal NO levels. In contrast to the results
obtained for ROS, afobazole alone had no effects on basal neuronal NO content.
However, the σ agonist significantly decreased Aβ25-35-evoked elevations in NO by 53 ±
5% (Figure 3.3B).
Afobazole suppression of Aβ25-35-evoked [Ca2+]i dysregulation and NO production
suggests that this compound may be neuroprotective in this injury model. Thus,
experiments were conducted to ascertain if afobazole can reduce Aβ25-35 cytotoxicity and
enhance cell survival following exposure of cortical neurons to this Aβ fragment. For
comparison, a second σ receptor agonist, DTG, which has been shown to augment
survival in other neuronal injury models but does not block Aβ25-35-elicited [Ca2+]i
increases was included. Neurons were incubated for 72 hr in 25 µM Aβ25-35 in the
absence and presence of 100 µM afobazole or 100 µM DTG and cell survival determined
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Figure 3.4
Afobazole, but not DTG, reduces neuronal death produced by application of Aβ25-35. A,
Photomicrographs showing EthD-1 labeling (red), a marker of cell death, observed
following 72 hr incubation of neurons in media alone (i), or media containing 25 µM Aβ2535 (ii), 100 µM afobazole (iii), 100 µM DTG (v), 25 µM Aβ + 100 µM afobazole (iv), or 25
µM Aβ + 100 µM DTG (vi). Fields of view shown are representative regions within larger
images used to calculate number of neurons labeled with EthD-1. B, Bar graph of
relative neuronal death observed for the same conditions as in (A). Data were
normalized to the average number of EthD-1-positive cells observed with media alone
(i.e. no Aβ or σ ligand). Asterisks denote significant difference between Control and Aβ
within Media and DTG groups, respectively (p < 0.001 for both). Pound symbol indicate
significant difference between Afob and the other groups within Aβ (p < 0.001) and
dagger indicates significant difference between DTG and the other groups within Control
(p < 0.05). For all groups, n ≥ 12. Scale bar in (i) is 20 µm.
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using EthD-1 to identify apoptotic cells. Figure 3.4A shows representative
photomicrographs of neurons labeled with EthD-1. While EthD-1 staining was noted in all
groups, a higher number of cells were observed when Aβ25-35 was applied alone or in the
presence of DTG (Figure 3.4A ii & vi), but not when co-applied with afobazole (Figure
3.4A iv). In identical experiments, incubation in Aβ25-35 resulted in a 130 ± 6% increase in
the percentage of cells exhibiting positive labeling with EthD-1, relative to control (media
alone, Figure 3.4B). When afobazole (100 µM) was applied alone, there was no change
in the percentage of dead cells noted. However, application of afobazole along with the
Aβ25-35 resulted in an 88 ± 4% reduction in the percentage of EthD-1 positive cells
relative to the Aβ fragment alone group, which was statistically significant (Figure 3.4B).
In contrast, DTG alone increased the percentage of EthD-1 positive cells compared to
control (Figure 3.4B). Moreover, DTG failed to reduce the percentage of cells exhibiting
EthD-1 staining when co-incubated with Aβ25-35 such that the number of apoptotic cells
seen with Aβ25-35 alone and Aβ25-35 + DTG were similar (Figure 3.4B).
Experiments were next focused on identifying underlying molecular mechanisms
contributing to the enhanced survival of cortical neurons following afobazole application.
Previous studies have shown that σ-1 receptor activation by the selective agonist, (+)SKF10047, can protect RGC-5 cells from glutamate-induced apoptosis by reducing
expression of the pro-apoptotic gene product Bax (Tchedre and Yorio, 2008). To
determine if a similar pathway is involved in afobazole-mediated neuroprotection during
Aβ25-35 exposure, the cellular expression of this protein was determined. Representative
photomicrographs of cells co-labeled with DAPI and an anti-Bax antibody are shown in
Figure 3.5A. While Bax is detected in control neurons (Figure 3.5A i), there is a marked
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Figure 3.5
Afobazole prevents upregulation of the pro-apoptotic gene product, Bax, caused by
application of Aβ25-35 in neurons. A, Photomicrographs of merged images of cultured
neurons exposed for 24 hr to media alone (Control) (i), or media containing 25 µM Aβ2535 (Aβ) (ii), 100 µM afobazole (Afob) (iii) or 25 µM Aβ25-35 + 100 µM afobazole (Aβ + Afob)
(iv). Neurons were double labeled with DAPI (blue) and anti-Bax antibody (green). Fields
of view shown are representative regions within larger images used to calculate Bax
expression. B, Bar graph of mean percent of Bax-positive neurons observed in multiple
experiments in which cells were exposed to the same conditions described in (A). Data
are expressed as mean percent (±SEM) of the total number of neurons staining positive
for DAPI. Asterisks denote significant difference between Control and Aβ within Media
and Afob groups, respectively (p < 0.001). Pound symbols indicate significant difference
between Afob and Media groups within Control (p < 0.05) and Aβ (p < 0.001). Scale bar
in (i) is 10 µm and n = 9 for all groups in (B).
increase following incubation in Aβ25-35 (Figure 3.5A ii). Bax is also expressed in low
levels in neurons exposed to afobazole alone (Figure 3.5A iii), and there is only a modest
increase when neurons are incubated in both 100 µM afobazole and the Aβ fragment
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(Figure 3.5A iv). Analysis of images collected from multiple experiments shows that Bax
is detected in less than half of the control cells, but following exposure to Aβ25-35 there is
a 100 ± 5% increase in the number of cells testing positive for this pro-apoptotic gene
(Figure 5B). Application of afobazole reduces Bax expression below that observed in
control cells by 13 ± 5%, and the increase in expression occurring after Aβ25-35
incubation is reduced to 58 ± 5% (Figure 3.5B). The net result is a 39 ± 5% reduction in
the total number of cells expressing Bax in response to Aβ25-35 when afobazole was
applied.
Given that σ receptors have also been linked to decreased caspase-3 expression
(Tchedre and Yorio, 2008), immunocytochemistry was also employed to examine how
afobazole affects the levels of the active form of this death protease after neuronal
exposure to Aβ25-35. Representative photomicrographs of cells labeled with DAPI and
anti-activated caspase-3 antibody show an increase in the number of caspase-3 positive
neurons 24 hr after incubation in Aβ25-35 relative to control (Figure 3.6A i & ii). Neuronal
expression of the active form of caspase-3 was not affected by incubation of the cells in
100 µM afobazole alone, but co-application of afobazole with Aβ25-35 significantly lowered
activated caspase-3 expression when compared to cells treated only with Aβ25-35 (Figure
3.6A iii & iv). Figure 3.6B shows a bar graph of mean (±SEM) percentages of active
caspase-3 positive neurons detected from multiple experiments using the same
conditions as in Figure 3.6A. There is a statistically significant upregulation of activated
caspase-3 expression following Aβ25-35 application, which results in a 104 ± 7% increase
in the percentage of neurons testing positive for the death protease. However, treatment
with afobazole reduces the increased cellular expression of activated caspase-3
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Figure 3.6
Afobazole reduces expression of activated caspase-3 in response to application of Aβ2535 in neurons. A, Photomicrographs of merged images of cultured neurons exposed for
24 hr to media alone (Control) (i), or media containing 25 µM Aβ25-35 (Aβ) (ii), 100 µM
afobazole (Afob) (iii) or 25 µM Aβ25-35 + 100 µM afobazole (Aβ + Afob) (iv). Neurons were
double labeled with DAPI (blue) and anti-active caspase-3 antibody (green). Fields of
view of each photomicrograph are representative regions within larger image used to
calculate caspase-3 expression. B, Bar graph of mean percent (±SEM) of neurons
testing positive for the active form of caspase-3 in experiments in which the cells were
exposed to the same conditions as (A). Asterisk denotes significant difference between
Control and Aβ within Media (p < 0.001). Pound symbol indicates significant difference
between Media and Afob within Aβ (p < 0.001). Scale bar in (i) is 10 µm and n = 9 for all
groups in (B).
produced by Aβ25-35 by 89 ± 7% (Figure 3.6B). Neuronal expression of active caspase-3
observed in cells treated with afobazole alone and afobazole with Aβ25-35 were not
statistically different (p = 0.20).
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Activation of σ receptors has been shown to provide neuroprotection against
toxicity produced by the HIV-1 protein gp120 via upregulation of the anti-apoptotic gene
Bcl-2 (Zhang et al., 2012). Therefore, we examined the possible involvement of Bcl-2 in
the protection provided by afobazole against Aβ25-35-induced cytotoxicity. A significant
number of neurons were found to express Bcl-2 in our culture model under all conditions
tested at both 24 and 48 hrs (Figure 3.7A i-vii). Quantification of the results indicates that
69 ± 6% of control neurons expressed Bcl-2, and that incubation in 25 µM Aβ25-35 for 24
hr increased this number to 90 ± 2% (Figure 3.7B). The addition of afobazole alone also
produced a 24 ± 2% increase in the percentage of Bcl-2 expressing cells, which was
statistically significant when compared to the control (Figure 3.7B). However, after a 24
hr incubation, no further increase in Bcl-2 was noted when afobazole was applied with
Aβ25-35 compared to incubation in Aβ25-35 alone. In contrast, increasing the incubation
time of the cells in Aβ25-35 to 48 hr resulted in reduction in the number of cells showing
positive labeling for Bcl-2 expression, with Bcl-2 being observed in 71 ± 1% of cells
incubated in media alone and 46 ± 2% of the cells incubated in media containing the Aβ
fragment (Figure 3.7B). Extending the application time of afobazole to 48 hr continued to
produce a similar increase in Bcl-2 expression as seen with the 24 hour incubation, with
85 ± 1% of the afobazole treated neurons showing Bcl-2 expression. However, the
addition of afobazole to Aβ25-35 prevented the Aβ-induced suppression of Bcl-2 seen at
48 hr, withBcl-2 being observed in 81 ± 1% of the neurons exposed to Aβ25-35 in the
presence of this drug (Figure 3.7B). In fact, in cultures exposed to afobazole + Aβ there
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was a 14 ± 2% increase in the number of neurons testing positive for Bcl-2 expression
compared to control (no Aβ or afobazole).

Figure 3.7
Afobazole prevents Bcl-2 down-regulation following 48 hr exposure of neurons to Aβ25-35.
A, Photomicrographs of merged images of cultured neurons exposed for 24 or 48 hr to
100 µM afobazole (Afob, i and iv), 25 µM Aβ25-35 (Aβ, ii and v), or 100 µM afobazole + 25
µM Aβ25-35 (Afob + Aβ, iii and vi). For comparison, a photomicrograph of merged images
of neurons exposed to media alone for 48 hr is shown (Control, vii). Neurons were
double labeled with DAPI (blue) and anti-Bcl-2 antibody (green). Fields of view of each
photomicrograph are representative regions within larger images used to calculate Bcl-2
expression. B, Bar graph of mean percent (±SEM) of Bcl-2-positive neurons exposed to
the conditions described in (A). Asterisks indicate significant difference between Control
and Aβ within the 24 hr and 48 hr groups, respectively. Pound symbols indicate
significant difference between Control and Afob within the 24 hr and 48 hr groups,
respectively, and between Aβ and Aβ + Afob within the 48 hr group. For 24 hr group n =
9 for all, for 48 hr group n = 12 for all, p ≤ 0.001 for all. Scale bar in (vii) is 10 µm.
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Discussion
The major finding reported in this study is that afobazole, acting via σ-1 receptors,
provides neuroprotection against Aβ25-35-induced toxicity in cortical neurons. Activation of
σ-1 receptors by afobazole appears to impinge on multiple molecular mechanisms
associated with the demise of neurons. First, afobazole, acting via σ-1 receptors,
decreases neuronal [Ca2+]i dyshomeostasis resulting from prolonged exposure (1 to 24
hr) of the cells to Aβ25-35. Second, afobazole mitigates Aβ25-35-evoked elevations in nitric
oxide production in cortical neurons that coincides with increases in ROS production,
thus nitrosative stress is likely lessened. Finally, afobazole blunts the pro-apoptotic
signaling induced by Aβ25-35 by inhibiting the upregulation of the pro-apoptotic gene
product Bax and the death protease, caspase-3, while preventing long-term
downregulation of the anti-apoptotic protein, Bcl-2.
In our culture system, Aβ25-35 was found to produce increases in [Ca2+]i after
cells were incubated in the Aβ fragment for ≥ 1 hr, with short applications ≤ 15 min failing
to alter [Ca2+]i. Maximal increases in [Ca2+]i were observed after 12 hr incubation of the
neurons in Aβ25-35 and [Ca2+]i remained significantly elevated even after 24 hr incubation
in the Aβ fragment. The observed 2-fold increase in [Ca2+]i caused by Aβ25-35 is similar to
that previously reported for rat cortical neurons incubated for 24 hr in Aβ25-35 (Ferreiro et
al., 2004). Incubation of neurons in 100 µM afobazole reduced Aβ25-35-evoked increases
in [Ca2+]i by ~60%. This decrease in [Ca2+]i is similar to that observed when afobazole
was used to inhibit [Ca2+]i increases produced in cortical neurons by acidosis (IC50 = 164
µM) (Cuevas et al., 2011a). Reducing Aβ25-35 perturbation of [Ca2+]i is likely to promote
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neuronal survival, since [Ca2+]i destabilization has been linked to cell death in AD
(Mattson and Chan, 2003b). Moreover, the Aβ25-35-induced changes in [Ca2+]i precede
pro-apoptotic signals in the model used here (e.g. decrease in Bcl-2 levels occurring 48
hrs after Aβ25-35 application).
The inhibition of Aβ25-35-elicited increases in [Ca2+]i by afobazole is due to
activation of σ-1, but not σ-2 receptors. Incubation in the σ-1 receptor antagonist, BD1047 (Matsumoto et al., 2004), reduced the effects of afobazole by ~40%. The
concentration and degree of block reported here is consistent with previous studies
showing BD-1047 inhibition of σ-1 receptor-mediated effects in cortical neurons and
retinal ganglion cells (Katnik et al., 2006, Cuevas et al., 2011a, Mueller et al., 2013). The
lack of involvement of σ-2 receptors is confirmed by results obtained using the σ-2
receptor antagonist, rimcazole (Gilmore et al., 2004). Rimcazole binds to σ-2 receptors
with nanomolar affinity, but to σ-1 receptor with low micro molar affinity (Ferris et al.,
1986, Husbands et al., 1999, Rybczynska et al., 2008). Given that 300 nM rimcazole
failed to inhibit the actions of afobazole on Aβ25-35-evoked increases in [Ca2+]i, but that
the higher concentration of the drug reduced these effects, it is unlikely that afobazole
activates σ-2 receptors to suppress Aβ25-35-evoked increases in [Ca2+]i. Surprisingly, a
second pan-selective σ receptor agonist, DTG, failed to mimic the effects of afobazole on
Aβ25-35-evoked [Ca2+]i perturbation. DTG and afobazole both block acidosis- and
ischemia-induced Ca2+ overload in neurons to a similar extent (Cuevas et al., 2011a). It
was shown that ischemia-induced [Ca2+]i increases were due primarily to Ca2+ influxes
through voltage-gated Ca2+ channels and NMDA receptors which were regulated by σ-1
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receptor activation (Katnik et al., 2006). However, the difference between afobazole and
DTG effects on Aβ modulation of [Ca2+]i, suggest these long-term [Ca2+]i increases
involve distinct mechanisms from those producing ischemia-induced [Ca2+]i overload.
Additionally, the lack of a DTG effect on Aβ-evoked [Ca2+]i overload suggests that not all
σ-1 agonists may promote neuronal survival in this model. This hypothesis is further
supported by our observation that DTG fails to decrease neuronal apoptosis following 24
hr incubation Aβ25-35. The difference in responses between afobazole and DTG may be
due to off-target effects of DTG counteracting the benefits of this pan-selective sigma
agonist. Such a possibility needs to be explored further.
It has been suggested that one of the downstream consequences of [Ca2+]i
dysregulation in neurons caused by Aβ25-35 is the production of ROS (Ekinci et al., 2000,
Abramov et al., 2004). Afobazole has been shown to reduce ROS accumulation in rat
brains after focal ischemia (Silkina et al., 2006). However, data presented here show that
afobazole does not block the ROS increases caused by the Aβ fragment. It has been
suggested that Aβ, and in particular Aβ25-35, can increase oxidative stress via
mechanisms independent of [Ca2+]i dysregulation (Varadarajan et al., 2001). Given that
afobazole inhibits [Ca2+]i dysregulation produced by Aβ25-35 in neurons but not the
increase in ROS, it is unlikely that afobazole is affecting this [Ca2+]i-independent ROS
production. It is important to note that while afobazole may not decrease ROS
production, it has been shown that σ-1 receptors decrease H2O2 evoked apoptosis
(Meunier and Hayashi, 2010). Thus, afobazole may in part decrease Aβ25-35-induced cell
death by acting downstream of the observed ROS increase.
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Aβ25-35 has been shown to increase nitric oxide synthase (NOS) activity and
produce neuronal injury via nitrosative stress (Parks et al., 2001, Cho et al., 2009). Aβ2535-evoked

increases in NO were significantly decreased following afobazole application.

Inhibition of inducible NOS (iNOS) has been proposed as a mechanism by which
activation of σ-1 receptors is neuroprotective after stroke (Vagnerova et al., 2006).
Similarly, functional downregulation of neuronal NOS (nNOS) has been shown to
contribute to σ receptor neuroprotection following ischemia in striatal neurons (Yang et
al., 2010). Since Aβ25-35 appears to increase both iNOS and nNOS in neurons (Limon et
al., 2009), activation of σ receptors by afobazole is predicted to reduce NO production by
both of these enzymes, and will ultimately contribute to protection from Aβ25-35 induced
injury.
One of the pro-apoptotic proteins upregulated in neurons both by the pathological
sequela induced by Aβ25-35 application and in patients with Alzheimer’s disease is Bax
(Paradis et al., 1996, Yao et al., 2005). Consistent with previous findings, the current
study shows that the number of Bax positive neurons is significantly increased following
24 hr incubation in Aβ25-35. However, when afobazole is applied in combination with Aβ2535,

Bax upregulation is diminished significantly. It has also been shown that the σ-1

agonist, PRE-084, can reduce apoptosis in cortical neurons caused by Aβ25-35 via
reduction in Bax (Marrazzo et al., 2005). However, glutamatergic neurotransmission was
blocked in those experiments (Marrazzo et al., 2005). Glutamatergic transmission is a
factor in Aβ25-35-induced cell death, and elevated glutamate levels have been shown to
induce Bax upregulation in neurons (Schelman et al., 2004, Revett et al., 2013). Thus,
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our data suggest that σ receptor activation by afobazole can reduce Bax expression and
concomitant cell death in the presence of Aβ25-35 even when glutamatergic transmission
is not blocked.
In addition to decreasing Bax levels, afobazole effectively reduced activated
caspase-3 expression in response to Aβ25-35. The active form of caspase-3 has been
implicated in the loss of hippocampal neurons in Alzheimer’s disease (Selznick et al.,
1999). In addition to serving as a late event involved in neuronal death during
Alzheimer’s disease, caspase activation may be an early event that promotes the
pathology of AD. Several caspases, including caspase-3, have been shown to cause
pathological tau filament assembly in neurons, which underlies AD etiology (Gamblin et
al., 2003). Selective inhibition of caspase-3 has been shown to protect neurons from
Aβ25-35-induced apoptosis (Allen et al., 2001). Sigma receptor activation has been shown
to decrease caspase-3 and to protect cortical neurons and RGC-5 cells against
excitotoxicity (Tchedre and Yorio, 2008, Griesmaier et al., 2012). Such a mechanism is
likely to contribute to afobazole neuroprotection from Aβ25-35 toxicity and may in part
explain the reduced neuronal death observed here.
The neuroprotective properties of afobazole following exposure to Aβ25-35 also
involves long-term upregulation of Bcl-2. Our data indicate that there is a biphasic
change in Bcl-2 levels in neurons following application of Aβ25-35 with an initial increase
at 24 hr followed by a suppression of Bcl-2 expression at 48 hr. A similar transient
expression pattern was previously reported in rat hippocampal neurons exposed to Aβ2535

(Kim et al., 1998). It was proposed that this initial increase in Bcl-2 expression is a

non-sustainable cellular response to the apoptotic pathways induced by Aβ (Kim et al.,
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1998). Our observations indicate that when afobazole is applied along with Aβ25-35, Bcl-2
levels do not drop below control at the 48 hr time point. Previous studies have shown
that Bcl-2 is a target for σ receptor mediated neuroprotection. The HIV-1 protein gp120
was shown to downregulate Bcl-2 in cortical neurons, but activation of σ receptors with
the σ ligand, PPBP, increased Bcl-2 expression (Zhang et al., 2012). PPBP was shown
to have a similar effect in a glutamate excitotoxicity model (Yang et al., 2007),
suggesting that Bcl-2 upregulation may occur after σ receptor stimulation under various
pathophysiological conditions.
In conclusion, our experiments show that afobazole can decrease Aβ25-35-evoked
neuronal apoptosis by activating σ-1 receptors. The activation of σ-1 receptors prevents
Aβ25-35-induced [Ca2+]i overload and is associated with a decrease in NO levels. The
molecular mechanisms mediating neuroprotection by afobazole include downregulation
of both Bax and activated caspase-3, and long-term upregulation of Bcl-2. Given the
importance of direct Aβ neurotoxicity in the etiology of Alzheimer’s disease, the findings
reported here suggest that σ-1 receptors are a putative target for AD therapy and that
the σ receptor agonist, afobazole, in particular, shows significant potential.
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CHAPTER 4

Stimulation of Sigma Receptors with Afobazole Blocks Activation of
Microglia and Reduces Toxicity Caused by Amyloid-β25-35
Introduction
Aβ has been shown to initiate a sequence of events in microglia, including a proinflammatory cascade and enhanced hemichannel formation, which ultimately produces
neuronal death (Orellana et al., 2011). In contrast, data also suggest that microglia may
be beneficial in AD by removing Aβ plaques (Wilcock et al., 2004, Herber et al., 2007). It
has been proposed that microglial senescence, and not activation, is a contributing factor
to late-onset Alzheimer's disease (Streit et al., 2009). Given the importance of microglial
cells in AD pathology, there is great interest in identifying molecular targets for
modulating the responses of these cells to Aβ, and for regulating their contribution to AD
pathology in general.
One possible target that has been explored for therapeutics in other pathological
states of the central nervous system but is not well-characterized in AD is sigma
receptors. Sigma (σ) receptors are found in numerous cell types distributed throughout
the mammalian body and modulate multiple signaling and regulatory pathways. Two
subtypes of σ receptors have been pharmacologically identified, σ-1 and σ-2.
Reprinted with permission of the American Society for Pharmacology and Experimental Therapeutics.
Copyright © 2013 by the American Society for Pharmacology and Experimental Therapeutics
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To date only the σ-1 receptor has been cloned (Walker et al., 1990, Quirion et al.,
1992, Seth et al., 1998). Sigma-1 receptors are intracellular chaperones that form a
complex within the endoplasmic reticulum (ER) and the mitochondrion-associated ER
membrane (MAM) (Kourrich et al., 2012). Activation of σ-1 receptors promotes migration
of these receptors away from the MAM to the sub-plasmalemmal ER, where the
receptors interact with and regulate numerous membrane channels (Zhang and Cuevas,
2002, 2005, Herrera et al., 2008, Zhang et al., 2009, Su et al., 2010, Cuevas et al.,
2011b). Less is known about σ-2 receptors, but these proteins seem to be involved in
regulation of inflammation, cell survival and calcium homeostasis (Vilner and Bowen,
2000, Crawford and Bowen, 2002, Zhang and Cuevas, 2002, Iniguez et al., 2013). Our
laboratory has shown that activation of σ receptors in microglia decreases ATP-induced
membrane ruffling and cell migration and lipopolysaccharide-induced cytokine production
(Hall et al., 2009a). Activation of σ receptors also protects microglia from ischemiainduced cell death (Cuevas et al., 2011b). These observations led our laboratory to
propose that the neuroprotection provided by σ receptor activation following stroke
involves both a decrease in the inflammatory response mediated by microglia and
enhanced survival of quiescent microglia (Cuevas et al., 2011b).
While the effects of σ receptor activation on microglial responses to ischemia
have been studied, there is little information on how σ receptors may affect microglial
responses to Aβ. In the absence of glutamatergic transmission, activation of σ-1
receptors has been shown to decrease neuronal apoptosis caused by Aβ25-35 (Marrazzo
et al., 2005), but it is unclear how σ-1 activation will affect survival of microglia exposed
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to Aβ. It has been reported that there is a reduction in the number of sigma ligand
binding sites and σ-1 receptors in the brains of AD patients (Jansen et al., 1993, Mishina
et al., 2008). If these receptors prevent microglial activation and/or senescence, a loss of
these receptors may contribute to AD progression. Thus, it is of significant interested to
determine how σ receptor activation influences microglial responses to Aβ.
Experiments were carried out to determine if afobazole, an agonist at both σ-1
and σ-2 receptors (Cuevas et al., 2011b), can reduce activation and toxicity of microglia
by Aβ25-35. Afobazole decreased membrane ruffling and migration evoked by Aβ25-35. The
effects of afobazole were dependent on activation of both σ-1 and σ-2 receptor and were
blocked by inhibition of these receptors with BD-1047 and rimcazole. Furthermore,
afobazole inhibited increases in the levels of the pro-apoptotic protein Bax and the death
protease caspase-3 induced by Aβ25-35, resulting in an increase in microglia survival.
Finally, afobazole was shown to prevent disruption of ATP signaling in microglia
incubated in Aβ25-35, indicating that afobazole preserves microglial function following Aβ
exposure.

Materials and Methods

Primary Cultures of Microglia
Primary cultures of microglia were prepared from Sprague-Dawley mixed sex rat
pups (post-natal day 2-3) as previously described by our laboratory (Hall et al., 2009a,
Cuevas et al., 2011b). The mixed glial cultures were incubated for 7-12 days at 37 o C
prior to experiments being carried out. Microglia were mechanically separated from the
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cultures by brief shaking. Isolated microglia were resuspended in DMEM PLUS
containing: 500 mL Dulbecco’s Modified Eagle Medium with 4.5 g/L glucose, L-glutamine
and sodium pyruvate (DMEM) (Corning Cellgro, Manassas, VA), 40 mL horse serum
(Corning Cellgro), 12.5 mL heat-inactivated fetal bovine serum (Thermo Scientific
Hyclone, Logan, UT ), and 5 mL 10x antibiotic/antimycotic (Corning Cellgro). These cells
were used immediately for migration and cytotoxicity assays or plated on glass
coverslips for one day for imaging experiments.

Membrane Morphology and Migration Assay
Morphological changes to microglia induced by ATP or Aβ25-35 were assessed by
plating the cells on poly-L-lysine coated coverslips, serum starving the cells for 4 h in
DMEM, and exposing the cells to100 µM ATP or 25 µM Aβ25-35 for 10 min at 37º C.
When afobazole or DTG were used, microglia were incubated in the σ ligands (in
DMEM) for 10 min prior to ATP or Aβ25-35 exposure. Membrane ruffling was visualized by
labeling the cells with the filamentous actin probe, phalloidin (AlexaFluor 488 conjugated,
Life Technologies, Grand Island, NY). Quantification of membrane ruffling was carried
out as previously described (Hall et al., 2009a). Briefly, cell ruffling was scored as: “0” –
no ruffling and multiple filopodia; “1” – ruffling and filopodia; “2” – fully ruffled with no
filopodia.
Migration assays were carried out using a 48-well chemotaxis chamber (neuro
Probe, Inc., Gaithersburg, MD) as previously described (Cuevas et al., 2011b). The
bottom wells of the chamber were filled with 25 µM Aβ25-35 in DMEM and the top wells
contained 1x106 freshly isolated microglia. These chambers were separated by a
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fibronectin coated polycarbonate membrane with 8 µm pores at a density of 1 x 103
pores/mm2. Each well had an exposed filter area of 8 mm2. Test compounds (i.e. σ
ligands) were added to both the top and bottom wells at identical concentrations. The
microglia were permitted to migrate for 2 hr while incubated at 37oC. The membranes
containing microglia were processed as previously described and mounted on slides
using Vectashield Hardset containing 4'-6-diamidino-2-phenylindole (DAPI) (Vector Labs,
Burlingame Ca) (Cuevas et al., 2011b). DAPI positive cells were counted in 4 random
fields of view per well and averaged to determine migration for that well. For each
experiment, a minimum of 2-3 wells were used, and at least three migration experiments
were carried out for each condition. The n values given represent the total number of
fields of view recorded.

Calcium Imaging Measurements
Intracellular Ca2+ concentrations ([Ca2+]i) as a function of time were measured
using fluorescent imaging techniques and fura-2 as previously reported (Hall et al.,
2009a, Cuevas et al., 2011b). Microglia plated on coverslips were incubated for 1 hour at
room temperature in DMEM-PLUS containing 25 µM Aβ and 3 µM acetoxymethyl ester
fura-2 and 0.3 % dimethyl sulfoxide. Prior to the experiments, the coverslips were
washed in Aβ and fura-2-free physiological saline solution (PSS) containing (in mM): 140
NaCl, 5.4 KCl, 1.3 CaCl2, 1.0 MgCl2, 20 glucose, and 25 HEPES (pH to 7.4 with NaOH).
For studies on ATP-evoked [Ca2+]i changes, ATP was applied in PSS using a rapid
application system as described previously (Cuevas and Berg, 1998).
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ROS and NO Imaging
Intracellular ROS and NO concentrations were measured in isolated microglia
using the fluorometric indicators di-hydroethidiumbromide (DHE) and diacetate (4-amino5-methylamino-2',7'-difluorofluorescein diacetate) (DAF-FM), respectively. Cells plated
on poly-L-lysine coated coverslips were incubated at 37°C in DMEM-PLUS containing 10
µM DHE with 0.25 % DMSO for 30 min or 5 µM DAF-FM with 0.1 % DMSO for 1 hr. Prior
to beginning the experiments, the coverslips were rinsed with PSS. DHE and DAF-FM
labeled microglia were measured by digital microscopy (CoolSnap HQ2; Photometrics,
Surrey, BC, Canada), excited at 518 nm and 495 nm and emission captured at 605 nm
and 515 nm, respectively. Excitation exposure times were auto-calibrated to the control
(absence of drugs or Aβ) using this function on the acquisition software (Nikon Elements;
Nikon, Melville, NY, USA) and used for all slides in that dish. Image analysis was
performed using the Nikon Elements software. Images were acquired every second for
ten seconds and the average of the acquisitions was used for the fluorescence
intensities (A.U.). Statistical analysis was performed using SigmaPlot 11 (Systat
Software, Inc., San Jose, CA).

Cell Death Assay
Microglia plated on coverslips were incubated at 37°C for 72 hr in DMEM-PLUS
with 25 µM Aβ25-35 in the absence (Control) and presence of 30 µM afobazole. The
coverslips were rinsed with phosphate buffered saline (PBS) and then incubated for 30
min in 4 µM EthD-1 solution at room temperature. The coverslips were washed with PBS
and deionized water, air dried and mounted on a microscope slide with Vectashield
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Hardset mounting media (Vector Labs, Burlingame, CA). EthD-1 positive cells were
visualized at 400x using a Zeiss Axioskop 2 and counted using Image-J software in four
random fields per slide. For each experiment, a minimum of three slides were used, and
the results of at least three experiments were averaged together. Coverslips were
visualized in bright field to confirm homogeneous cell density.

Immunocytochemistry
Microglia plated on poly-L-lysine coverslips were incubated at 37°C for 24 hr in
DMEM-PLUS with 25 µM Aβ25-35 in the absence (Control) and presence of 30 µM
afobazole. The coverslips were rinsed three times, followed by a step-wise ethanol
fixation, permeabilized with 0.1 % Triton X, rehydrated and blocked with 2 % BSA.
Primary antibodies were diluted in PBS with 0.5 % BSA and incubated at 4°C for 24 hr.
The following dilutions were used: anti-Bax 1:20, anti-activated Caspase-3 1:25 and antiBcl-2 1:100. The secondary antibodies used were Alexa Fluor 488 conjugated antimouse or anti-rabbit, as appropriate, and diluted at a ratio of 1:300 in PBS with 0.5%
BSA. Coverslips were mounted onto slides using VectaShield with DAPI. Excitation and
emission wavelengths used were 359 nm and 461 nm (DAPI) and 485 nm and 530 nm
(Alexa Fluor 488), respectively. Cells were imaged at 400x and counted in four random
fields per slide using Image-J software. The average for the fields was used as the value
for each slide. For each experiment, a minimum of three slides were analyzed, and the
results of at least three experiments were averaged together, with n values representing
number of experiments.
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Reagents and Antibodies
All test compounds were applied in DMEM-PLUS for 10 min prior to Aβ25-35
exposure, and throughout the Aβ25-35 incubation. The following drugs were used in this
investigation: DTG and BD-1047 (Tocris Biosciences, Ellisville, MO); rimcazole (SigmaAldrich, St. Louis, MO); fura-2 acetoxymethyl ester, DHE, DAF-FM, Live/Dead
Viability/Cytotoxicity Kit, Alexa Fluor 488 Phalloidin (A-12379), Alexa Fluor 488 antimouse (A-11001) and anti-rabbit (A-11008) (Invitrogen, Grand Island, NY); Bax
(ab5714), activated caspase-3 (ab32351) and Bcl-2 (ab32370) (abcam, Cambridge, MA);
Afobazole was generously provided by IBC Generium (Moscow, Russian Federation).
Aβ25-35 was obtained from (American Peptides, Sunnyvale, CA).
Data Analysis
Fura-2 fluorescence intensities as a function of time were recorded from microglia
in the same manner as previously described (Katnik et al., 2006, Cuevas et al., 2011a,
Cuevas et al., 2011b) and converted to [Ca2+]i using an in situ calibration kit (Invitrogen).
Data were analyzed using SigmaPlot 11 (Systat Software, Inc., San Jose, CA). Data
points represent peak means ± standard error of the mean (S.E.M.). One- or two-way
analysis of variance were used for determining significant differences for multiple group
comparisons, as appropriate, followed by post hoc analysis using the Holm-Sidak test.
Results were considered statistically significant if p < 0.05.

Results
Previously, our laboratory has shown that the pan-selective σ agonist DTG
prevents activation of microglia occurring in response to various stimuli, including
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Figure 4.1
Afobazole blocks membrane ruffling induced by ATP in microglial cells. A,
Photomicrographs of microglial cells exposed for 10 min (37° C) to media alone
(Control), media containing 30 µM afobazole (Afob), or media containing 30 µM DTG
(DTG) in the absence (i, iii, v) and presence (ii, iv, vi) of 100 µM ATP, respectively. Insets
show zoomed in images of the indicated regions. Scale bar = 3 µm. B, Bar graph of
mean degree of membrane ruffling (±SEM) observed in cells exposed to the same
conditions as (A). Asterisks denote significant difference between Control and ATP
groups within Media, Afob and DTG (p < 0.001, 0.05, & 0.01, respectively); pound
symbols denote significant difference within ATP between Media and Afob or Media and
DTG (p < 0.001 for both). For all groups, n > 67.
lipopolysaccharide, ATP and MCP-1 (Hall et al., 2009a, Cuevas et al., 2011b). While
afobazole preserves the functional capacity of microglia and responsiveness to ATP
(Figure 4.1), data from our laboratory suggest that afobazole can reduce activation of
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these cells by ATP (Cuevas et al., 2011b). This previous work had shown that afobazole
inhibits migration of microglia, but did not examine if afobazole prevents the
morphological changes evoked by ATP in microglial. Incubation of the microglia in 100
µM ATP for 10 min (37° C) resulted in retraction of filopodia and increased membrane
ruffling (Figure 4.1A ii). Co-incubation of the cells in 30 µM afobazole or 30 µM DTG
decrease membrane ruffling elicited by ATP (Figure 4.1A iv & vi). Quantification of the
degree of membrane ruffling shows that ATP significantly increases membrane ruffling
by 271 ± 14% and that this change is statistically reduced by both afobazole and DTG,
49 ± 5 and 37 ± 5% respectively (Figure 4.1B).
Experiments were carried out to see afobazole could also block microglial
activation caused by application of amyloid-β25-35 (Aβ25-35). One of the events associated
with microglial activation that has been shown to be regulated by σ receptors is
membrane ruffling (Hall et al., 2009a). Thus, we examined how afobazole affects
morphological changes induced by the amyloid peptide in these cells. In cultured,
quiescent microglia, filopodia are readily observed, and these membrane processes are
not directly affected by incubation of the cells in 30 µM afobazole or a second panselective σ agonist, DTG (30 µM) (Figure 4.2A). Incubation of the microglia in 25 µM
Aβ25-35 for 10 min (37° C) resulted in retraction of filopodia and increased membrane
ruffling (Figure 4.2A ii). When afobazole (30 µM) was applied along with the Aβ fragment,
there was a decrease in membrane ruffling compared to Aβ25-35 alone (Figure 4.2A iv).
Pronounced membrane ruffling was still observed when DTG was added with Aβ25-35
(Figure 4.2A vi). Quantification of the degree of membrane ruffling in microglia in
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Figure 4.2
Afobazole blocks membrane ruffling induced by Aβ25-35 in microglial cells. A,
Representative photomicrographs of microglial cells exposed for 10 min (37° C) to
media, media containing 30 µM afobazole, or media containing 30 µM DTG in the
absence (i, iii, v) and presence (ii, iv, vi) of 25 µM Aβ25-35, respectively. Fields of view of
each photomicrograph are representative regions within larger image used to calculate
membrane ruffling. Insets show expanded images of the indicated regions. Scale bar = 3
µm. B, Bar graph of mean degrees of membrane ruffling (±SEM) observed in cells
incubated in media alone (Media), media with 30 µM Afobazole (Afob), and media with
30 µM DTG (DTG), in the absence (Control) or presence of 25 µM Aβ25-35 (Aβ). Asterisks
denote significant difference between Control and Aβ groups within Media and DTG,
respectively (p < 0.001 for both). Pound symbols denote significant difference from
Media within Aβ (Afob, p < 0.001; DTG p < 0.05), and dagger indicates significant
difference between Afob and DTG, also within Aβ (p < 0.001). For all groups, n ≥ 35.
experiments identical to those of Figure 4.2A shows that Aβ25-35 increases membrane
ruffling by more than 5-fold (Figure 4.2B). Incubation of the cells in either afobazole or
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DTG significantly reduced the degree of membrane ruffling caused by Aβ25-35 (Figure
4.2B). However, the effect of afobazole on Aβ25-35-induced membrane ruffling was
significantly greater than that produced by DTG, with the membrane ruffling being
decreased by 70 ± 7% and 21 ± 9% by these drugs, respectively (Figure 4.2B).
In addition to membrane ruffling, Aβ25-35 induces chemotaxis of microglia, and σ
receptor activation has been shown to disrupt migration of microglia in response to other
stimuli (Hall et al., 2009a, McLarnon, 2012). Experiments were therefore carried out to
determine if application of afobazole can inhibit microglial migration caused by Aβ25-35. A
concentration-response relationship for afobazole reduction in microglial migration when
Aβ25-35 is used as the chemoattractant is shown in Figure 4.3A. Afobazole, at
concentrations as low as 10 µM, reduced the number of microglia migrating in response
to Aβ25-35. Half maximal inhibition of Aβ25-35-induced migration was observed at 122 µM
afobazole and maximal recorded block was achieved at 1 mM afobazole (Figure 4.3A).
To verify that σ receptors are involved in afobazole suppression of microglial
activation by Aβ25-35, the σ receptor subtype-specific antagonists BD-1047 and rimcazole
were used to block the effects of afobazole on migration. Afobazole was applied at 30
µM in the absence and presence of the selective σ-1 and σ-2 receptor antagonist, BD1047 (10 µM) (Matsumoto et al., 1995) and rimcazole (300 nM) (Gilmore et al., 2004),
and migration in response to Aβ25-35 was assessed. Afobazole alone decreased
microglial migration caused by Aβ25-35 by 29 ± 1%.This inhibition was reduced to 10 ± 1%
and 8 ±1% when afobazole was combined with BD-1047 and rimcazole, respectively

83

(Figure 4.3B). Therefore, inhibition of either σ-1 or σ-2 significantly reduced afobazolemediated suppression of microglial activation by Aβ25-35.

Figure 4.3
Afobazole blocks the migration of microglia elicited by Aβ25-35. A, Concentrationresponse relationship for afobazole inhibition of microglial migration evoked by 25 µM
Aβ25-35. Solid line represents best fit to the data using a one-component Langmuir-Hill
equation, with the IC50 value and Hill coefficient being 122 µM and 0.6, respectively. Points
represent mean (±SEM) normalized to control values (no afobazole), for all points n = 36.
B, Bar graph of the mean (± S.E.M.) percent inhibition of Aβ25-35-induced migration of
microglial cells by afobazole (30 µM) in the absence (Control) and presence of 10 µM
BD-1047 (BD-1047) or 300 nM rimcazole (Rimcazole). Asterisks denote significant
difference from Control (p < 0.001 and n = 24 for all).
The microglia-mediated inflammatory response caused by Aβ is in part mediated via
upregulation in the production of ROS and NO (Weldon et al., 1998, Bianca et al., 1999,
Combs et al., 2001). Therefore, experiments were carried out to determine if afobazole
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affects ROS or NO levels in microglia following incubation in Aβ25-35. Incubation in
afobazole alone produced a decrease in basal levels of ROS in isolated microglia (Figure
4.4A). As predicted, incubation of microglia for 24 hr in Aβ25-35 increased ROS in the
cells. However, afobazole failed to block this increase in ROS. Unlike ROS, basal NO

Figure 4.4
Afobazole does not decrease microglial ROS or NO production induced by Aβ25-35. A,
Bar graph of mean (±SEM) DHE fluorescence intensity (ROS levels) measured in
microglial cells incubated for 24 hr in the absence (Control) or presence of 25 µM Aβ25-35
(Aβ) without (Media) and with 30 µM Afobazole (Afob). Asterisks denote significant
difference between Control and Aβ within Media and Afob groups, respectively (p <
0.05). Pound symbol indicates significant difference between Media and Afob groups
within Control (p < 0.05). For all groups, n ≥ 149. B, Bar graph of mean (±SEM) DAF-FM
fluorescence intensity (NO levels) measured in microglia incubated for 24 hr in absence
(Control) or presence of 25 µM Aβ25-35 (Aβ) without (Media) and with 30 µM Afobazole
(Afob). Asterisks denote significant difference between Control and Aβ groups within
Media and Afob groups (p < 0.05 for both). For all groups, n ≥ 200.

85

levels in microglia were not significantly affected by afobazole (Figure 4.4B). Aβ25-35 did
produce a small but statistically significant increase in NO, and as with ROS, afobazole
failed to block this effect of the amyloid peptide (Figure 4.4B).
Given that microglial cell senescence has been suggested to contribute to AD
pathology and that Aβ has been shown to produce microglial apoptosis (Korotzer et al.,
1993, Streit et al., 2009), experiments were carried out to determine how activation of σ
receptors with afobazole affects microglial survival following application of Aβ25-35. Figure
4.5A shows representative photomicrographs of microglia labeled with EthD-1 following
72 hr (37º C) incubation in media alone or media containing Aβ25-35 in the absence and
presence of 30 µM afobazole. Few apoptotic microglia were detected when the cells
were incubated in media alone (Figure 4.5A i), but there was a significant increase in
EthD-1-positive cells following Aβ25-35 application (Figure 4.5A ii). Afobazole alone did
not visibly alter the number of EthD-1-positive cells (Figure 4.5A iii), but there was a
decrease in the number of apoptotic cells in the afobazole- Aβ25-35 group (Figure 4.5A iv)
relative to Aβ25-35 alone (Figure 4.5A ii). In identical experiments, Aβ25-35 was found to
produce a nearly 3-fold increase in the number of apoptotic cells relative to control (no
Aβ25-35) (Figure 4.5B). However, afobazole application significantly counteracted the proapoptotic effects of Aβ25-35 such that no significant increase in EthD-1 labeling was
observed in the Aβ25-35 + afobazole group (Figure 4.5B).
Microglial cell death induced by Aβ25-35 has been linked to upregulation of the proapoptotic gene, Bax (Jang et al., 2005). Immunocytochemical experiments were
conducted to determine if levels of Bax expression increase in our rat microglia model
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and if afobazole can affect expression of this protein. Representative photomicrographs
of microglia double labeled with DAPI and anti-Bax antibody are shown in Figures 4.6A.
Whereas Bax labeling was rarely observed in control (untreated) microglia, Bax
immunolabeling was prominent in cultures treated for 24 hr (37º C) with Aβ25-35 (Figures
4.6A i & ii). Incubation of microglia in afobazole alone had no effect on Bax expression

Figure 4.5
Afobazole decreases microglial cell death produced by application of Aβ25-35. A,
Photomicrographs showing EthD-1 labeling (red) of microglial cells following 72 hr
incubation in media alone (i), or media containing 25 µM Aβ25-35 (Aβ) (ii), 30 µM
afobazole (Afob) (iii), or 30 µM afobazole + 25 µM Aβ25-35 (iv). Fields of view shown are
representative regions within larger images used to calculate cell death. B, Bar graph of
the mean (±SEM) relative number of apoptotic cells identified by EthD-1 labeling in
multiple experiments when the cultures were incubated under the same conditions as
(A). Data for each experiment were normalized to the mean cell death observed with
media alone (Media, Control). Asterisk denotes significant difference between Control
and Aβ groups within Media (p < 0.05). Pound symbol indicates significant difference
between Media and Afob groups within Aβ (p < 0.05) (n ≥ 12) Scale bar in (i) is 10 µm.
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levels, but application of the σ agonist inhibited Aβ25-35 -induced elevated Bax expression
(Figure 4.6A iii & iv). Compilation of data from several identical experiments indicates

Figure 4.6
Afobazole reduces Aβ25-35-evoked expression of the pro-apoptotic gene product Bax, in
microglia. A, Photomicrographs of merged images of cultured microglia exposed for 24
hr to media alone (i), or media containing 25 µM Aβ25-35 (Aβ) (ii), 30 µM afobazole (iii) or
25 µM Aβ25-35 + 30 µM afobazole (iv). Microglia were double labeled with DAPI (blue)
and anti-Bax antibody (green). Fields of view shown are representative regions within
larger images used to calculate Bax expression. B, Bar graph of the mean (±SEM)
number of Bax-positive microglia in experiments in which the cells were exposed to
media (Control) or 25 µM Aβ25-35 (Aβ) in the absence (Media) or presence of 30 µM
afobazole (Afob). Data are expressed as the percent of Bax positive microglia, using
DAPI to identify the number of microglia per slide. Asterisks denote significant difference
between Control and Aβ within Media and Afob (p < 0.001 for both). Pound symbol
indicates significant difference between Media and Afob within Aβ (p < 0.001). For all, n
= 9. Scale bar in (i) is 10 µm.
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that approximately 20% of control microglia expressed Bax, but that this number
increases to over 80% following Aβ25-35 incubation (Figure 4.6B). While an increase in
Bax expression was noted when microglia were incubated in a combination of afobazole
and Aβ25-35, there was a 54 ± 4% reduction in the number of cells showing Bax reactivity
when compared to microglia incubated in Aβ25-35 alone (Figure 4.6B).
Caspase-3 has also been implicated in Aβ25-35-induced microglial apoptosis, and
σ-1 receptor activation has been shown to induce caspase-3 downregulation in these
cells (Jang et al., 2005, Tchedre and Yorio, 2008). Thus, we examined the effects of
afobazole on the levels of the death protease, caspase-3, after microglial cell were
exposed to Aβ25-35 for 24 hr (37º C). Incubation of microglia in Aβ25-35 increased the
number of cells expressing the active form of caspase-3 relative to control (Figure 4.7A i
& ii). While afobazole alone had no significant effect on activated caspase-3 expression,
afobazole inhibited the increases in active caspase-3 evoked by Aβ25-35 (Figure 4.7A iii &
iv). In identical experiments, comparing the number of cells expressing activated
caspase-3 in cultures treated with Aβ25-35 alone to those treated with Aβ25-35 + afobazole
indicates that afobazole reduces caspase-3 expression by 47 ± 5% (Figure 4.7B).
The anti-apoptotic gene product, Bcl-2, has been shown to be upregulated by
interventions that decrease microglial cell death caused by Aβ25-35 (Jang et al., 2005). In
neurons, the expression levels of this protein increase after 24 hr exposure to Aβ and
then decreases after 48 hr (Kim et al., 1998). Thus, to explore how afobazole protects
microglia from Aβ25-35-induced apoptosis, we used the 48 hr time point to assess how
afobazole affects Bcl-2 expression. Bcl-2 was readily detected at 48 hr in microglia under
all conditions tested (Figures 4.8A). Quantification of the data shows that afobazole
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application produced a small, but significant, increase of 14 ± 1% in the number of
microglia expressing Bcl-2 (Figure 4.8B). Similarly, Aβ25-35 alone increased the number
of cells expressing Bcl-2 by 11 ± 1%. While afobazole co-application did not increase

Figure 4.7
Afobazole reduces expression of activated caspase-3 in response to application of Aβ2535 in microglia. A, Photomicrographs of merged images of cultured microglia exposed for
24 hr to media alone (i) or media containing 25 µM Aβ25-35 (ii), 30 µM afobazole (iii) or 25
µM Aβ25-35 + 30 µM afobazole (iv). Microglia were double labeled with DAPI (blue) and
anti-activated caspase-3 antibody (green). Fields of view shown are representative
regions within larger images used to calculate activated caspase-3 expression. Scale bar
in (i) is 10 µm. B, Bar graph of mean (±SEM) percent of caspase-3 positive microglia in
experiments in which the cells were exposed to media (Control) or 25 µM Aβ25-35 (Aβ) in
the absence (Media) or presence of 30 µM afobazole (Afob). Asterisks denote significant
difference between Control and Aβ groups within Media and Afob (p < 0.001); pound
symbol indicates significant difference between Media and Afob within Aβ (p < 0.001).
For all condition, n =9.
90

Bcl-2 expression significantly above afobazole alone, the combination of afobazole and
Aβ25-35 yielded a small but significant increase (4 ± 1%) in the number of microglia
expressing Bcl-2 after 48 hr when compared to Aβ alone (Figure 4.8B).

Figure 4.8
Afobazole has minor effects on Bcl-2 levels in microglia following application of Aβ25-35.
A, Photomicrographs of merged images of cultured microglia exposed for 24 hr to media
alone (i) or media containing 25 µM Aβ25-35 (ii), 30 µM afobazole (iii) or 25 µM Aβ25-35 +
30 µM afobazole (iv). Microglia were double labeled with DAPI (blue) and anti-Bcl-2
antibody (green). Areas shown are representative regions within larger images used to
calculate Bcl-2 expression. Scale bar in (i) is 10 µm. B, Bar graph of mean (±SEM)
percent of Bcl-2 positive microglia in experiments in which the cells were exposed to
media (Control) or 25 µM Aβ25-35 (Aβ) in the absence (Media) or presence of 30 µM
afobazole (Afob). Asterisk denotes significant difference between Control and Aβ within
Media (p < 0.01). Pound symbols indicate significant difference between Media and Afob
within Control and Aβ, respectively (p < 0.01 for both, n = 9 for all).
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While our observations indicate that activation of σ receptors with afobazole
decreases microglial cell death, it is unclear if the surviving cells have been
compromised such that they fail to exhibit responses to normal stimuli. Thus, functional
studies were carried out to evaluate microglia using ATP to stimulate changes in [Ca2+]i
following Aβ25-35 application in the absence and presence of afobazole. Figure 4.9A
shows a series of traces of [Ca2+]i as a function of time recorded from four microglia
incubated in Aβ25-35 for 24 hr and exposed to ATP in the absence and presence of
afobazole. Focal application of 100 µM ATP produced transient elevations in [Ca2+]i in
microglia under control conditions and when the cells were incubated in 25 µM Aβ25-35
(Figure 4.9A, top traces). However, the ATP-induced elevations in [Ca2+]i were greatly
reduced in the microglia incubated in Aβ25-35. In contrast, microglia incubated in 30 µM
afobazole displayed similar ATP-induced increases in [Ca2+]i in absence and presence of
the Aβ fragment (Figure 4.9A, bottom traces). In identical experiments, ATP evoked
comparable increases in [Ca2+]i in microglia incubated in media alone (Control) and 30
µM afobazole (Figure 4.9B). However, microglia incubated in Aβ25-35 showed a
statistically significant 34 ± 4% reduction in ATP-evoked [Ca2+]i responses (Figure 4.9B).
While afobazole pre-incubation did not have a long-term effect on ATP-evoked
responses, co-application of 30 µM afobazole along with the 25 µM Aβ25-35 rescued the
ATP-evoked responses such that the increases in [Ca2+]i observed in this group were
statistically similar to both the Control group and the afobazole alone group. The [Ca2+]i
responses in the afobazole + Aβ25-35 group were 44 ± 8% greater than the Aβ25-35 only
group (Figure 4.9B).
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Figure 4.9
Afobazole preserves [Ca2+]i responses to ATP in microglial cells exposed to Aβ25-35. A,
representative traces of [Ca2+]i as a function of time recorded from four microglia during
10 second application of 100 µM ATP following 24 hr incubation in media alone
(Control), or media containing 25 µM Aβ25-35 (Aβ), 30 µM Afobazole (Afob) or 25 µM
Aβ25-35 + 30 µM Afobazole (Afob + Aβ). The afobazole and Aβ were washed out for 5 min
prior to application of ATP. Line above [Ca2+]i responses indicates duration of ATP
application. B, Bar graph of mean (± SEM) peak increases in [Ca2+]i (∆[Ca2+]i) evoked by
application of 100 µM ATP onto isolated microglia. [Ca2+]i responses were recorded from
microglia in experiments identical to those performed in (A). Asterisk symbolizes
significant difference between Control and Aβ within Media (p < 0.001). Pound symbol
denotes significant difference between Media and Afob within Aβ (p < 0.001). For all
conditions, n ≥ 33.
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Discussion
The most salient finding reported here is that activation of both σ-1 and σ-2
receptors by afobazole rescues microglia from the deleterious consequences of Aβ25-35
exposure. Afobazole application reduced the activation of microglia caused by incubation
of the cells in Aβ25-35 as evident by a decrease in membrane ruffling and cell migration
induced by the Aβ fragment. The apoptosis of microglia induced by Aβ25-35 was also
reduced by afobazole. This decrease in cell death is likely due to a reduction in the
expression of the pro-apoptotic gene, Bax, and the death protease, caspase-3.
Afobazole also preserved functional responses of the microglia to ATP after Aβ25-35
incubation, which has significant implications for Alzheimer’s disease progression.
Afobazole application reduced the activation of microglia caused by incubation of
the cells in ATP, as evident by a decrease in membrane ruffling. Previous studies from
our laboratory have shown that microglia quickly become activated and withdraw their
filopodia when exposed to various stimuli, such as LPS and ATP (Hall et al., 2009a).
This activated state, which allows the microglia to migrate to the site of injury, is
preceded by the release of neurotoxic substances (Kierdorf and Prinz, 2013). Previously
we have shown that microglia, in response to ATP, alter their morphology to a less
ramified state and this reaction was inhibited by DTG (Hall et al., 2009a). Afobazole
effectively blocked membrane ruffling by approximately 50% in response to ATP. For
comparison we used a second pan-selective σ receptor agonist, DTG, which reduced
ruffling comparable to afobazole and to the extent as previously reported.
Previous studies have shown that microglia rapidly respond to Aβ by withdrawing
their filopodia and assuming an amoeboid, ruffled morphology (Araujo and Cotman,
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1992). This early event is indicative of microglial activation and precedes the
inflammatory response that includes release of neurotoxic substances from the microglia
(Combs et al., 2001, Garcao et al., 2006, Orellana et al., 2011). Afobazole (30 µM)
effectively blocked membrane ruffling in response to Aβ25-35. While a second panselective σ receptor agonist, DTG (30 µM), also decreased membrane ruffling caused by
Aβ25-35, this drug was significantly less potent than afobazole. It has been shown that
higher concentrations of DTG (100 µM) are also required to block ATP-induced
microglial membrane ruffling (Hall et al., 2009a).
Afobazole also effectively blocked microglial migration induced by Aβ25-35. It has
been shown previously that various Aβ fragments, including Aβ25-35, are microglial
chemotactic agents (Davis et al., 1992). The Aβ-induced chemotaxis is in part due to
release of ATP from microglia following Aβ25-35 application and subsequent activation of
P2Y2 receptors on these cells (Kim et al., 2012). We have previously shown that
afobazole blocks microglial migration induced by activation P2Y receptors (Cuevas et al.,
2011b). Afobazole appears to inhibit microglial migration caused by UTP via σ receptormediated disruption in P2Y signaling, since afobazole treatment also inhibited P2Yinduced elevation in [Ca2+]i in microglia (Cuevas et al., 2011b). The IC50 for afobazole
inhibition of microglial migration caused by Aβ25-35 is 120 µM, which is similar to the lowaffinity site reported for afobazole inhibition of UTP-induced microglial migration (102
µM) (Cuevas et al., 2011b). Therefore, afobazole may in part prevent microglial
chemotaxis caused by Aβ25-35 via σ receptor-mediated inhibition of P2Y receptors in
these cells.
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Data shown here indicate that both σ receptor subtypes are involved in afobazole
inhibition of Aβ25-35-evoked microglial activation. Afobazole-mediated inhibition of
microglial migration was reduced by ~50% by 10 µM BD 1047, which is indicative of a σ1 receptor mediated effect (Matsumoto et al., 1995). An identical concentration of BD
1047 had a similar effect on afobazole inhibition of ATP-induced microglial cell migration
(Cuevas et al., 2011b). Likewise, involvement of σ-2 receptors is confirmed by results
obtained using the σ receptor antagonist, rimcazole, which binds to σ-2 receptors with
nanomolar affinity (Ferris et al., 1986, Rybczynska et al., 2008). Nanomolar
concentrations of rimcazole also blocked afobazole inhibition of microglial migration in
response to ATP (Cuevas et al., 2011b).
Given that one of the consequences of microglial activation is increased oxidative
and nitrosative stress, which leads to Aβ25-35 toxicity (Weldon et al., 1998, Bianca et al.,
1999, Combs et al., 2001), we examined how afobazole affects Aβ25-35-induced
increases in cellular ROS and NO levels. Consistent with previous reports, both ROS
and NO levels were increased significantly following Aβ25-35 application. However,
afobazole failed to attenuate the increases in ROS and NO evoked by the Aβ fragment.
Activation of σ receptors has been shown to decrease oxidative injury and nitrosative
stress in various models. It was recently shown, using σ receptor knockout mice, that σ-1
has a dual function of both reducing oxidative stress and activating antioxidant response
elements (Pal et al., 2012). In microglia, stimulation of σ receptors by DTG reduces NO
production in response to lipopolysaccharide (Hall et al., 2009a). Taken together,
however, our data suggest that the reduction in Aβ-evoked microglial cell toxicity
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provided by afobazole application is not the result of σ receptor-mediated decrease in
oxidative or nitrosative stress.
While decreased activation of microglia will be beneficial in AD by reducing the
neuroinflammatory response, recent data suggests that enhanced microglial survival is
also important for improved outcomes given the ability of these cells to phagocytose Aβ
plaques (Streit et al., 2009, Solito and Sastre, 2012). Application of 30 µM afobazole
significantly reduced the number of microglia undergoing apoptosis following 72 hr
incubation in Aβ25-35. The concentrations of afobazole shown to be effective here are
identical to those previously shown to decrease microglial cell death caused by ischemia
in a σ receptor dependent manner and consistent with the binding affinity of afobazole
for σ-1 receptors (Seredenin et al., 2009, Cuevas et al., 2011a, Cuevas et al., 2011b).
This observation suggests that afobazole is similarly acting through σ receptor activation
to prevent microglial cell death. Both melatonin and N-acetylcysteine have been shown
to decrease Aβ25-35-evoked apoptosis in microglia via a reduction in ROS (Jang et al.,
2005). Given that afobazole does not appear to affect Aβ25-35-elicited increases in ROS,
it is unlikely that afobazole provides cytoprotection via a similar mechanism to these
compounds.
Our findings demonstrate that afobazole mitigates Aβ25-35-induced apoptosis of
microglia by decreasing expression of the pro-apoptotic gene, Bax, and the death
protease caspase-3 while preserving the levels of the anti-apoptotic gene, Bcl-2. An
increase in Bax levels has been observed in both neurons and microglia of AD brains
(Su et al., 1997). Moreover, interventions that decrease Aβ25-35-induced microglial
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apoptosis have been shown to lower Bax expression (Jang et al., 2005, Shang et al.,
2012). Likewise, caspase activity has been detected in plaque-associated neurons and
microglia in AD brains (Yang et al., 1998). Caspase-3 levels have been shown to be
upregulated in microglia following Aβ administration, while reduced levels of this death
protease have been associated with inhibition of Aβ toxicity (Shang et al., 2012).
Conversely, expression of the anti-apoptotic gene, Bcl-2, is inversely correlated with
disease severity in AD. Increases in Bcl-2 levels promote microglial survival following
exposure to Aβ25-35 (Satou et al., 1995, Jang et al., 2005). Therefore, afobazole likely
enhances microglial survival and resistance to Aβ25-35 toxicity via a complex response
involving both anti-apoptotic and pro-apoptotic genes. This multifaceted effect is
consistent with afobazole acting as a σ agonist, since σ receptor activation has been
shown to modulate Bax, caspase-3 and Bcl-2 levels (Tchedre and Yorio, 2008, Meunier
and Hayashi, 2010).
Importantly, not only did afobazole protect microglia from Aβ25-35-evoked
apoptosis, but application of the σ agonist preserved the functional capacity of these
cells, as evident from the continued [Ca2+]i responses to ATP. Ultimately, one of the
theoretical benefits to increased microglial survival would be continued clearance of Aβ,
as this peptide has been shown to be phagocytosed by microglia (Wilcock et al., 2004,
Herber et al., 2007). This hypothesis is further supported by the recent observation that
microglial clearance of Aβ directly correlates with expression of the gene CD33, such
that a CD33 deficiency reduces brain levels of both insoluble Aβ1-42 and amyloid plaque
burden in a mouse AD model (Griciuc et al., 2013). Moreover, there is a decrease in both
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CD33 expression and insoluble Aβ1-42 in the brains of individuals expressing the minor
allele of the CD33 (SNP rs3865444) gene, which was identified previously as imparting
protection against AD (Naj et al., 2011, Griciuc et al., 2013). The fact that responses to
ATP itself are preserved is significant, since the clearance of Aβ has been shown to be
dependent of the activation of P2Y2 receptors. Microglia respond to Aβ by releasing ATP
and this nucleotide functions in a paracrine manner, acting on P2Y2 receptors expressed
on the microglia to enhance Aβ uptake by these cells (Kim et al., 2012). We have
previously shown that in our model these increases in [Ca2+]i are due to activation of P2Y
receptors, since they can be elicited by UTP (Cuevas et al., 2011b). Therefore, by
preserving ATP responses in microglia, afobazole will permit these cells to respond to Aβ
in vivo and potentially decrease amyloid burden.
In conclusion, our study demonstrates that afobazole can mitigate activation of
microglial cells in response to Aβ25-35. Afobazole also reduced microglial toxicity caused
by Aβ25-35, but this cytoprotection does not involve regulation of either ROS or NO
production caused by the amyloid peptide. The observed decrease in apoptosis is due to
afobazole-mediated regulation of multiple genes, with a noted decrease in Bax and
caspase-3 and a concomitant increase in Bcl-2 expression. In addition to the decrease in
cell death, afobazole preserved functional activity of the cells as evident by the
conserved ATP-induced increases in [Ca2+]i following prolonged incubation in Aβ25-35.
Taken together our data suggest that afobazole may prevent microglia from entering the
activated state associated with neurotoxicity following exposure to Aβ, and increasing
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their survival, which will facilitate clearance of the amyloid peptide. These properties
make afobazole an attractive drug for potential Alzheimer’s therapeutics.
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CHAPTER 5

Activation of Sigma Receptors via Afobazole Modulates Microglial but not
Neuronal Apoptotic Expression in Response to Long-Term Ischemia Exposure

Introduction
Our laboratory has previously shown that stroke is a multicellular disease and that
any attempts to treat this disease must involve several different cell types (Hall et al.,
2009b, Leonardo et al., 2010, Cuevas et al., 2011a, Cuevas et al., 2011b). Neurons have
previously been the sole target in the treatment of stroke, but we have shown that
microglia cells play a dynamic roll the pathophysiology of stroke (Hall et al., 2009a,
Cuevas et al., 2011b). In response to stroke or other types of CNS injury, microglia
become activated and migrate to the site of injury (Kierdorf and Prinz, 2013), while the
initial action is neuroprotective in nature, overtime microglial cells become over-activated
and neurotoxic (Hellwig et al., 2013). It is possible that the injury occurring, following the
days and weeks after a stroke, is due to microglia over-activation (Hellwig et al., 2013).
However, completely inhibiting activation and migration of microglial cells would result in
unintended, detrimental side effects as microglia play an important, neuroprotective role
in the early stages following a stroke insult (Kitamura et al., 2004). Therefore, it is
important to provide neuroprotection by regulating neuronal and microglial mechanisms.
Previously studies have shown that sigma (σ) receptors play a vital role in
neuroprotection and cell regulation as a whole (Ajmo et al., 2006, Katnik et al., 2006, Su
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et al., 2010). Largely distributed throughout the mammalian body, these receptors
perform a number of functions such as regulating membrane ion channels (Hayashi et
al., 2000, Tchedre et al., 2008), altering expression of antiapoptotic and proapoptotic
transcription factors (Yang et al., 2007, Tchedre and Yorio, 2008, Meunier and Hayashi,
2010) and modulating activation and migration of microglial cells (Hall et al., 2009a).
Once thought to be a type of opioid receptor, sigma receptors were later placed into their
own class of opioid-like receptors (Walker et al., 1990, Seth et al., 1998). Consisting of
two subtypes, σ-1 & σ-2, these receptors have been shown to provide protection to both
neurons and glial cells following in vitro ischemia and in vivo middle cerebral artery
occlusion (MCAO) stroke models (Ajmo et al., 2006, Katnik et al., 2006). The σ-1
receptor is an inter-organelle chaperone localized to the mitochondrion-associated ER
membrane (MAM) (Su et al., 2010). This σ-1 receptor-MAM complex plays an important
role in cell signaling, mitochondrial function, maintaining intracellular calcium
homeostasis and the expression of cellular proteins (Tsai et al., 2009). In contrast, σ-2
receptors are not well understood, in part because the gene encoding this receptor has
not been cloned. However, σ-2 receptors are known to play important roles in regulating
intracellular calcium (Vilner and Bowen, 2000) and are involved in the activation and
migration of microglial cells (Cuevas et al., 2011b, Iniguez et al., 2013).
Our laboratory has previously shown the pan-selective sigma receptor agonist
afobazole (5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole), an anxiolytic currently
used clinically in Russia, to be protective in neurons (Cuevas et al., 2011a) and microglia
(Cuevas et al., 2011b) in an in vitro chemical ischemia and acidosis model. Furthermore,
afobazole prevented neuronal and glial cell death in an in vivo MCAO stroke model
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(Katnik et al., 2013). Other studies have suggested that afobazole may provide
neuroprotection in a variety of pathophysiological diseased states, which involve
oxidative stress and glutamate toxicity (Zenina et al., 2005). Recently our laboratory
showed that afobazole maintained neuronal and microglial cell viability when exposed to
amyloid-β25-35 by the downregulation of the pro-apoptotic protein Bax and the death
protease caspase-3, while preserving Bcl-2 expression (Behensky et al., 2013a, b).
Experiments were carried out to determine how afobazole affects neuronal and
microglial responses to chemical ischemia. Afobazole also reduced ischemia-induced
cell death in both microglia and neurons. In addition, afobazole application prevented
upregulation of the proapoptotic protein Bax and death protease caspase-3 in microglia
but not in neurons. Conversely, Bcl-2 expression was preserved in microglia, but not
neurons, by afobazole following exposure to ischemia. This study demonstrates that one
way in which afobazole maintains cellular viability in microglia cells is through the
regulation of apoptotic proteins. We also show that afobazole provides neuroprotection
against chemical ischemia in neurons, but by mechanisms other than direct regulation of
apoptosis.

Materials and Methods

Primary Cultures of Microglia
Primary cultures of microglia were prepared from Sprague-Dawley mixed sex rat
pups (post natal day 2-3) as previously described by our laboratory (Hall et al., 2009a,
Cuevas et al., 2011b). The mixed glial cultures were incubated for 7-12 days at 37 o C
prior to experiments being carried out. Microglia were mechanically separated from the
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cultures by brief shaking. Isolated microglia were resuspended in DMEM PLUS
containing: 500 mL Dulbecco’s Modified Eagle Medium with 4.5 g/L glucose, L-glutamine
and sodium pyruvate (DMEM) (Corning Cellgro, Manassas, VA), 40 mL horse serum
(Corning Cellgro), 12.5 mL heat-inactivated fetal bovine serum (Thermo Scientific
Hyclone, Logan, UT ), and 5 mL 10x antibiotic/antimycotic (Corning Cellgro). These cells
were used immediately for cytotoxicity assays or plated on glass coverslips for one day
for imaging experiments.

Preparation of Cortical Neurons
All experiments were carried out on cultured cortical neurons from mixed sex
embryonic day 18 (E18) Sprague-Dawley rats (Harlan, Indianapolis, IN). Methods used
here were identical to those previously reported for the isolation and culturing of these
cells (Katnik et al., 2006). Cortical neurons were plated on poly-L-lysine coated
coverslips and cultured in B27 and L-glutamine supplemented Neurobasal medium
(Neurobasal Complete) (Life Technologies, Grand Island, NY). Cells were used for
experiments after 10-21 days in culture, which permits synaptic contact formation and
yields robust responses to other pathophysiological conditions such as in vitro ischemia
and acidosis (Katnik et al., 2006, Herrera et al., 2008). Animals were cared for in
accordance with the regulations and guidelines set forth by the University of South
Florida’s College of Medicine Institution on Animal Care and Use Committee.

Live/Dead Cell assay
Neurons or microglia plated on poly-L-lysine coverslips were incubated at 37°C for
72 hr in Neurobasal Complete or DMEM Plus, respectively, with 4 mM sodium azide in
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the absence (Control) and presence of 100 µM afobazole for neurons and 30 µM
afobazole or for microglia. The coverslips were rinsed with PBS followed by 30 min
incubation at room temperature in PBS with 4 µL of a 2mM ethidium homodimer-1 (EthD1) dissolved in 1:4 DMSO:H2O solution. The coverslips were washed with PBS and
deionized water, dried, and mounted on a microscope slide with Vectashield Hardset
mounting media (Vector Labs, Burlingame, CA). EthD-1 loaded cells were illuminated
with light at 530 nm and visualized at 645 nm using a Zeiss Axioskop 2 equipped with a
20X objective. EthD-1-positive cells were identified and counted using Image-J in four
random fields per slide, and the average for the fields used as the value for the slide. For
each experiment, a minimum of three slides were used, and the results of at least three
experiments were averaged together for each condition tested.

Immunocytochemistry
Neurons or microglia plated on poly-L-lysine coverslips were incubated at 37°C for
24 hr in Neurobasal complete or DMEM Plus with 4 mM sodium azide in the absence
and presence of 100 µM or 30 µM afobazole, respectively. The coverslips were rinsed
with phosphate-buffered saline (PBS) followed by an ethanol step-wise fixation. The cells
were permeabilized with 0.1% Triton X in PBS for 15 min, then rehydrated with PBS and
washed with 0.5% bovine serum albumin (BSA) in PBS. Blocking was achieved with 45
min incubation in 2% BSA, followed by multiple washes with 0.5% BSA. Primary
antibodies were diluted in PBS with 0.5% BSA and applied onto cells at 4°C for 24 hr.
Primary antibody dilutions were as follows: Bax 1/20, Caspase-3 1/25 and Bcl-2 1/100.
The cells were then washed multiply times with 0.5% BSA in PBS and then incubated in
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secondary antibodies for 60 min at room temperature. Secondary antibodies were either
Alexa Fluor 488 conjugated anti-mouse or anti-rabbit diluted at a ratio of 1/300 in PBS
with 0.5% BSA. Following incubation in secondary antibodies, cells were washed with
0.5% BSA in PBS and then with PBS alone. Coverslips were rinsed with deionized water
and inverted onto a slide VectaShield containing DAPI. DAPI and the Alexa Fluor 488
conjugated secondary antibodies were illuminated at 359 and 485 nm and visualized at
461 and 530 nm, respectively, using a Zeiss Axioskop 2 outfitted with a 40X objective.
Images of DAPI and Alexa Fluor 488 positive cells were counted and merged to
demonstrate co-localization using Image-J software. Four random fields per slide were
used to determine an average value for the slide. For each experiment, a minimum of
three slides were used, and the results of at least three experiments were averaged
together.

Calcium Imaging
Intracellular Ca2+ concentrations were measured in isolated cortical neurons using
ratiometric fluorometry as previously described (Katnik et al., 2006). Neurons were
loaded with fura-2 by adding 3 µg/ml of the acetoxymethylester form of fura-2 (fura-2
AM) in 0.3% DMSO to the media and incubating the cells at room temperature for 1 hr.
Prior to beginning the experiments, the coverslips were rinsed with physiological saline
solution (PSS) consisting of (in mM): 140 NaCl, 5.4 KCl, 25 HEPES, 20 glucose, 1.3
CaCl2, and 1.0 MgCl2 (pH to 7.4 with NaOH). For each cell, [Ca2+]i was measured once a
second for a 100 second period and the values averaged to determine mean peak and
net [Ca2+]i.
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Compounds, Reagents and Antibodies
The following compounds and reagents were used in this investigation: DTG
(Tocris Biosciences, Ellisville, MO); Live/Dead Viability/Cytotoxicity Kit (Life
Technologies); Sodium Azide (ACROS Organics, Fair Lawn, NJ). The following
antibodies were also used: Alexa Fluor 488 anti-mouse (A-11001) and anti-rabbit (A11008) (Life Technologies); anti-Bax (ab5714), anti-activated caspase-3 (ab32351) and
anti-Bcl-2 (ab32370) (abcam, Cambridge, MA). Afobazole was generously provided by
IBC Generium (Moscow, Russian Federation). Vehicle for drugs and reagents used were
either water (H2O), ethanol (EtOH) or dimethyl sulfoxide (DMSO), and appropriate
vehicle controls were carried out for each study.

Data Analysis
Fluorescence intensities were recorded from cortical neurons and microglia in the
same manner as previously described (Katnik et al., 2006, Cuevas et al., 2011a, Cuevas
et al., 2011b). Data were analyzed using Image J or SigmaPlot 11 software (Systat
Software, Inc., San Jose, CA). Data points represent peak means ± standard error of the
mean (S.E.M.). One-, two- and three-way analysis of variance were used for determining
significant differences for multiple group comparisons, as appropriate, followed by post
hoc analysis using the Holm-Sidak method. Results were considered statistically
significant if p < 0.05.

Results
Previous studies suggested that activation of σ receptors decreased microglial cell death
in response to ischemia. To further examine the effects of ischemia on survival of
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microglia, the Live/Dead cytotoxicity assay was used. Ethidium Homodimer-1 (EthD-1)
labeled cells were counted in microglia cultures in the absence (Control) and presence of
ischemia (Isch). There was significant microglia death when exposed to 72 hr ischemia

Figure 5.1
Afobazole reduces microglia death produced by application of ischemia. A,
Photomicrographs showing EthD-1 labeling (red) of microglial cells following 72 hr
incubation in media alone (i), or media containing 4 mM Azide (in vitro ischemia, Isch)
(ii), 30 µM afobazole (Afob) (iii), or 30 µM afobazole + 4 mM Azide (iv). Fields of view
shown are representative regions within larger images used to calculate cell death. B,
Bar graph of relative cell death observed following 72 hr incubation of microglia in control
(Control) or ischemic condition (Isch), with (Afob) or without (Media) 30 µM afobazole (n
> 12). Data were normalized to cell death observed with media alone (Control). Asterisks
denote significant difference between Control and Isch within Media and Afob,
respectively (p < 0.001 & = 0.001, respectively); pound symbol indicates difference
between Afob and Media within Isch (p < 0.001).
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(Figure 5.1). Afobazole significantly mitigated microglial cell death when co-incubated
with ischemia. 72hr incubation in media alone or media with 30µM afobazole had no
effect on microglia death, respectively. Counting the number EthD-1-positive cells
showed that afobazole mitigates ischemia induced cell death by 75 ± 8%.
The mechanism by which activation of σ receptors may decrease cell death
remain unknown. Thus, experiments were carried out to determine if activation of σ
receptors alters the expression of molecules involved in cell apoptosis. One proapoptotic gene product that has been shown to be affected by ischemia and may
regulated by σ receptors is the protein Bax (Schelman et al., 2004, Tchedre and Yorio,
2008). Immunocytochemical experiments were conducted to measure Bax levels
following 24 hr ischemia incubation to ascertain and whether afobazole application
affects the levels of protein. Ischemia significantly increases the pro-apoptotic gene, Bax,
in microglia (Figure 5.2). Co-labeling of microglia with DAPI and an anti-Bax antibody
shows that Bax is rarely detected in control cells but is readily visible in microglia
following ischemia. Afobazole alone had no effect on Bax levels, but this drug reduced
Bax expression after ischemia incubation. Nearly all microglia show Bax expression after
ischemia, but this is reduced by 41 ± 1% when afobazole is co-applied. This reduction in
Bax expression was found to be statistically significant (Figure 5.2).
Bax-dependent caspase-3 activation is a key component in cellular apoptosis
(Cregan et al., 1999). Therefore, we examined how afobazole effects the levels of the
death protease, caspase-3, in microglia after ischemia treatment. Following ischemic
exposure, the activated form of caspase-3 was observed in a greater number of cells
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Figure 5.2
Afobazole prevents upregulation of the pro-apoptotic gene, Bax, observed in response to
ischemia in microglia. Microglia were double labeled with DAPI (blue) and anti-Bax
antibody followed by Alexa Fluor 488 conjugated secondary antibody (green). A,
Photomicrographs of merged images of cultured microglia exposed for 24 hr to media
alone (i) or media containing 4 mM Azide (Isch) (ii), 30 µM afobazole (iii) or 4 mM Azide
+ 30 µM afobazole (iv). Microglia were double labeled with DAPI (blue) and anti-Bax
antibody (green). Fields of view shown are representative regions within larger images
used to calculate Bax expression. Scale bar in (i) is 10 µm. B, Bar graph of mean
number of Bax-positive microglia in experiments in which the cells were exposed to
normal conditions (Control) or ischemia (Isch) in the absence (Media) or presence of 30
µM afobazole (Afob). Data are expressed as percent (± SEM) of total number of
microglia per slide (n = 9). Asterisk denotes significant difference between Control and
Isch within Media and Afob, respectively (p < 0.001 for both). Pound symbol indicates
significant difference between Media and Afob within Isch (p < 0.001).
relative to control (Figure 5.3). Afobazole alone significantly decreased caspase-3 levels
relative to the control, and diminished the increases in caspase-3 evoked by ischemia.
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Examining the number of cells showing caspase-3 signal demonstrates that afobazole
reduced the number of caspase-3 positive cells by 53 ± 6% in the absence of ischemia.

Figure 5.3
Afobazole reduces expression of caspase-3 in response to ischemia in microglia.
Microglia were double labeled with DAPI (blue) and anti-caspase-3 antibody followed by
Alexa Fluor 488 conjugated secondary antibody (green). A, Photomicrographs of merged
images of cultured microglia exposed for 24 hr to media alone (i) or media containing 4
mM Azide (Isch) (ii), 30 µM afobazole (iii) or 4 mM Azide + 30 µM afobazole (iv). Fields
of view shown are representative regions within larger images used to calculate
activated caspase-3 expression. Scale bar in (i) is 10 µm. B, Bar graph of mean number
of caspase-3-positive microglia in experiments in which the cells were exposed to normal
conditions (Control) or ischemia (Isch) using media alone (Media) of media with 30 µM
afobazole (Afob). Data are expressed as percent (± SEM) of total number of microglia
per slide (n = 9). Asterisks denote significant difference between Control and Isch within
Media and Afob (p < 0.001 for both). Pound symbols indicate significant difference
between Media and Afob within Control and Isch, respectively (p < 0.001 for both).
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Following ischemia, afobazole reduced caspase-3 levels by 59 ± 5%, such that the levels
of caspase-3 were similar to those observed under control conditions (no ischemia or
afobazole) both of which were statistically significant.
The effects of Bax can be counteracted by upregulation of the anti-apoptotic
protein Bcl-2 (Hockenbery et al., 1993, Korsmeyer et al., 1993, Oltvai et al., 1993), which
may be a second mechanism by which σ receptors reduce cell death following ischemia.
The relationship between afobazole and expression of the anti-apoptotic gene, Bcl-2,
during ischemia in microglia was examined via immunocytochemistry. Following
ischemia, the levels of Bcl-2 expressed by microglia decreased by ~20% compared to
that of control (Figure 5.4). Afobazole alone produced a ~10% increase in the number of
cells expressing Bcl-2. Moreover, afobazole rescued Bcl-2 expression following
ischemia. Both afobazole and afobazole with ischemia treated microglia showed nearly
100% expression in all cells.
Previous studies showed that σ receptor activation can decrease neuronal death
following a 24 hr ischemic event in vitro. However, it has not been determined if
neuroprotection occurs following longer ischemic events such as those used for
microglia here. Thus, experiments were carried out to see if afobazole can decrease
neuronal death under these conditions. Neurons labeled with EthD-1 were counted in the
absence (Control) and presence of ischemia (Isch). There was significant neuronal death
when exposed to 72 hr Isch (Figure 5.5). Afobazole significantly mitigated neuronal cell
death when co-incubated with ischemia. Incubation in media alone (Control) set the
limits of normal neuronal death, whereas media with 100µM afobazole had reduced
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neuron death beyond control levels. Counting the number EthD-1 positive cells showed
that afobazole mitigates ischemia-induced cell death by 49 ± 9%.

Figure 5.4
Afobazole enhances Bcl-2 expression under control conditions and following ischemia in
microglia. Microglia were double labeled with DAPI (blue) and anti-Bcl-2 antibody
followed by Alexa Fluor 488 conjugated secondary antibody (green). A,
Photomicrographs of merged images of cultured microglia exposed for 24 hr to media
alone (i) or media containing 4 mM Azide (ii), 30 µM afobazole (iii) or 4 mM Azide + 30
µM afobazole (iv). Areas shown are representative regions within larger images used to
calculate Bcl-2 expression. Scale bar in (i) is 10 µm. B, Bar graph of mean number of
Bcl-2-positive microglia in experiments in which the cells were exposed to normal
conditions (Control) or ischemia (Isch), in the absence (Media) and presence of 30 µM
afobazole (Afob). Data are expressed as percent (± SEM) of total number of microglia
per slide (n = 9). Asterisk denotes significant difference between Control and Isch within
Media (p < 0.001); pound symbols indicate significant difference between Media and
Afob within Control and Isch, respectively (p < 0.01 for Control & < 0.001 for Isch).
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Experiments were next carried out to determine if the enhanced neuronal survival
observed following σ receptor stimulation in neurons involves a pathway similar to that
observed in microglial cells. As in microglia, ischemia significantly increased the proapoptotic gene, Bax, in neurons (Figure 5.6). Co-labeling neurons with DAPI and an antiBax antibody showed that Bax is detected in control cells but increased in neurons

Figure 5.5
Afobazole reduces neuronal death induced under ischemic conditions. Bar graph of
relative cell death observed following 72 hr incubation of neurons in media (Media) or
media containing ischemia (Isch), 100 µM afobazole (Afob) or ischemia + 100 µM
afobazole (Isch + Afob) (n > 12). Data were normalized to cell death observed with
media alone (Control). Asterisks denote significant difference between Control and Isch
within Media and Afob, respectively (p < 0.001 for both); pound symbol indicates
significant difference between Media and Afob within Control and Ischemia, respectively
(p < 0.05 for Control & < 0.001 for Isch).
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following ischemia. Afobazole alone showed a slight reduction in Bax levels but this was
not significant. When afobazole is co-applied with ischemia, Bax expression was
reduced by ~ 10%, however this was not significant. Thus, unlike the case in microglia, σ
receptor activation fails to significantly block ischemia-induced upregulation of the proapoptotic gene, Bax, in neurons.

Figure 5.6
Afobazole fails to prevent upregulation of the pro-apoptotic gene, Bax, observed in
response to extended ischemia in neurons A, Photomicrographs of merged images of
cultured neurons exposed for 24 hr to media alone (Control) (i), or media containing 4
mM Azide (ii), 100 µM afobazole (Afob) (iii) or 4 mM Azide + 100 µM afobazole (Isch +
Afob) (iv). Neurons were double labeled with DAPI (blue) and anti-Bax antibody (green).
Fields of view shown are representative regions within larger images used to calculate
Bax expression. Scale bar in (i) is 10 µm. B, Bar graph of mean number of Bax-positive
neurons in experiments in which the cells were exposed to the same conditions as A.
Data are expressed as percent (± SEM) of total number of neurons. Asterisks denote
difference between Control and Isch within Media and Afob, respectively (p < 0.001) (n =
9).
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We further examined how afobazole effects the levels of the death protease,
caspase-3, in neurons after an ischemic insult. Following ischemia, caspase-3
expression was observed in a greater number of cells relative to control (Figure 5.7).

Figure 5.7
Afobazole fails to reduce expression of caspase-3 in response to prolonged ischemia in
neurons. A, Photomicrographs of merged images of cultured neurons exposed for 24 hr
to media alone (Control) (i), or media containing 4 mM Azide (Isch) (ii), 100 µM
afobazole (Afob) (iii) or 4 mM Azide + 100 µM afobazole (Isch + Afob) (iv). Neurons were
double labeled with DAPI (blue) and anti-active caspase-3 antibody (green). Fields of
view of each photomicrograph are representative regions within larger image used to
calculate caspase-3 expression. Scale bar in (i) is 10 µm. B, Bar graph of mean percent
of caspase-3-positive neurons in experiments in which the cells were exposed to
conditions identical to A. Data are expressed as percent (± SEM) of total number of
neurons. Asterisks denote significant difference between Control and Isch within Media
and Afob groups (p < 0.001 for both); pound symbol indicates significant difference
between Media and Afob within Isch (p < 0.05) (n = 9).
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Afobazole alone decreased caspase-3 levels relative to control, but failed to diminished
the increase in caspase-3 levels evoked by ischemia. Examining the number of cells
showing caspase-3 signal demonstrates that afobazole reduces the number of caspase3 positive cells by 38 ± 16% in the absence of ischemia. Following ischemia, afobazole

Figure 5.8
Afobazole alone upregulates the anti-apoptotic gene, Bcl-2, but does not enhance Bcl-2
levels following 24 hr ischemic incubation in neurons. Neurons were double labeled with
DAPI (blue) and anti-Bcl-2 antibody followed by Alexa Fluor 488 conjugated secondary
antibody (green). A, Photomicrographs of merged images of cultured neurons exposed
for 24 hr to media alone (i) or media containing 4 mM Azide (ii, Isch), 100 µM afobazole
(iii) or 4 mM Azide + 100 µM afobazole (iv). Areas shown are representative regions
within larger images used to calculate Bcl-2 expression. Scale bar in (i) is 10 µm. B, Bar
graph of mean percent of Bcl-2-positive neurons in experiments in which the cells were
exposed to conditions identical to A. Data are expressed as percent (± SEM) of total
number of neurons. Asterisk denote significant difference between Control and Isch
within Media and Afob, respectively (p < 0.05 & < 0.01) (n = 9).
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reduced caspase-3 levels by ~14%, unlike microglia levels of caspase-3, which were
significantly different than the control, neuronal levels where similar to those observed
under ischemic conditions.
We wanted to see if the relationship between afobazole and the expression of the
anti-apoptotic gene, Bcl-2, was similar to what we saw in microglia after ischemia
incubation. Following ischemia, the levels of Bcl-2 expressed by the neurons decreased
by ~20% compared to that of control levels (Figure 5.8). Afobazole alone produced a

Figure 5.9
Afobazole prolongs neuronal survival but fails to preserve function after prolonged
ischemia. A, bar graph of mean change in depolarization-induced increase in peak
[Ca2+]i, evoked by application of high K+ (30 mM KCl) (±S.E.M.) in isolated cortical
neurons incubated for 72 hr in media alone (Media) or media containing 4mM azide +
100µM afobazole (Isch + Afob). B, in experiments are identical to (A) shows the total net
calcium influx. For each condition, n ≥ 79. Asterisk denotes significant difference
between Media and Isch + Afob (p < 0.001).
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~10% increase in the number of cells expressing Bcl-2. However, afobazole failed to
rescue Bcl-2 expression following ischemia. Both ischemia and afobazole with ischemia
treated neurons showed a statistically significant decrease in the expression of Bcl-2 by
21 ± 3 and 36 ± 8%, respectively.
The failure of σ receptors to affect Bax, caspase 3 and Bcl-2 in neurons following
ischemia suggests that a distinct pathway may be involved in σ receptor protection of
neurons and microglia. However, a second possibility is that these neurons are
significantly injured and will eventually undergo programmed cell death. Thus,
experiments were carried out to determine if the surviving neurons were functionally
compromised, and thus likely to proceed towards apoptosis. Fluorometric calcium
imaging experiment were carried out to determine if surviving cortical neurons showed
functional responses consistent with membrane depolarizations. Neurons incubated
under ischemic conditions in the absence and presence of 100 µM afobazole for 72 hrs
followed by focal application of 30mM KCl failed to have any response compared to
control neurons. These data suggest that the surviving neurons are not depolarizing and
are thus functionally compromised (Figure 5.9).

Discussion
The novel findings reported in this study are that the σ receptor agonist,
afobazole, rescues microglia from ischemia-induced cell death through mechanisms
involving the regulated expression of apoptosis-regulating proteins. Subsequently,
afobazole provides neuroprotection against ischemia-induced toxicity in cortical neurons
but not through changes in the expression of these proteins. This decrease in microglial
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cell death is likely due to a reduction in the expression of the pro-apoptotic gene, Bax
and the death protease, caspase-3. Further reduction in microglial cell death likely
results from the preserved Bcl-2 expression caused by afobazole. In contrast, afobazole
failed to inhibit the pro-apoptotic signaling induced by ischemia as the pro-apoptotic gene
product, Bax and the death protease, caspase-3, were not depressed following
afobazole application nor was the ischemia-induced downregulation of the anti-apoptotic
protein, Bcl-2 prevented. These findings suggest that activation of σ receptors
differentially affects survival mechanisms in neurons and microglia. Furthermore,
treatment with the sigma receptor agonist, afobazole did not preserve neuronal function
after prolonged ischemia.
It has been suggested that over-activation of microglia result in neuronal death
(Hellwig et al., 2013). However, the need to maintain viable microglia that respond to
sites of injury are equally necessary. Neurons exposed to ischemic conditions release
cytotoxic and neurotropic factors that both activate and attract microglia to the area of
injury (Hellwig et al., 2013, Kierdorf and Prinz, 2013). Unfortunately, in disease states
like stroke, over-activation of microglia is a common occurrence and often times result in
neuronal and microglial cell death. Thus it is of great importance to identify factors that
contribute to the demise of microglia and find treatments to combat these mechanisms.
Exposure of microglia cells to ischemia resulted in approximately 150-fold increase in
cell death from control alone. Afobazole reduced the number of dyeing microglia by 75 ±
8% when co-incubated with ischemia.
Our laboratory has previously shown that afobazole can mitigate intracellular
calcium dyshomeostasis in neurons and microglia following ischemia, acidosis and ATP
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exposure (Katnik et al., 2006, Herrera et al., 2008, Cuevas et al., 2011a, Cuevas et al.,
2011b). A rise in intracellular concentration, if unresolved, can promote the initiation of
apoptosis (Mattson and Chan, 2003a). In addition to regulating intracellular calcium
homeostasis, our findings show that afobazole mitigates ischemia-evoked apoptosis of
microglia by decreasing expression of the pro-apoptotic gene, Bax, and death protease
caspase-3 while preserving the levels of the anti-apoptotic gene, Bcl-2. Experiments
were conducted to ascertain the mechanism by which afobazole mitigates microglia cell
death following ischemia. Following a stroke, cells in the core undergo necrosis and in
the days and weeks following the insult if the penumbra is not rescued from undergoing
apoptosis, it too will die and become part of the core (Butler et al., 2002). Previous
studies have shown that activation of σ-1 receptors protect RGC-5 cells from apoptosis
by regulating the expression of the proapoptotic protein, Bax and death protease,
caspase-3 (Tchedre and Yorio, 2008). We carried out immunocytochemical experiments
to determine if afobazole affects expression of the pro-apoptotic protein Bax or the death
caspase-3 following 24 hr ischemic exposure. Both Bax and caspase-3 expression
increased > 270 and 150% from the control, respectively. We found that afobazole alone
decreased caspase-3 expression and when co-incubated with ischemia both Bax and
caspase-3 expression were mitigated approximately 42 and 59%, respectively. Further
experiments were conducted to determine if levels of Bcl-2 were affected by ischemia
and to what if affect afobazole had on its expression. Microglia cells were incubated for
24 hr in the absence (Control) and presents of ischemia, with and with afobazole.
Following ischemia incubation, microglial Bcl-2 expression was decreased by ~ 21%
from that of the control. Incubation with afobazole alone increased Bcl-2 expression by a
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modest but significant 10%. However, when co-incubated with ischemia, afobazole
preserved Bcl-2 expression by approximately 24%, making it comparable to afobazole
alone.
Following suit, we wanted to know if afobazole conveyed neuroprotection in a
similar mechanism as shown previously with microglia. Immunocytochemical
experiments were carried out to determine if one mechanism by which afobazole is
neuroprotective is through sigma receptor regulation of apoptotic expression. Both Bax
and caspase-3 expression were observed under all conditions. Following ischemic
exposure, both Bax and caspase-3 levels increased by ~ 47 and 135%, respectively.
However, unlike the results we observed in microglia cells, afobazole did not mitigate
increases in Bax or caspase-3 expression in neurons. The ratio of Bcl-2:Bax has been
shown to positively correlate to cell survival in neurons exposed to Aβ (Patel and Brewer,
2008). Likewise, the ratio of Bcl-2:Bax is important in regulating cell survival following
glutamate excitotoxicity (Schelman et al., 2004) and previous studies have shown that
Bcl-2 is a target for σ receptor mediated neuroprotection (Yang et al., 2007, Meunier and
Hayashi, 2010). Additionally, experiments were performed to determine if afobazole
could preserve expression of Bcl-2 levels following ischemia. As we observed with
microglia, Bcl-2 expression decreased in neurons under ischemic conditions. We found
that afobazole alone increased Bcl-2 expression; however, when co-incubated with
ischemia, afobazole failed to preserve Bcl-2 expression levels and were comparable to
ischemia alone. Exposing cells to ischemic conditions has been shown to decrease cell
viability. Our laboratory has shown that afobazole mitigates death following 2 hr ischemia
exposure (Cuevas et al., 2011a, Cuevas et al., 2011b). This model resembles injury
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caused by reperfusion of the tissues with oxygen, more of a transient ischemic model.
We wanted to see to what extent afobazole could be neuroprotective following 72 hr
exposure to ischemic conditions, more a permanent occlusion model. There was an
approximant 3-fold increase in the number of expired neurons from that of the control.
This increase in the demise of neurons was mitigated by approximately 55% when
neurons were co-incubated with afobazole and ischemia. Incidentally, afobazole alone
reduced neuronal cell death from control levels by ~ 49%. This data indicates that even
under prolonged ischemic conditions afobazole was to some extent neuroprotective.
However, when functional integrity of these surviving neurons was examined by
attempting to depolarize them with a focal application of 30mM KCl, we found them
unresponsive.
In conclusion, our study demonstrates that afobazole reduce microglial toxicity
and cell death following ischemic exposure. This cytoprotection most likely involves
regulation of multiple genes, with a noted decrease in Bax and caspase-3 and a
concomitant increase in Bcl-2 expression. Furthermore, our experiments show that
afobazole can decrease ischemia-evoked neuronal cell death. However, the molecular
mechanisms mediating neuroprotection by afobazole following an ischemic insult appear
to be different than with microglia and do not involve the downregulation of both Bax and
activated caspase-3, nor preserving upregulation of Bcl-2 expression. Taken together our
data suggest that afobazole may prevent microglia from entering the activated state
associated with neurotoxicity following exposure to ischemia, and increasing the survival
of both microglia and neurons following an ischemic insult. These properties make
afobazole an attractive drug for treatment of ischemia.
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CHAPTER 6

Afobazole Abolishes Amyloid-β25-35 Potentiation of Ischemia-Acidosis
Evoked Increases in Neuronal Intracellular Calcium Levels

Introduction
In addition to large vessel ischemic strokes there are a subset known as lacunar
infarcts, which account for approximately 25% of all ischemic insults (Samuelsson et al.,
1996). These strokes result from the blockage of small penetrating arteries to the
subcortical regions of the brain (Kang et al., 2012). While the injury from these strokes
were once thought to be negligible, lacunar infarcts can and do result in death and longterm disability. This type infarct is a leading cause of cognitive impairment and vascular
dementia (Charidimou and Werring, 2012). While the risk factors resulting in lacunar
verse large artery infarcts differ, the resulting cellular cascade promoting cerebral cell
death may have overlapping mechanisms. One of these mechanisms may be the
increased production and toxicity of the amyloid-β peptide, which has been shown to be
upregulated following an ischemic event (Popa-Wagner et al., 1998, Guglielmotto et al.,
2009, Pluta et al., 2013). The presence of Aβ has been shown to increase [Ca2+]i levels,
increase ROS production and promote apoptosis (Behensky et al., 2013a, b). In addition,
the accumulation of Aβ can contribute to vascular dementia, which has been shown to
significantly increase the chances of having a recurrent stroke (Pendlebury and Rothwell,
2009). Furthermore, this Aβ-induced arterial weakening may potentiate the chances of
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having a hemorrhagic stroke significantly increasing the patient’s chance of developing
serious long-term disability or even death (Sudduth et al., 2013, Sudduth et al., 2014).
The mechanisms that contribute to the injury of both lacunar and large vessel
ischemia are still unclear. However, the activation of NMDA receptors is known to
contribute, in part, to both of these types of strokes (Shih et al., 2013). This brings into
question the prospect that even though lacunar and large-vessel strokes occur via
different vascular pathologies the mechanisms promoting their injury may overlap. Data
from our laboratory has shown that activation of sigma receptors mitigates ischemia,
acidosis and Aβ-induced calcium overload (Katnik et al., 2006, Herrera et al., 2008,
Behensky et al., 2013a, b). This calcium overload if left unchecked will promote
apoptosis through pathways including NMDA receptor activation. Our laboratory has also
shown that acid-sensing ion channel 1a (ASIC1a) contributes to the downstream activity
of NMDA receptors (Mari et al., 2014). Aβ levels increase following ischemia, which may
lead to potentiated responses that increase the risk for various vascular dementias and
ultimately result increased cell death. Currently, the mechanisms contributing to this
interaction remain unknown.
Experiments were carried out to determine the effects of Aβ on ischemia +
acidosis evoked elevations in intracellular Ca2+ overload in cortical neurons. Aβ
incubation was found to significantly potentiate the ischemia + acidosis induced
increases in [Ca2+]i but required 24 hr incubation before affects were seen, indicating that
non-acute mechanisms are involved. Furthermore, afobazole co-incubation was found to
abolish the Aβ-induce intracellular Ca2+ increase. The kinetics of the [Ca2+]i overload
produced by ischemia + acidosis following pre-incubation in Aβ were indicative of acid125

sensing ion channels 1a (ASIC1a) involvement. In conclusion, our data show a
mechanism by which Aβ may enhance neuronal injury during ischemia, increased [Ca2+]i
overload, and identify ASIC1a as the channel mediating this phenomenon. Finally, our
data suggest that activation of σ receptors may represent a therapeutic strategy for
mitigating injury produced by Aβ and stroke.

Materials and Methods

Preparation of Rat Cortical Neurons
All experiments were carried out on cultured cortical neurons from mixed sex
embryonic day 18 (E18) Sprague-Dawley rats (Harlan, Indianapolis, IN). Methods used
here were identical to those previously reported for the isolation and culturing of these
cells (Katnik et al., 2006). Cortical neurons were plated on poly-L-lysine coated
coverslips and cultured in B27 and L-glutamine supplemented Neurobasal medium
(Neurobasal Complete) (Life Technologies, Grand Island, NY). Cells were used for
experiments after 10-21 days in culture, which permits synaptic contact formation and
yields robust responses to other pathophysiological conditions such as in vitro ischemia
and acidosis (Katnik et al., 2006, Herrera et al., 2008). Animals were cared for in
accordance with the regulations and guidelines set forth by the University of South
Florida’s College of Medicine Institution on Animal Care and Use Committee.

Calcium Imaging
Intracellular Ca2+ concentrations were measured in isolated cortical neurons using
ratiometric fluorometry as previously described (Katnik et al., 2006, Cuevas et al., 2011a,
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Cuevas et al., 2011b). For most experiments, cultured neurons were incubated in 25 µM
Aβ25-35 for 24 hr prior to [Ca2+]i being measured. Neurons were loaded with fura-2 by
adding 3-5 µg/ml of the acetoxymethylester form of fura-2 (fura-2 AM) in 0.3% DMSO to
the media and incubating the cells at room temperature for 1 hr. Prior to beginning the
experiments, the coverslips were rinsed with physiological saline solution (PSS)
consisting of (in mM): 140 NaCl, 5.4 KCl, 25 HEPES, 20 glucose, 1.3 CaCl2, and 1.0
MgCl2 (pH to 7.4 with NaOH). For neurons, [Ca2+]i was measured once every second for
approximately a 4 min period and the ischemia-acidosis induced values for baseline,
peak, area and slope (± SEM) [Ca2+]i was calculated.
Electrical Recordings
Proton-activated membrane currents were recorded using the protocol previously
described by our laboratory (Herrera et al., 2008). Briefly, neurons plated on glass
coverslips were transferred to a recording chamber and membrane currents were
amplified, filtered at 1 kHz, digitized at 5 kHz, and acquired using Clampex 9 (Axon), a
MultiClamp 700A amplifier and a Digidata 1322A. Electrical access was achieved using
the amphotericin B perforated patch method to preserve intracellular integrity of neurons
(Rae et al., 1991). An amphotericin B stock solution (60 mg/ml in DMSO) was made
fresh daily and diluted to 240 μg/ml (0.4% DMSO) in control pipette solution immediately
prior to seal formation. The control pipette solution consisted of (in mM): 75 K2SO4, 55
KCl, 5 MgSO4, and 10 HEPES (titrated to pH 7.2 with N-methyl-d-glutamine). Patch
electrodes were pulled from thin-walled borosilicate glass (World Precision Instruments
Inc., Sarasota, FL) using a Sutter Instruments P-87 pipette puller (Novato, CA) and had
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resistances of 1.0–1.5 MΩ. Access resistance (Rs) was monitored throughout
experiments for stable values ≤ 30 MΩ and were compensated at 40% (lag, 10 μs). In all
electrical recordings, cells were voltage-clamped at −70 mV.
Compounds, Reagents and Peptides
The following compounds and reagents were used in this investigation: Amyloid-β
fragments 25-35 (62-0-72), 35-25 (62-0-33) 1-40 (62-0-78) and 1-42 (62-0-30)
(American Peptides, Sunnyvale, CA); Tetrodotoxin and YM244769 (Tocris Biosciences,
Ellisville, MO); fura-2 acetoxymethyl ester (Life Technologies); Psalmotoxin-1
(ab120483) (abcam, Cambridge, MA. Vehicle for drugs and reagents will be either water
(H2O) or dimethyl sulfoxide (DMSO), and appropriate vehicle controls will be carried out
for each study. For the Aβ oligomerization experiment, Aβ25-35 was made to stock
concentration (1mM) and allowed to oligomerize for 24 hr at 37º C prior to cell
incubation. Afobazole was generously provided by IBC Generium (Moscow, Russian
Federation).

Data Analysis
Fura-2 fluorescence intensities as a function of time were recorded in the same
manner as previously described (Katnik et al., 2006, Cuevas et al., 2011a, Cuevas et al.,
2011b) and converted to [Ca2+]i using control values obtained with an in situ calibration
kit (Invitrogen). Electrophysiology data was converted to text files and imported into
Clampfit 9 for analysis. Data was analyzed using SigmaPlot 11 (Systat Software, Inc.,
San Jose, CA). Data points represent peak means ± standard error of the mean
(S.E.M.). Statistical analysis involved the use of paired or unpaired t-tests, as
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appropriate, and one- or two-way analysis of variance for determining significant
differences for multiple group comparisons, followed by post hoc analysis using the
Holm-Sidak test. Results were considered statistically significant if p < 0.05.

Results
Experiments were carried out to determine if incubation of 25 µM amyloid-β25-35
affects the elevations in [Ca2+]i in response to ischemia, acidosis and ischemia + acidosis
application in rat cortical neurons. Figure 6.1A-C shows representative traces of [Ca2+]i
as a function of time recorded from two cells during focal application of ischemia,
acidosis or ischemia + acidosis that produced robust elevations in [Ca2+]i in the neurons,
consistent with previous reports (Katnik et al., 2006, Herrera et al., 2008, Mari et al.,
2014). Following 12 hour incubation in media with 25 µM amyloid-β25-35, neurons were
exposed to a focal application of ischemia, acidosis or ischemia + acidosis, which
produced increases in [Ca2+]i levels similar to the control. Quantification of these calcium
increases showed that 12 hr of Aβ incubation did not increase the peak calcium levels.
However, there was a small but significant increase in the total net calcium influx evoked
from all three conditions (Figure 6.1D).
Given that Aβ modulation of these responses may require a longer incubation time,
neurons were exposed to applications of ischemia, acidosis or ischemia + acidosis
following 24 hr incubation in media alone, or media containing 25 µM of Aβ25-35. Figure
6.2A-C shows representative traces of [Ca2+]i as a function of time recorded from two
cells during focal application of ischemia, acidosis or ischemia + acidosis that produced
robust elevations in [Ca2+]i in the neurons. Calcium increases in the Aβ-treated group
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Figure 6.1
Incubation for 12 hr with amyloid-β25-35 does not potentiate intracellular calcium
responses to focal ischemia, acidosis or ischemia + acidosis application. A-C, show
representative traces of [Ca2+]i as a function of time recorded from two neurons during
application of ischemia, acidosis and ischemia + acidosis following 12 hr incubation in
media alone (Control), or media containing 25 µM Aβ25-35 (Aβ), respectively. Aβ was
washed out for 1hr prior to focal application. Line above [Ca2+]i responses indicates
duration of ischemia, acidosis or ischemia + acidosis application. D, Bar graph of mean
(± SEM) peak and total net increases in [Ca2+]i evoked by focal applications following 12
hr Aβ in isolated cortical neurons. [Ca2+]i responses were recorded from neurons in
experiments identical to those performed in (A-C). Asterisk symbolizes significant
difference between Control and Aβ (p < 0.05). For all conditions, n ≥ 74.
were significantly higher than the respective controls. When quantified, Aβ evoked a
significant increase in both the peak and the total net calcium influx following ischemia by
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Figure 6.2
24 hr incubation with amyloid-β25-35 significantly potentiates the intracellular calcium
responses to ischemia, acidosis and ischemia + acidosis application. A-C, show
representative traces of [Ca2+]i as a function of time recorded from two neurons during
application of ischemia, acidosis and ischemia + acidosis following 24 hr incubation in
media alone (Control), or media containing 25 µM Aβ25-35 (Aβ), respectively. Aβ was
washed out for 1hr prior to focal application. Line above [Ca2+]i responses indicates
duration of ischemia, acidosis or ischemia + acidosis application. D, Bar graph of mean
(± SEM) peak and total net increases in [Ca2+]i evoked by focal applications following 24
hr Aβ in isolated cortical neurons. [Ca2+]i responses were recorded from neurons in
experiments identical to those performed in (A-C). Asterisk symbolizes significant
difference between Control and Aβ (p < 0.001). For all conditions, n ≥ 81.
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72 ± 6 and 82 ± 6%, acidosis 42 ± 7 and 33 ± 10% and ischemia + acidosis 43 ± 4 and
85 ± 2% applications, respectively (Figure 6.2D).
Amyloid-β peptide has been shown to induce toxicity in several disease states
including AD and cerebral amyloid angiopathy through a number of mechanisms
including calcium toxicity, reactive species and hemichannel formation to name a few
(Mantha et al., 2006, Rezende et al., 2007, Orellana et al., 2011, Lazzari et al., 2015). To
ensure that the fragment Aβ25-35 shows similar toxicity to other more researched

Figure 6.3
Amyloid-β fragments 25-35 and 1-42 potentiate ischemia + acidosis induce [Ca2+]i
increases. A, shows a bar graph of mean peak (± SEM) of neurons incubated for 24 hr in
25µM Amyloid-β, either fragment 25-35, 1-40 or 1-42. Asterisk indicates a significant
difference from the Control, whereas the pound symbol shows significance from
fragment 1-40. B, is a bar graph of the mean total net Ca2+ influx (± SEM) in experiments
identical to A. Asterisk indicates a significant difference from the Control, whereas the
pound symbol shows significance from fragment 1-42 and 25-35 or 1-40 (p < 0.001 for
all) (n ≥ 158).
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fragments, experiments were conducted to assess various Aβ fragments effects on
potentiating increases in [Ca2+]i evoked by ischemia + acidosis application. Figure 6.3
shows a bar graph of the peak and total net calcium influx-induced by ischemia +
acidosis application following 24 hr incubation in media with Aβ fragments 25-35, 1-40 or
1-42. While fragment 1-40 showed no significance from the control, both fragment 25-35
and 1-42 showed a potentiation in the peak [Ca2+]i induced by ischemia + acidosis by 65
± 1 and 51 ± 9%, respectively. This potentiation in peak [Ca2+]i level by the Aβ fragments
25-35 and 1-42 were not significantly different from each other. Moreover, pre-incubation
with these fragments resulted in an increase in the total net calcium influx by 19 ± 2 and
37 ± 3% following focal application of ischemia + acidosis.

Figure 6.4
Oligomerized amyloid-β25-35 fails to potentiate ischemia + acidosis evoked increases in
[Ca2+]i following a 1 hr incubation. Bar graph of the mean peak and total net Ca2+ influx
(±SEM) in neurons incubated for 1 hr in media alone or media (Control) with 25 µM
oligomerized Aβ25-35 (Aβ) (n ≥ 43).
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Even though Aβ has been shown to bind directly to various ion channels including
NMDA and nAChRs (Nagele et al., 2002, Texido et al., 2011) it has been suggested that
the effects seen on Aβ-potentiated increases in [Ca2+]i be due to the oligomerized and
not the free Aβ. Therefore, experiments were conducted to determine if 1 hr incubation
with the oligomerized Aβ25-35 produced significant increases in [Ca2+]i following ischemia
+ acidosis application. Figure 6.4 shows a bar graph of the peak and total net calcium
influx in neurons incubated in media alone or media with the oligomerized Aβ. Following
application of ischemia + acidosis there was no significant difference between the media
or Aβ incubated increases in [Ca2+]i levels.
Given that afobazole has been shown to reduced ischemia and acidosis evoked
elevations in [Ca2+]i (Cuevas et al., 2011a) and that σ-1 receptor activation has been
shown to reduce Aβ-induced toxicity (Marrazzo et al., 2005), experiments were
conducted to determine if afobazole could mitigate the Aβ potentiated increase in [Ca2+]i
following ischemia + acidosis application. Figure 6.5A shows representative traces of
[Ca2+]i as a function of time recorded from 3 cells during ischemia + acidosis. Increases
in [Ca2+]i were observed in all groups with a potentiated increase in the Aβ incubated
cells with responses similar to those observed in experiments from Figure 6.2C. In cells
were afobazole was co-incubated with Aβ, [Ca2+]i elevations were not statistically
different from the control (Figure 6.5B&C), indicating that afobazole blocked the Aβinduced potentiation of [Ca2+]i overload.
The kinetics of the [Ca2+]i overload produced by ischemia + acidosis following preincubation with Aβ suggest that the acid-sensing ion channels 1a (ASIC1a) is involved in
the potentiation. To determine if Aβ is potentiating ASIC or only downstream effector
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targets of these channels, patch-clamp electrophysiological recordings were carried out.
Figure 6.6A shows proton-evoked membrane currents recorded from two neurons

Figure 6.5
Afobazole inhibits increases in [Ca2+]i evoked by ischemia + acidosis application
following 24hr Aβ25-35 incubation. A, Representative traces of [Ca2+]i as a function of time
recorded from three neurons during focal application of ischemia + acidosis in the
absence (Control) and presence of 25µM amyloid-β25-35 (Aβ) or 25µM amyloid-β25-35 and
100 µM afobazole (Afob + Aβ). Afobazole was co-incubated with Aβ for 24 hr and
washed out 1 hr prior to Ischemia + acidosis application. In experiments identical to A,
bar graphs of mean peak and total net Ca2+ influx (±SEM) measured in neurons.
Asterisks denote significant difference between Aβ and Control or Aβ + Afob (p < 0.001)
(B & C) (n ≥ 137).
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following 24 hr incubation in media alone or media with 25 µM Aβ25-35 held at a
membrane potential of -70 mV. Application of protons evoked a rapid inward current
which was potentiated by 68 ± 17% in Aβ incubated neurons. Varying pH showed that
Aβ potentiated responses at both pH 6.5 and pH 6.0, but not pH 7.0 (Figure 6.6B).
These data suggest that Aβ is potentiating the responses rather than shifting the half
maximal activation of ASIC to a higher pH.
The elevations of [Ca2+]i evoked by protons in cortical neurons are due to
activation of ASIC, but these channels themselves account for only a small portion of the
increase in [Ca2+]i observed during acidosis (Herrera et al., 2008). One possible
contributor to Aβ increases in [Ca2+]i that are downstream of ASIC are the ion

Figure 6.6
Amyloid-β25-35 incubation potentiates proton-evoked currents in cortical neurons. A,
Representative current traces recorded from two neurons held at -70 mV during acidosis
in neurons incubated in media alone (Control) or media with 25µM Amyloid-β25-35 (Aβ). B,
Bar graph of mean peak (±SEM) of the proton-evoked inward current in experiments
identical to A (n ≥ 8). Asterisk denotes significant difference between Aβ and respective
controls (p < 0.05).
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exchangers. Thus, calcium imaging experiments were conducted to determine if reversal
of the sodium/calcium exchanger (NCX) contributed to the calcium overload evoked by
Aβ incubation. Figure 6.7 is a bar graph of the mean peak and area of [Ca2+]i elevations
evoked by focal application of ischemia + acidosis following 24 hr incubation in media
alone or media with 25 µM Aβ. Similar to previous experiments, incubation with Aβ
produced a potentiated increase in the [Ca2+]i levels. Following the initial recording,
neurons were incubated with the NCX reversal mode inhibitor YM244769 (YM,1µM) for

Figure 6.7
Aβ potentiated calcium influx involves reversal of the sodium/calcium exchanger. A, Bar
graphs of mean (±SEM) increases in peak [Ca2+]i or net [Ca2+]i (Area, area under the
trace) elicited by focal ischemia + acidosis application in neurons incubated for 24 hr in
media alone (Media) or media with 25 µM amyloid-β25-35 (Aβ), before (Control) and after
20 min pre-incubation with YM224769 (YM, 1µM). Asterisks denote significant difference
between Control and YM within Media and Aβ groups (p < 0.001). Pound symbol
indicates significant difference between Controls within Media and Aβ groups (p <
0.001). B, Bar graph of relative YM inhibition of [Ca2+]i. Asterisks denote significant
difference (p <0.01). For all groups, n ≥ 171.
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20 minutes. YM incubation produced a significantly reduced increase in the ischemia +
acidosis evoked [Ca2+]i peak and net elevations by 38 ± 2 and 36 ± 2%, respectively.
This YM-induced reduction in calcium influx through the reversal NCX was also observed
in Aβ incubated neurons, which lead to a 40 ± 2 and 44 ± 1% reduction in the peak and
net Aβ-potentiated increase in [Ca2+]i, respectively. This resulted in relative inhibition of
YM blocking a small but significant 3.2 ± 0.7 and 10 ± 1.8% influx in the peak and total
net calcium potentiated by Aβ incubation, respectively. While blocking the reversal NCX
in neurons that were incubated in Aβ reduced the total calcium influx, we cannot yet be
sure that Aβ is having a direct effect on NCX or if it is an upstream mechanism(s), which
is increasing the sodium loading and thus increasing the ion concentration gradient.
Continuing to assess the role of ion exchangers in the Aβ potentiated increase in
[Ca2+]i elevations following focal application of ischemia + acidosis, we decided to look at
the sodium/calcium potassium-dependent exchanger (NCKX). Experiments were
conducted following a 24 hr incubation in media or media with 25 µM Aβ25-35, using a
physiological saline solution (PSS) with varying concentrations of K+ in attempts to
assess the role of NCKX. Figure 6.8A shows representative traces of [Ca2+]i as a
function of time recorded from 2 cells during ischemia + acidosis. Responses under
control conditions (K+=5.4mM), were identical to previous experiments for both media
and Aβ incubated neurons with Aβ having statistically higher peak and total net calcium
influx then media. However, when we changed the PSS to low or high K+ (2.7 & 10.8
mM, respectively) the ischemia + acidosis induced elevations in [Ca2+]i levels were not
as pronounced. Furthermore, there was no longer a significant difference between the
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media and Aβ incubated neurons. Indicating to us that the NCKX may not be contributing
to the potentiation we observe in Aβ treated neurons (Figure 6.8B&C).

Figure 6.8
Amyloid-β25-35 potentiation of [Ca2+]i increases evoked by ischemia + acidosis is not
dependent of the sodium/calcium potassium-dependent exchanger (NCKX). A,
representative traces of focal application of ischemia + acidosis recorded from two
neurons following 24 hr incubation in media (Media) or media with 25 µM Aβ25-35 (Aβ).
Neuron were pre-incubated for 10 min in PSS with varying concentrations of K+ (in mM,
normal = 5.4, low = 2.7, high = 10.8). B, bar graph of mean change in peak [Ca2+]i from
experiments identical to A. Asterisk identifies significance Control and Aβ within 5.4 (p <
0.001). Pound represents significance between Control or Aβ within groups 5.4, 2.7 and
10.8 (Control p < 0.01, Aβ p < 0.001). Dagger denotes significance between Aβ within
2.7 and 10.8. C, bar graph of mean net [Ca2+]i from experiments identical to A. Asterisk
identifies significance between Control and Aβ within 5.4 (p < 0.001). Pound represents
significance between Control or Aβ within groups 5.4, 2.7 and 10.8 (both p < 0.001).
Dagger denotes significance between Control within 2.7 and 10.8 (n ≥ 80).
139

Figure 6.9
Amyloid-β25-35 potentiation of the net [Ca2+]i increases evoked by ischemia + acidosis
may involve intracellular protons. A, representative traces of focal application of ischemia
+ acidosis recorded from two neurons following 24 hr incubation in media (Media) or
media with 25 µM Aβ25-35 (Aβ). Neuron were pre-incubated for 10 min in PSS without
(Control) and with 26 mM HCO3- (HCO3-). B, bar graph of mean change in peak [Ca2+]i
from experiments identical to A. Asterisk identifies significance Control and HCO3- within
Media and Aβ groups (p < 0.001). Pound represents significance between Control or
HCO3- within groups Media and Aβ (Peak p < 0.05, Net p < 0.001). C, bar graph of
relative HCO3- inhibition of [Ca2+]i from experiments identical to A. Asterisk identifies
significance between Media and Aβ within Area (p < 0.001) (n ≥ 66).
Since following an ischemic event cells undergo acidosis we were interested in
looking at the roles of proton exchangers, specifically the sodium/hydrogen exchanger
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(NHE) and the mitochondrial calcium/hydrogen exchanger (LETM1). To achieve this we
used PSS with 26 mM HCO3- to sequester the intracellular protons. Prior to recording
neurons were incubated for 24 hr in media alone or media with 25 µM Aβ25-35. Figure
6.8A shows representative traces of [Ca2+]i as a function of time recorded from 2 cells
during ischemia + acidosis before and after 10 min incubation in HCO3- PSS. As we have
previously seen in identical experiments Aβ incubation potentiates both the peak and
total net calcium influx following ischemia + acidosis application. Pre-incubation with
HCO3- reduced the media and Aβ incubated peak by 36 ± 4 and 31 ± 3%, as well as the
total net calcium influx by 49 ± 1 and 34 ± 1%, respectively (Figure 6.8B). When
comparing the relative inhibitions that HCO3- had between the media and Aβ treated
cells we found no significance in the peak levels, however there was a 30 ± 2% reduction
in the total net calcium influx of media incubated neurons (Figure 6.8C). While still
unclear, intracellular protons may be contributing to the calcium overload, possibly
through the aforementioned exchangers.

Discussion
The major findings reported in the present study are that amyloid-β potentiates
ischemia + acidosis evoked increases in [Ca2+]i in a time-dependent manner and through
an acid-sensing ion channel 1a-dependent mechanism. The responses were also
dependent on the use of amyloid-β fragments 25-35 or 1-42, whereas the fragment 1-40
did not potentiate the increase in intracellular calcium. Moreover, co-incubation with the
pan-selective σ receptor agonist, afobazole, completely abolished this potentiation.
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Neuronal cultures were used to determine if incubation with 25 µM amyloid-β25-35
produced an increase in the [Ca2+]i levels evoked by ischemia + acidosis application.
Incubation for 12 hr failed to potentiate Ca2+ elevations. It has been shown that longer
periods are needed (i.e. 24 hr) to up-regulate gene expression (Behensky et al., 2013a,
b). Therefore, neurons were incubated for 24 hr with Aβ and found to have potentiated
ischemia, acidosis and ischemia + acidosis induced increases in [Ca2+]i levels. We found
that acidosis application alone produced an increase in mean peak [Ca2+]i by ~42%.
Furthermore, application of ischemia alone or ischemia + acidosis also produced
potentiated elevations in both the peak and total net calcium influx by ~72 and 82% for
ischemia and ~43 and 85% for ischemia + acidosis, respectively. This dual potentiation
in [Ca2+]i may indicated that the mechanism in these response involve multiple pathways
including ASIC1a, VGCCs, NMDA and AMPA/kainate receptors. Previous studies from
our laboratory have shown that ischemia-induced elevations in [Ca2+]i involved the
activation of NMDA receptors (Katnik et al., 2006), whereas acidosis application
activates ASIC1a receptors (Herrera et al., 2008). Moreover, the ischemia + acidosis
activation of NMDA and ACIS1a receptors results in a synergistic increase in [Ca2+]i
levels. This is a complicated interaction with NMDA receptors functionally up-regulating
ASIC1a, while at the same time ASIC1a potentiates NMDA receptor activity (Mari et al.,
2014).
Since activation of ASIC1a has been shown to potentiate ischemia-induced [Ca2+]i
levels through NMDA receptors, we were interested in determining where Aβ potentiation
occurred. Previous studies have shown that only a small part of the ischemia + acidosis
evoked Ca2+ influx is directly due to ACIS1a with VGCCs, NMDA and AMPA/kainate
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receptors contributing to the bulk influx (Gonzalez-Alvear and Werling, 1995, Alonso et
al., 2000). However, fluorometric calcium imaging showed that Aβ-induced a potentiated
proton activated Ca2+ influx. Therefore, whole-cell patch-clamp experiments were
performed to determine whether this potentiation was due to directly to ASIC1a activity
or via ASIC1a enhanced downstream channels. Neurons incubated with Aβ for 24 hr
were voltage-clamped at -70 mV, which prevents NMDA receptor and VGCC activation,
demonstrated a ~68% increase in the proton evoked inward current. Taken together, our
results indicate that Aβ incubation is directly up-regulating ASIC1a activity as well as the
ASIC1a potentiated down-stream channels.
These channels contribute directly and indirectly to the [Ca2+]i overload. Following
ischemia there is a loss of ATP production and consequently Na+ loading due to failure in
the Na+/K+ ATPase. This shift in the Na+ concentration gradient results in the reversal of
the Na+/Ca2+ exchanger, which can contribute to the Ca2+ overload. Imaging experiments
found that following Aβ incubation there was an increase NCX function, which was
blocked by the NCX (reversal) inhibitor YM244769 (1µM). However, we are not able to
say whether this increase in reversal NCX activity is the result of Aβ on NCX or due to
increased Na+ loading, which increases the driving force of the exchanger. An additional
consequence of the Na+/K+ ATPase failure is the accumulation of extracellular K+, which
can result in the depolarization of neighboring neurons. However, it can also increase the
activity of the Na+/Ca2+ K+-dependent exchanger (NCKX), which can further contribute to
the [Ca2+]i overload. To assess the role of NCKX on Aβ potentiated increase in [Ca2+]i
evaluations following focal application of ischemia + acidosis experiments were
conducted using a physiological saline solution (PSS) with varying concentrations of K+.
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Responses under control conditions (K+ = 5.4mM), were identical to previous
experiments for both media and Aβ incubated neurons with Aβ having statistically higher
peak and total net calcium influx then media. However, when we changed the PSS to
low or high K+ (2.7 & 10.8 mM, respectively) the ischemia + acidosis induced elevations
in [Ca2+]i levels were not as pronounced. Furthermore, there was no longer a significant
difference between the media and Aβ incubated neurons. Indicating to us that the NCKX
may not be contributing to the potentiation we observe in Aβ treated neurons.
Reducing the Ca2+ overload produced by an ischemic insult is crucial to mitigating
stroke injury. Previous studies from our laboratory have shown that σ-1 receptor
activation in neurons can elevate the Ca2+ overload induced by ischemia, acidosis and
Aβ (Cuevas et al., 2011a, Behensky et al., 2013a). However, not all sigma receptor
agonists were shown to be as effective under these conditions (Behensky et al., 2013a).
The pan-selective agonist afobazole was one such drug that did mitigate Ca2+ overload
induced under all three conditions. Therefore, 100 µM afobazole was co-incubated with
Aβ for 24 hr to assess what function activation of sigma receptors would have on the Aβ
up-regulated function. Co-incubation with afobazole completely abolished the potentiated
increases in [Ca2+]i levels-induced via focal application of ischemia + acidosis. Reducing
the Aβ up-regulated Ca2+ increases will likely translate to an increase in neuronal
survival.
In conclusion, our data show one mechanism by which Aβ may potentiate
neuronal injury during ischemia-acidosis is through increased [Ca2+]i overload, and
identify ASIC1a as the channel mediating this phenomenon. Finally, our data suggest
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that activation of σ receptors by afobazole may represent a therapeutic strategy for
mitigating injury produced by Aβ and stroke.

145

CHAPTER 7

Discussion

Conclusions
Stroke is the fifth leading cause of death and continues to be a major cause of
serious long-term disability in the United States (Mozaffarian et al., 2015). An ischemic
stroke accounts for about 87% of all strokes and occurs when blood flow to the brain is
occluded by a thrombus or embolus. The only treatment currently approved by the FDA
for ischemic stroke is recombinant tissue plasminogen activator (rtPA), a thrombolytic
agent used to restore blood-flow interrupted by a blood clot (Weintraub, 2006). However,
rtPA therapy is time sensitive, and the drug must be administered < 4.5 hours postinfarct. In addition, aging patients presenting various comorbidities leads to an increase
in rtPA’s risk to benefit ratio, resulting in less than 4% of patients being able to use it
(Armstead et al., 2010). The goal of future therapies would be to treat these patients at
24 to 48 hrs follow the insult.
Our laboratory has shown that DTG can mitigate neuronal and glial cell injury
following in vitro stroke models through activation of σ receptors (Katnik et al., 2006, Hall
et al., 2009a). In attempts to improve upon the efficacy of DTG we conducted
experiments, which involved shifting and removal of the methyl moiety of DTG. Our
findings with the DTG analogues show that rearrangement of the methyl moiety did not
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produce a compound which behaves differently from the parent compound in terms of
modulating [Ca2+]i increases induced via ischemia and acidosis. Removal of the group
entirely (DPhG) produces a significant 18.3 ± 0.05% increase over o-DTG in inhibiting
elevations in [Ca2+]i during acidosis. Similarly, DPhG show a 12.2 ± 0.04% greater
inhibition than o-DTG in the ischemia assay, but this difference was not statistically
significant. Previous studies have reported that the σ receptor binding affinities for o-, m-,
and p-DTG are approximately 30, 50, and 530 nM, respectively; whereas the affinity of
DPhG for σ receptors is ~400 nM (Scherz et al., 1990, Reddy et al., 1994). Results from
our functional studies, therefore, do not reflect the decrease in affinity observed for the pDTG or DPhG. Calcium elevations evoked by ischemia and acidosis are in part due to
activation of NMDA receptors (Katnik et al., 2006, Herrera et al., 2008). However, neither
p-DTG nor DPhG shows increased affinity for NMDA receptors compared to o-DTG
(Scherz et al., 1990, Reddy et al., 1994), and thus actions on that receptor cannot
account for the discrepancy between σ receptor binding and functional effects. Since the
earlier studies did not examine specifically σ receptor subtype binding affinity, the
difference may be due to changes in affinity for one receptor subtype versus the other
(i.e. σ-2 receptor affinity decreases significantly but σ-1 receptor affinity remains
unchanged).
While migration and removal of the methyl moiety failed to alter functional
properties of the molecule significantly, pronounced enhancement in potency were found
with halide substitutions. Data presented in this study show that substituting a chloro for
a methyl moiety in the meta and para positions of DTG produced compounds that had
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~15% higher potency relative to the parent compound (o-DTG) at 100 µM concentration
in the ischemia-induced increases in [Ca2+]i assay. The enhancement in potency was
even more pronounced in the acidosis-evoked [Ca2+]i dysregulation assay. In this assay,
m- and p-ClDPhG (100 µM) produced blocks of >100% greater than o-DTG. In contrast,
substitution of a chloro moiety in the ortho position did not alter the functional effects of
the parent compound in either the ischemia or acidosis assay. Similar observations were
made using compounds with bromo substitutions (BrDPhG) of DTG in the meta and para
positions with an ~22% increase of inhibition during ischemia and an ~160% increase
during acidosis applications over o-DTG, respectively. The most potent compound tested
was p-BrDPhG, which had an IC50 indicating 8-fold and 34-fold greater potency over that
of o-DTG in the acidosis [Ca2+]i and ischemia [Ca2+]i assays, respectively.
Functional assays indicated that p-BrDPhG was significantly more potent than oDTG, but a radioligand binding assay showed decreased affinity for both σ receptor
subtypes. Our experiments showed that o-DTG binds σ-1 and σ-2 receptors with an
affinity in the range of 60-90 nM, which is similar to what was previously reported in the
literature (Torrence-Campbell and Bowen, 1996). In contrast, p-BrDPhG was found to
bind σ-1 and σ-2 receptors with 296 ± 46 nM and 800 ± 57 nM affinities, respectively,
with the σ-2 receptor affinity being significantly lower. These values are similar to a
previous report which indicates that p-BrDPhG binds guinea pig brain membrane
extracts with an affinity of 540 ± 25 nM (Scherz et al., 1990). That study also
demonstrated that p-BrDPhG has lower binding affinity for the NMDA receptor than the
parent compound (o-DTG), and therefore, the increased functional potency cannot be
explained by increased action at the NMDA receptor.
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Confirmation that p-BrDPhG mitigates [Ca2+]i dysregulation via activation of σ-1
receptors was achieved via the use of the σ-1 receptor antagonist BD-1063. Using the
acidosis [Ca2+]i functional assay, BD-1063 was shown to inhibit the effects of p-BrDPhG
by >50% at a concentration of 10 nM, which is consistent with p-BrDPhG acting via σ-1
receptors (Matsumoto et al., 1995, Herrera et al., 2008). To date, only activation of the σ1 receptor has been shown to affect ischemia- and acidosis-evoked [Ca2+]i dysregulation
(Katnik et al., 2006, Herrera et al., 2008), and thus effects by the σ-2 receptor were not
tested in these assays.
The current study shows that p-BrDPhG also inhibits microglial activation and this
DTG analogue is 4-fold more potent than the parent compound and a second panselective σ agonist, afobazole (Hall et al., 2009a, Cuevas et al., 2011b). Unlike ischemiaand acidosis-evoked [Ca2+]i dysregulation, which appears to be exclusively affected by σ1 receptor activation, both σ-1 and σ-2 receptors can modulate microglial migration
(Cuevas et al., 2011b). This observation may explain why p-BrDPhG, which has even
lower affinity for σ-2 than σ-1, is only 4-fold more potent than o-DTG in the microglial
migration assay but 8- to 34-fold more potent than the parent compound in the [Ca2+]i
dysregulation experiments. The observation that p-BrDPhG is more potent than o-DTG
in inhibiting microglial activation may have important therapeutic implications. Previous
studies have demonstrated that activation of microglia following an ischemic insult
results in the release of pro-inflammatory cytokines by these cells, which promotes
neuronal death (Lee et al., 2001).
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One mechanism which may explain the discrepancy between decreased binding
affinity but increased functional potency of p-BrDPhG may be increased membrane
permeability of the compound. It has been shown that chloro and bromo substitution in
the para position on phenylalanine increases hydrophobicity and blood-brain barrier
permeability of a drug (Gentry et al., 1999). Likewise, halogenation of small molecules
has been demonstrated to increase membrane permeation (Gerebtzoff et al., 2004). It
has been shown that increasing membrane permeability of a σ ligand by deprotonation
increases potency of the compound, which was interpreted to suggest that the binding
site for ligands such as BD-1063 are intracellular (Vilner and Bowen, 2000). Immunolabeling studies have confirmed this hypothesis, showing that σ-1 receptors localize to
the endoplasmic reticulum (Dussossoy et al., 1999, Seminerio et al., 2012). Moreover,
the proposed binding site for drugs such as o-DTG are, in part, located in the
transmembrane domain of the receptor (Pal et al., 2007). Thus, by increasing membrane
permeability, chloro and bromo substitution more than compensate for the decreased
binding affinity.
Our data, however, also suggest that factors other than membrane permeability
are likely involved in the effects of the halogenation and methylation. Electronegativity
and conformation of the molecule are also important. For example, fluoro substitution of
a distal phenyl group of a piperidine greatly increased the lipophilicity of the compound
(de Candia et al., 2009). Despite the likely increased lipid permeability, our findings show
that fluoro substitution does not result in increased inhibition of [Ca2+]i dysregulation
evoked via ischemia or acidosis relative to o-DTG. One possibility is that while the fluoro
substitution may increase the drugs lipophilicity, the added increase in electronegativity
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caused by addition of a fluoro moiety may have disrupted binding of the compound to the
σ receptors. While fluorine has an electronegativity of 4.0, that of chlorine and bromine
are ~ 3.0. Moreover, our data suggest that location of chloro and bromo substitutions on
the phenyl ring for enhanced potency were limited to either the meta or para positions. A
previous report on structure-activity relationship of DTG analogues suggested that the
ortho position was the most tolerant to structural modifications, including addition of
electronegative moiety (Scherz et al., 1990). However, that report did not distinguish
between σ-1 and σ-2 receptor binding, and thus the effects of those modifications on the
respective receptors remains to be determined.
It has been shown that following a stroke there is an increase in the production
of the amyloid-β peptide (Stephenson et al., 1992, Jablonski et al., 2011, Pluta et al.,
2013). There are currently no studies that have looked at potential therapeutic targets to
mitigate post-stroke amyloid-β induce toxicity. Aβ25-35 was found to produce increases in
[Ca2+]i after cells were incubated in the Aβ fragment for ≥ 1 hr, with short applications ≤
15 min failing to alter [Ca2+]i. Maximal increases in [Ca2+]i were observed after 12 hr
incubation of the neurons in Aβ25-35 and [Ca2+]i remained significantly elevated even after
24 hr incubation in the Aβ fragment. The observed 2-fold increase in [Ca2+]i caused by
Aβ25-35 is similar to that previously reported for rat cortical neurons incubated for 24 hr in
Aβ25-35 (Ferreiro et al., 2004). Despite the DTG analogue p-BrDPhG showing a greater
potency for mitigating ischemia- and acidosis-induced increases in [Ca2+]i elevations, we
decided to use another pan-selective sigma receptor agonist. The decision to use
afobazole was predominately two-fold. First, the guanidine compounds are known to be
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“dirty” (i.e. bind to many receptors), whereas afobazole has minimal non-target effects.
Second, afobazole has been better characterized and is currently being used clinically.
Therefore, neurons were incubated in 100 µM afobazole and found to reduce Aβ25-35evoked increases in [Ca2+]i by ~60%. This decrease in [Ca2+]i is similar to that observed
when afobazole was used to inhibit [Ca2+]i increases produced in cortical neurons by
acidosis (IC50 = 164 µM) (Cuevas et al., 2011a). Reducing Aβ25-35 perturbation of [Ca2+]i
is likely to promote neuronal survival, since [Ca2+]i destabilization has been linked to cell
death in AD (Mattson and Chan, 2003b). Moreover, the Aβ25-35-induced changes in
[Ca2+]i precede pro-apoptotic signals in the model used here (e.g. decrease in Bcl-2
levels occurring 48 hrs after Aβ25-35 application).
The inhibition of Aβ25-35-elicited increases in [Ca2+]i by afobazole is due to
activation of σ-1, but not σ-2 receptors. Incubation in the σ-1 receptor antagonist, BD1047 (Matsumoto et al., 2004), reduced the effects of afobazole by ~40%. The
concentration and degree of block reported here is consistent with previous studies
showing BD-1047 inhibition of σ-1 receptor-mediated effects in cortical neurons and
retinal ganglion cells (Katnik et al., 2006, Cuevas et al., 2011a, Mueller et al., 2013). The
lack of involvement of σ-2 receptors is confirmed by results obtained using the σ-2
receptor antagonist, rimcazole (Gilmore et al., 2004). Rimcazole binds to σ-2 receptors
with nanomolar affinity, but to σ-1 receptor with low micro molar affinity (Ferris et al.,
1986, Husbands et al., 1999, Rybczynska et al., 2008). Given that 300 nM rimcazole
failed to inhibit the actions of afobazole on Aβ25-35-evoked increases in [Ca2+]i, but that
the higher concentration of the drug reduced these effects, it is unlikely that afobazole
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activates σ-2 receptors to suppress Aβ25-35-evoked increases in [Ca2+]i. Surprisingly, a
second pan-selective σ receptor agonist, DTG, failed to mimic the effects of afobazole on
Aβ25-35-evoked [Ca2+]i perturbation. DTG and afobazole both block acidosis- and
ischemia-induced Ca2+ overload in neurons to a similar extent (Cuevas et al., 2011a). It
was shown that ischemia-induced [Ca2+]i increases were due primarily to Ca2+ influxes
through voltage-gated Ca2+ channels and NMDA receptors which were regulated by σ
receptor activation (Katnik et al., 2006). However, the difference between afobazole and
DTG effects on Aβ modulation of [Ca2+]i, suggest these long-term [Ca2+]i increases
involve distinct mechanisms from those producing ischemia-induced [Ca2+]i overload.
Additionally, the lack of a DTG effect on Aβ-evoked [Ca2+]i overload suggests that not all
σ-1 agonists may promote neuronal survival in this model. This hypothesis is further
supported by our observation that DTG fails to decrease neuronal apoptosis following 24
hr incubation Aβ25-35. The difference in responses between afobazole and DTG may be
due to off-target effects of DTG counteracting the benefits of this pan-selective sigma
agonist.
It has been suggested that one of the downstream consequences of [Ca2+]i
dysregulation in neurons caused by Aβ25-35 is the production of ROS (Ekinci et al., 2000,
Abramov et al., 2004). Afobazole has been shown to reduce ROS accumulation in rat
brains after focal ischemia (Silkina et al., 2006). However, data presented here show that
afobazole does not block the ROS increases caused by the Aβ fragment. It has been
suggested that Aβ, and in particular Aβ25-35, can increase oxidative stress via
mechanisms independent of [Ca2+]i dysregulation (Varadarajan et al., 2001). Given that
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afobazole inhibits [Ca2+]i dysregulation produced by Aβ25-35 in neurons but not the
increase in ROS, it is unlikely that afobazole is affecting this [Ca2+]i-independent ROS
production. It is important to note that while afobazole may not decrease ROS
production, it has been shown that σ-1 receptors decrease H2O2 evoked apoptosis
(Meunier and Hayashi, 2010). Thus, afobazole may in part decrease Aβ25-35-induced cell
death by acting downstream of the observed ROS increase.
Aβ25-35 has been shown to increase nitric oxide synthase (NOS) activity and
produce neuronal injury via nitrosative stress (Parks et al., 2001, Cho et al., 2009). Aβ2535-evoked

increases in NO were significantly decreased following afobazole application.

Inhibition of inducible NOS (iNOS) has been proposed as a mechanism by which
activation of σ-1 receptors is neuroprotective after stroke (Vagnerova et al., 2006).
Similarly, functional downregulation of neuronal NOS (nNOS) has been shown to
contribute to σ receptor neuroprotection following ischemia in striatal neurons (Yang et
al., 2010). Since Aβ25-35 appears to increase both iNOS and nNOS in neurons (Limon et
al., 2009), activation of σ receptors by afobazole is predicted to reduce NO production by
both of these enzymes, and will ultimately contribute to protection from Aβ25-35 induced
injury.
One of the pro-apoptotic proteins upregulated in neurons both by the
pathological sequela induced by Aβ25-35 application and in patients with Alzheimer’s
disease is Bax (Paradis et al., 1996, Yao et al., 2005). Consistent with previous findings,
the current study shows that the number of Bax positive neurons is significantly
increased following 24 hr incubation in Aβ25-35. However, when afobazole is applied in
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combination with Aβ25-35, Bax upregulation is diminished significantly. It has also been
shown that the σ-1 agonist, PRE-084, can reduce apoptosis in cortical neurons caused
by Aβ25-35 via reduction in Bax (Marrazzo et al., 2005). However, glutamatergic
neurotransmission was blocked in those experiments (Marrazzo et al., 2005).
Glutamatergic transmission is a factor in Aβ25-35-induced cell death, and elevated
glutamate levels have been shown to induce Bax upregulation in neurons (Schelman et
al., 2004, Revett et al., 2013). Thus, our data suggest that σ receptor activation by
afobazole can reduce Bax expression and concomitant cell death in the presence of
Aβ25-35 even when glutamatergic transmission is not blocked.
In addition to decreasing Bax levels, afobazole effectively reduced activated
caspase-3 expression in response to Aβ25-35. The active form of caspase-3 has been
implicated in the loss of hippocampal neurons in Alzheimer’s disease (Selznick et al.,
1999). In addition to serving as a late event involved in neuronal death during
Alzheimer’s disease, caspase activation may be an early event that promotes the
pathology of AD. Several caspases, including caspase-3, have been shown to cause
pathological tau filament assembly in neurons, which underlies AD etiology (Gamblin et
al., 2003). Selective inhibition of caspase-3 has been shown to protect neurons from
Aβ25-35-induced apoptosis (Allen et al., 2001). Sigma receptor activation has been shown
to decrease caspase-3 and to protect cortical neurons and RGC-5 cells against
excitotoxicity (Tchedre and Yorio, 2008, Griesmaier et al., 2012). Such a mechanism is
likely to contribute to afobazole neuroprotection from Aβ25-35 toxicity and may in part
explain the reduced neuronal death observed here.
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The neuroprotective properties of afobazole following exposure to Aβ25-35 also
involves long-term upregulation of Bcl-2. Our data indicate that there is a biphasic
change in Bcl-2 levels in neurons following application of Aβ25-35 with an initial increase
at 24 hr followed by a suppression of Bcl-2 expression at 48 hr. A similar transient
expression pattern was previously reported in rat hippocampal neurons exposed to Aβ2535

(Kim et al., 1998). It was proposed that this initial increase in Bcl-2 expression is a

non-sustainable cellular response to the apoptotic pathways induced by Aβ (Kim et al.,
1998). Our observations indicate that when afobazole is applied along with Aβ25-35, Bcl-2
levels do not drop below control at the 48 hr time point. Previous studies have shown
that Bcl-2 is a target for σ receptor mediated neuroprotection. The HIV-1 protein gp120
was shown to downregulate Bcl-2 in cortical neurons, but activation of σ receptors with
the σ ligand, PPBP, increased Bcl-2 expression (Zhang et al., 2012). PPBP was shown
to have a similar effect in a glutamate excitotoxicity model (Yang et al., 2007),
suggesting that Bcl-2 upregulation may occur after σ receptor stimulation under various
pathophysiological conditions.
Previous studies from our laboratory have shown that microglia quickly become
activated and withdraw their filopodia when exposed to various stimuli, such as LPS and
ATP (Hall et al., 2009a). This activated state, which allows the microglia to migrate to the
site of injury, is preceded by the release of neurotoxic substances (Kierdorf and Prinz,
2013). Previously we have shown that microglia, in response to ATP, alter their
morphology to a less ramified state and this reaction was inhibited by DTG (Hall et al.,
2009a). Afobazole effectively blocked membrane ruffling by approximately 50% in
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response to ATP. For comparison we used a second pan-selective σ receptor agonist,
DTG, which reduced ruffling comparable to afobazole and to the extent as previously
reported. In addition, afobazole was recently shown to mitigate microglial migration in a
concentration dependent manor in response to ATP and UTP. Other studies have shown
that microglia rapidly respond to Aβ by withdrawing their filopodia and assuming an
amoeboid, ruffled morphology (Araujo and Cotman, 1992). This early event is indicative
of microglial activation and precedes the inflammatory response that includes release of
neurotoxic substances from the microglia (Combs et al., 2001, Garcao et al., 2006,
Orellana et al., 2011). Afobazole (30 µM) effectively blocked membrane ruffling in
response to Aβ25-35. While a second pan-selective σ receptor agonist, DTG (30 µM), also
decreased membrane ruffling caused by Aβ25-35, this drug was significantly less potent
than afobazole. It has been shown that higher concentrations of DTG (100 µM) are also
required to block ATP-induced microglial membrane ruffling (Hall et al., 2009a).
Afobazole also effectively blocked microglial migration induced by Aβ25-35. It has
been shown previously that various Aβ fragments, including Aβ25-35, are microglial
chemotactic agents (Davis et al., 1992). The Aβ-induced chemotaxis is in part due to
release of ATP from microglia following Aβ25-35 application and subsequent activation of
P2Y2 receptors on these cells (Kim et al., 2012). We have previously shown that
afobazole blocks microglial migration induced by activation P2Y receptors (Cuevas et al.,
2011b). Afobazole appears to inhibit microglial migration caused by UTP via σ receptormediated disruption in P2Y signaling, since afobazole treatment also inhibited P2Yinduced elevation in [Ca2+]i in microglia (Cuevas et al., 2011b). The IC50 for afobazole
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inhibition of microglial migration caused by Aβ25-35 is 120 µM, which is similar to the lowaffinity site reported for afobazole inhibition of UTP-induced microglial migration (102
µM) (Cuevas et al., 2011b). Therefore, afobazole may in part prevent microglial
chemotaxis caused by Aβ25-35 via σ receptor-mediated inhibition of P2Y receptors in
these cells.
Data shown here indicate that both σ receptor subtypes are involved in afobazole
inhibition of Aβ25-35-evoked microglial activation. Afobazole-mediated inhibition of
microglial migration was reduced by ~50% by 10 µM BD 1047, which is indicative of a σ1 receptor mediated effect (Matsumoto et al., 1995). An identical concentration of BD
1047 had a similar effect on afobazole inhibition of ATP-induced microglial cell migration
(Cuevas et al., 2011b). Likewise, involvement of σ-2 receptors is confirmed by results
obtained using the σ receptor antagonist, rimcazole, which binds to σ-2 receptors with
nanomolar affinity (Ferris et al., 1986, Rybczynska et al., 2008). Nanomolar
concentrations of rimcazole also blocked afobazole inhibition of microglial migration in
response to ATP (Cuevas et al., 2011b).
Given that one of the consequences of microglial activation is increased oxidative
and nitrosative stress, which leads to Aβ25-35 toxicity (Weldon et al., 1998, Bianca et al.,
1999, Combs et al., 2001), we examined how afobazole affects Aβ25-35-induced
increases in cellular ROS and NO levels. Consistent with previous reports, both ROS
and NO levels were increased significantly following Aβ25-35 application. However,
afobazole failed to attenuate the increases in ROS and NO evoked by the Aβ fragment.
Activation of σ receptors has been shown to decrease oxidative injury and nitrosative
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stress in various models. It was recently shown, using σ receptor knockout mice, that σ-1
has a dual function of both reducing oxidative stress and activating antioxidant response
elements (Pal et al., 2012). In microglia, stimulation of σ receptors by DTG reduces NO
production in response to lipopolysaccharide (Hall et al., 2009a). Taken together,
however, our data suggest that the reduction in Aβ-evoked microglial cell toxicity
provided by afobazole application is not the result of σ receptor-mediated decrease in
oxidative or nitrosative stress.
While decreased activation of microglia will be beneficial following a stroke by
reducing the neuroinflammatory response, recent data suggests that enhanced
microglial survival is also important for improved outcomes given the ability of these cells
to phagocytose Aβ plaques (Streit et al., 2009, Solito and Sastre, 2012). Application of
30 µM afobazole significantly reduced the number of microglia undergoing apoptosis
following 72 hr incubation in Aβ25-35. The concentrations of afobazole shown to be
effective here are identical to those previously shown to decrease microglial cell death
caused by ischemia in a σ receptor dependent manner and consistent with the binding
affinity of afobazole for σ-1 receptors (Seredenin et al., 2009, Cuevas et al., 2011a,
Cuevas et al., 2011b). This observation suggests that afobazole is similarly acting
through σ receptor activation to prevent microglial cell death. Both melatonin and Nacetylcysteine have been shown to decrease Aβ25-35-evoked apoptosis in microglia via a
reduction in ROS (Jang et al., 2005). Given that afobazole does not appear to affect
Aβ25-35-elicited increases in ROS, it is unlikely that afobazole provides cytoprotection via
a similar mechanism to these compounds.
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Our findings demonstrate that afobazole mitigates Aβ25-35-induced apoptosis of
microglia by decreasing expression of the pro-apoptotic gene, Bax, and the death
protease caspase-3 while preserving the levels of the anti-apoptotic gene, Bcl-2. An
increase in Bax levels has been observed in both neurons and microglia of AD brains
(Su et al., 1997). Moreover, interventions that decrease Aβ25-35-induced microglial
apoptosis have been shown to lower Bax expression (Jang et al., 2005, Shang et al.,
2012). Likewise, caspase activity has been detected in plaque-associated neurons and
microglia in AD brains (Yang et al., 1998). Caspase-3 levels have been shown to be
upregulated in microglia following Aβ administration, while reduced levels of this death
protease have been associated with inhibition of Aβ toxicity (Shang et al., 2012).
Conversely, expression of the anti-apoptotic gene, Bcl-2, is inversely correlated with
disease severity in AD. Increases in Bcl-2 levels promote microglial survival following
exposure to Aβ25-35 (Satou et al., 1995, Jang et al., 2005). Therefore, afobazole likely
enhances microglial survival and resistance to Aβ25-35 toxicity via a complex response
involving both anti-apoptotic and pro-apoptotic genes. This multifaceted effect is
consistent with afobazole acting as a σ agonist, since σ receptor activation has been
shown to modulate Bax, caspase-3 and Bcl-2 levels (Tchedre and Yorio, 2008, Meunier
and Hayashi, 2010).
Importantly, not only did afobazole protect microglia from Aβ25-35-evoked
apoptosis, but application of the σ agonist preserved the functional capacity of these
cells, as evident from the continued [Ca2+]i responses to ATP. Ultimately, one of the
theoretical benefits to increased microglial survival would be continued clearance of Aβ,
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as this peptide has been shown to be phagocytosed by microglia (Wilcock et al., 2004,
Herber et al., 2007). This hypothesis is further supported by the recent observation that
microglial clearance of Aβ directly correlates with expression of the gene CD33, such
that a CD33 deficiency reduces brain levels of both insoluble Aβ1-42 and amyloid plaque
burden in a mouse AD model (Griciuc et al., 2013). Moreover, there is a decrease in both
CD33 expression and insoluble Aβ1-42 in the brains of individuals expressing the minor
allele of the CD33 (SNP rs3865444) gene, which was identified previously as imparting
protection against AD (Naj et al., 2011, Griciuc et al., 2013). The fact that responses to
ATP itself are preserved is significant, since the clearance of Aβ has been shown to be
dependent of the activation of P2Y2 receptors. Microglia respond to Aβ by releasing ATP
and this nucleotide functions in a paracrine manner, acting on P2Y2 receptors expressed
on the microglia to enhance Aβ uptake by these cells (Kim et al., 2012). We have
previously shown that in our model these increases in [Ca2+]i are due to activation of P2Y
receptors, since they can be elicited by UTP (Cuevas et al., 2011b). Therefore, by
preserving ATP responses in microglia, afobazole will permit these cells to respond to Aβ
in vivo and potentially decrease amyloid burden.
It has been suggested that over-activation of microglia result in neuronal death
(Hellwig et al., 2013). However, the need to maintain viable microglia that respond to
sites of injury are equally necessary. Neurons exposed to ischemic conditions release
cytotoxic and neurotropic factors that both activate and attract microglia to the area of
injury (Hellwig et al., 2013, Kierdorf and Prinz, 2013). Unfortunately, in disease states
like stroke, over-activation of microglia is a common occurrence and often times result in
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neuronal and microglial cell death. Thus it is of great importance to identify factors that
contribute to the demise of microglia and find treatments to combat these mechanisms.
Exposure of microglia cells to ischemia resulted in approximately 150-fold increase in
cell death from control alone. Afobazole reduced the number of dyeing microglia by 75 ±
8% when co-incubated with ischemia.
Our laboratory has previously shown that afobazole can mitigate intracellular
calcium dyshomeostasis in neurons and microglia following ischemia, acidosis and ATP
exposure (Katnik et al., 2006, Herrera et al., 2008, Cuevas et al., 2011a, Cuevas et al.,
2011b). A rise in intracellular concentration, if unresolved, can promote the initiation of
apoptosis (Mattson and Chan, 2003a). Immunocytochemical experiments were
conducted to determine if afobazole affects microglial expression of the pro-apoptotic
protein Bax or the death protease, caspase-3, following 24 hr ischemic exposure. Both
Bax and caspase-3 expression increased > 270 and 150% from the control, respectively.
We found that afobazole alone decreased caspase-3 expression and when co-incubated
with ischemia both Bax and caspase-3 expression were mitigated approximately 42 and
59%, respectively. Further experiments were conducted to determine if levels of Bcl-2
were affected by ischemia and to what if affect afobazole had on its expression.
Following ischemic incubation, microglial Bcl-2 expression was decreased by ~ 21%
from that of the control. However, when co-incubated with ischemia, afobazole preserved
Bcl-2 expression by approximately 24%, making it comparable to afobazole alone.
Exposing cells to ischemic conditions has been shown to decrease cell viability.
Our laboratory has shown that afobazole mitigates death following 2 hr ischemia
exposure (Cuevas et al., 2011a, Cuevas et al., 2011b). This model resembles injury
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caused by reperfusion of the tissues with oxygen, more of a transient ischemic model.
Experiments were conducted to determine to what extent afobazole could be
neuroprotective following prolonged ischemic exposure (72 hr). There was an
approximant 3-fold increase in the number of expired neurons from that of the control.
This increase in the demise of neurons was mitigated by approximately 55% when coincubated with afobazole. This data indicates that even under prolonged ischemic
conditions afobazole was to some extent neuroprotective. Immunocytochemical
experiments were carried out to determine if one mechanism by which afobazole is
neuroprotective is through sigma receptor regulation of apoptotic expression. Both Bax
and caspase-3 expression were observed under all conditions. Following ischemic
exposure, both Bax and caspase-3 levels increased by ~ 47 and 35%, respectively.
However, unlike the results we observed in microglia cells, afobazole did not mitigate
increases in Bax or caspase-3 expression in neurons. The ratio of Bcl-2:Bax has been
shown to positively correlate to cell survival in neurons exposed to Aβ (Patel and Brewer,
2008). Likewise, the ratio of Bcl-2:Bax is important in regulating cell survival following
glutamate excitotoxicity (Schelman et al., 2004) and previous studies have shown that
Bcl-2 is a target for σ receptor mediated neuroprotection (Yang et al., 2007, Meunier and
Hayashi, 2010). Additionally, experiments were performed to determine if afobazole
could preserve expression of Bcl-2 levels following ischemia. As we observed with
microglia, Bcl-2 expression decreased in neurons under ischemic conditions. We found
that afobazole alone increased Bcl-2 expression; however, when co-incubated with
ischemia, afobazole failed to preserve Bcl-2 expression levels and were comparable to
ischemia alone.
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However, when functional integrity of these surviving neurons was examined by
attempting to depolarize them with a focal application of 30mM KCl, we found them
unresponsive. It appeared that afobazole might not be as neuroprotective as we first
thought against prolonged ischemic exposure. However we realized that the conditions
in which these neurons were exposed resembled a near core environment and not the
penumbra. Neuronal necrosis contributes to the expansion of the core into the
penumbra. The fact that afobazole prevents the dumping of neuronal cellular contents
into surrounding tissue and allows for these damaged cells to undergo controlled cell
death.
Lastly, In addition to large vessel ischemic strokes there are small vessel ischemic
stroke known as lacunar infarcts, which account for approximately 25% of all ischemic
insults (Samuelsson et al., 1996). These strokes result from the blockage of small
penetrating arteries to the subcortical regions of the brain (Kang et al., 2012). This type
infarct is a leading cause of cognitive impairment and vascular dementia (Charidimou
and Werring, 2012). While the risk factors resulting in lacunar verse large artery infarcts
differ, the resulting cellular cascade promoting cerebral cell death may have overlapping
mechanisms. One of these mechanisms may be the increased production and toxicity of
the amyloid-β peptide, which has been shown to be upregulated following an ischemic
event (Popa-Wagner et al., 1998, Guglielmotto et al., 2009, Pluta et al., 2013). Neuronal
cultures were used to determine if incubation with 25 µM amyloid-β25-35 produced an
increase in the [Ca2+]i levels evoked by ischemia + acidosis application. Incubation for 12
hr failed to potentiate Ca2+ elevations. Given that Aβ modulation of these responses may
require longer incubation period for gene up-regulation. Therefore, neurons were
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incubated for 24 hr with Aβ and found to have potentiated ischemia, acidosis and
ischemia + acidosis induced increases in [Ca2+]i levels. We found that acidosis
application alone produced an increase in mean peak [Ca2+]i by ~42%. Furthermore,
application of ischemia alone or ischemia + acidosis also produced potentiated
elevations in both the peak and total net calcium influx by ~72 and 82% for ischemia and
~43 and 85% for ischemia + acidosis, respectively. This dual potentiation in [Ca2+]i may
indicated that the mechanism in these response involve multiple pathways including
ASIC1a, VGCCs, NMDA and AMPA/kainate receptors. Previous studies from our
laboratory have shown that ischemia-induced elevations in [Ca2+]i involved the activation
of NMDA receptors (Katnik et al., 2006), whereas acidosis application activates ASIC1a
receptors (Herrera et al., 2008). Moreover, the ischemia + acidosis activation of NMDA
and ACIS1a receptors results in a synergist increase in [Ca2+]i levels. This is a
complicated interaction with NMDA receptors functionally up-regulating ASIC1a, while at
the same time ASIC1a potentiates NMDA receptor activity (Mari et al., 2014).
Since activation of ASIC1a has been shown to potentiate ischemia-induced
[Ca2+]i levels through NMDA receptors, we were interested in determining were Aβ
potentiation occurred. Previous studies have shown that only a small part of the ischemia
+ acidosis evoked Ca2+ influx is directly due to ACIS1a with VGCCs, NMDA and
AMPA/kainate receptors contributing to the bulk influx (Gonzalez-Alvear and Werling,
1995, Alonso et al., 2000). However, fluorometric calcium imaging showed that Aβinduced a potentiated proton activated Ca2+ influx. Therefore, whole-cell patch-clamp
experiments were performed to determine whether this potentiation was due to directly to
ASIC1a activity or via ASIC1a enhanced downstream channels. Neurons Aβ-incubated
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for 24 hr were voltage-clamped at -70 mV, which prevents NMDA receptor and VGCC
activation, demonstrated a ~68% increase in the proton evoked inward current. Taken
together, our results indicate that Aβ incubation is directly up-regulating ASIC1a activity
as well as the ASIC1a potentiated down-stream channels.
Reducing the Ca2+ overload produced by an ischemic insult is crucial to mitigating
stroke injury. Previous studies from our laboratory have shown that σ-1 receptor
activation in neurons can elevate the Ca2+ overload induced by ischemia, acidosis and
Aβ (Cuevas et al., 2011a, Behensky et al., 2013a). However, not all sigma receptor
agonists were shown to be as effective under these conditions (Behensky et al., 2013a).
The pan-selective agonist afobazole was one such drug that did mitigate Ca2+ overload
induced under all three conditions. Therefore, 100 µM afobazole was co-incubated with
Aβ for 24 hr to assess what function activation of sigma receptors would have on the Aβ
up-regulated function. Co-incubation with afobazole completely abolished the potentiated
increases in [Ca2+]i levels-induced via focal application of ischemia + acidosis. Reducing
the Aβ up-regulated Ca2+ increases will likely translate to an increase in neuronal
survival.
The overall significance of this study shows that sigma receptor activation via
afobazole can decrease both ischemic- and Aβ-induced injury following a stroke. The
activation of σ-1 receptors prevented Aβ25-35-induced [Ca2+]i overload and mediated
neuroprotection by downregulation of both Bax and activated caspase-3, and long-term
upregulation of Bcl-2. This translated to a decrease in Aβ25-35-evoked neuronal
apoptosis. In addition, afobazole through σ-1 and σ-2 receptors mitigated the activation
and migration of microglial cells in response to Aβ25-35. The observed decrease in
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apoptosis is due to afobazole-mediated regulation of multiple genes, with a noted
decrease in Bax and caspase-3 and a concomitant increase in Bcl-2 expression. In
addition to the decrease in cell death, afobazole preserved functional activity of the cells
as evident by the conserved ATP-induced increases in [Ca2+]i following prolonged
incubation in Aβ25-35. Taken together our data suggest that afobazole may prevent
microglia from entering the activated state associated with neurotoxicity following
exposure to Aβ, and increasing their survival, which will facilitate clearance of the
amyloid peptide. Our data show one mechanism by which Aβ may potentiate neuronal
injury during ischemia-acidosis is through increased [Ca2+]i overload, and identify
ASIC1a as the channel mediating this phenomenon. Finally, our data suggest that
activation of σ receptors by afobazole may represent a therapeutic strategy for mitigating
concurrent injury produced by Aβ and stroke.
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